Šw‰ï”•\i2003”NˆÈ~j
1. ŠÖŒû•x”üŽq, XŒû°, •Ÿ“‡Žu•à, ˆäê—S—¢Žq, ”©ŽR Ži, ’Ø“c^”¿, •½–{Žu‰——¢, ‰ª“c‘ìÆ, –L‰ª®Ž÷, “c’†G˜a, ˆ°“c—²Ži, ¼‘º “ž, 씨“ÄŽjD“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3,
28-31, ‰¡•liƒ|ƒXƒ^[j
2.
‹{–{•ü‰ÀAŒj–Ø‘ŽqA–Ø‘º Œ’A씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹“Š—^‚ª‚ñŠ³ŽÒ‚É‚¨‚¢‚ÄŒŒ‰t‹ÃŒÅ”\’ቺ‹y‚ÑR‹ÃŒÅ–ò‚Ì•¹—p‚ª‰»Šw—Ö@—U”«––½_ŒoáŠQ‚É‹y‚Ú‚·‰e‹¿D“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3,
28-31, ‰¡•liŒû“ªj
3.
ŽR–{‘쎑AŠâªŽDA‹{–{•ü‰ÀA’Ø“c^”¿AŠÖŒû•x”üŽqA匴Š²•vAª–{ ˜iA’O–ìFˆêA씨“ÄŽjDƒAƒ“ƒWƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò‚ÆAT1Žó—e‘ÌhR–ò‚É‚æ‚é—L’É«“œ”A•a «_ŒoáŠQ‚Ì—}§F•ÛŒ¯–ò‹Ç‚̃ŒƒZƒvƒgƒf[ƒ^‰ðÍ‚É‚æ‚錟ØD“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3, 28-31, ‰¡•liŒû“ªj
4.
‘q‹´ãÄ‘¾˜YA¼–샒jAÎì‰À“ÞA씨“ÄŽjA‚‹´Ž”VA匴Š²•vA‘å’¹ “ODÝ‘îŽ{ÝŠ³ŽÒ‚É‚¨‚¯‚éáy‚Ý‚ÌŒ»ó‚ƃXƒLƒ“ƒPƒA‚ÌŽÀ‘Ô’²¸D“ú–{–òŠw‰ï‘æ144”N‰ïC2024, 3, 28-31, ‰¡•liƒ|ƒXƒ^[j
5.
Kawabata, A. Distinct modulation of Cav3.2
function by sulfide and polysulfide. 6th International Calcium Channel Conference.
2024, 2, 25 – 3, 1, Boracay Island, Phillipine (Invited speaker)
6. 씨“ÄŽjDZinc‚Æsulfide‚É‚æ‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠˆ«’²ß‚Æ’É‚ÝEáy‚ÝD’É‚ÝŒ¤‹†‰ï2023. 2024”N1ŒŽ11-12“úA‰ªèiŒû“ªjD
7. 씨“ÄŽjD•ÂŒo‚É‚æ‚éƒGƒXƒgƒƒQƒ“Œ¸‚Ɖ»Šw—Ö@—U”«––½_ŒoáŠQD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïAƒVƒ“ƒ|ƒWƒEƒ€u«ƒzƒ‹ƒ‚ƒ“‚Æ’É‚ÝEáy‚ÝviƒI[ƒKƒiƒCƒU[F–ØŒûE씨jD2023, 12, 14-16, _ŒËiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
8. ŠÖŒû•x”üŽqAXŒû°A•Ÿ“‡Žu•àAˆäê—S—¢ŽqA’Ø“c^”¿A•½–{Žu‰——¢A‰ª“c‘ì–çA–L‰ª®Ž÷A“c’†G˜aAˆ°“c—²ŽiA¼‘º“žA씨“ÄŽjDH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚ð‘jŠQ‚·‚éƒJƒ‹ƒrƒhƒp‚ƃxƒ“ƒZƒ‰ƒWƒh‚̓{ƒ‹ƒeƒ]ƒ~ƒuŠ´Žó«‚¨‚æ‚Ñ’ïR«‘½”«œ‘Žî×–E‚̶‘¶‚ð—}§‚·‚éD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiŒû“ªj
9. ²‹vŠÔŠC’nA’†–ì—yAŠâªŽDA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDƒŒƒvƒ`ƒ“Žó—e‘̈â“`ŽqŒ‡‘¹‚¨‚æ‚Ñ‚Ž‰–bHÛŽæ‚É‚æ‚é2Œ^“œ”A•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ì—L’É«––½_ŒoáŠQ‚Ö‚ÌHMGB1‚ƃAƒiƒtƒBƒ‰ƒgƒLƒVƒ“C5a‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiŒû“ªj
10. ”©ŽRŽiA’Ø“c^”¿Aˆäê—S—¢ŽqAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjDV‹Kpimozide—U“±‘ÌKTtp38‚ÍTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹ˆË‘¶«‚Ì‘Ì«’É‚¨‚æ‚Ñ“à‘Ÿ’É‚ð—}§‚·‚éD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12, 14-16, _ŒËiŒû“ªj
11. ’Ø“c^”¿A²X–؉ÔØAShin EunkyungA‰ª‘º—I‘¾A“°–{从ÑAŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚ÌŒ‹’°‰ß•q‚ÉŠÖ—^‚·‚éHMGB1‚Ì—R—ˆ×–E‚Ì“¯’è‚ÆRAGEhR–òazeliragon‚¨‚æ‚ÑŠÖ߉ŠE’°‰ŠŽ¡—Öòsulfasalazine‚ð—p‚¢‚½—\–h“I‰î“üD‘æ97‰ñ“ú–{–ò—Šw‰ï”N‰ïD2023, 12,
14-16, _ŒËiƒ|ƒXƒ^[j
12. ŠÖçç“lAŠÝ–{Ê–ìA“°–{从ÑAš¢”öŒ«ŒåA“c“‡˜aŽ÷A¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N––½_ŒoáŠQ‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚¨‚æ‚Ñ•â‘ÌC5a/CaRŒn‚ÌŠÖ—^D‘æ73‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2023, 10,
14, _ŒËiŒû“ªj
13. ²‹vŠÔŠC’nA’†–ì—yA‘å“Œ–ƒÆAŠâªŽDA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDˆâ“`«‚¨‚æ‚Ñ‚Ž‰–bHÛŽæ‚É‚æ‚é2Œ^“œ”A•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é—L’É«––½_ŒoáŠQ‚ɑ΂·‚éthrombomodulin
alfa ‚Ì—}§Œø‰ÊFHMGB1‚Æ•â‘ÌC5a‚Ì•sŠˆ«‰»‚ªŠÖ—^‚·‚é‰Â”\«‚ɂ‚¢‚ÄD‘æ73‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2023, 10,
14, _ŒËiƒ|ƒXƒ^[j
14. ‘å“Œ–ƒÆA’†–ì—yA²‹vŠÔŠC’nAŠâªŽDA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjD‚Ž‰–bHÛŽæ‚É‚æ‚é2Œ^“œ”A•aƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é—L’É«––½_ŒoáŠQ‚Ì”Œ»‚É‚ÍHMGB1Aƒ}ƒNƒƒtƒ@[ƒW‚¨‚æ‚ÑŒŒ¬”‚ªŠÖ—^‚·‚éD‘æ73‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2023, 10,
14, _ŒËiƒ|ƒXƒ^[j
15. •y“cŽDAª–{˜iA‹{–{•ü‰ÀA—Ñ—F“TA“c’†‰ëKA‘Å’J˜a‹LA¬ò—SˆêA•½“c“ÖŽmA’Ø“c^”¿AŠÖŒû•x”üŽqA’O–ìFˆêA씨“ÄŽjDƒŒƒjƒ“EƒAƒ“ƒMƒIƒeƒ“ƒVƒ“Œn‘jŠQ–ò‚Í“œ”A•a«––½_ŒoáŠQ‚̔ǂð—}§‚·‚éF3•a‰@‚Å‚ÌŒã‚ëŒü‚«ƒRƒz[ƒgŒ¤‹†‚ÆŠî‘bŒ¤‹†‚Å‚ÌŒŸØD‘æ33‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2023, 11, 3-5, å‘äiŒû“ªjD
16. 씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Æ—°‰»•¨Fáu’ÉE‘~áyŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«DƒVƒ“ƒ|ƒWƒEƒ€‚Ruáu’ÉŒ¤‹†‚ÌV“WŠJ`Šî‘bŒ¤‹†‚©‚ç—Õ°‰ž—p‚Ü‚Å`vA‘æ42‰ñ’Á’É–òEƒIƒsƒIƒCƒhƒyƒvƒ`ƒhƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 9, 2-3, “Œ‹žiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
17. ŠÖçç“lAŠÝ–{Ê–ìA“°–{从ÑAš¢”öŒ«ŒåA“c“‡˜aŽ÷A¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDOxaliplatin—U”«––½_ŒoáŠQ‚̔Nj@˜‰ðÍFŒŒ¬”—R—ˆHMGB1‚Æ•â‘ÌC5a/C5aRŒn‚ÌŠÖ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒ|ƒXƒ^[j
18. ‹àŒõ“‰ÀA’Ø“c^”¿AŠÖçç“lA¼–{ˆŸŽÑØA—F–ì–õŽqA¼–x³—mA씨“ÄŽjD”’‹à»Ücisplatin‚¨‚æ‚у^ƒLƒTƒ“Œn»Üpaclitaxel‚É‚æ‚éƒ}ƒEƒX‚̉»Šw—Ö@—U”«––½_ŒoáŠQ‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚ÌŠÖ—^¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒ|ƒXƒ^[j
19. ”©ŽRŽiA’Ø“c^”¿Aˆäê—S—¢ŽqAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒ|ƒXƒ^[j
20. 씨“ÄŽjD’É‚Ý‚ÆŒŒ‰t‹ÃŒÅŒnDƒVƒ“ƒ|ƒWƒEƒ€u’É‚Ý‚Ì‘½–Ê«F“«áu’É‚ÉŠÖ—^‚·‚鑽—l‚ȶ‘̃VƒXƒeƒ€‚ɂ‚¢‚ÄvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2023D2023, 8, 24-25, “¿“‡iƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
21. Kawabata, A. Role of HMGB1 and thrombin/thrombomodulin in somatic and
visceral pain processing. Symposium gHMGB1 and proteinases in inflammation and
pain: possible druggable targetsh organized by M. Cunningham and A. Kawabata,
19th World Congress of Basic and Clinical Pharmacology. 2023, 7,
2-7, Glasgow, UK (Symposium speaker).
22. ¼‘ºÊ‰ÔA’Ø“c^”¿AŽRãp•à–²A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¢‚Äthrombomodulin
alfa‚Íthrombin ˆË‘¶«HMGB1•sŠˆ«‰»ì—p‚ɉÁ‚¦‚ÄTAFIŠˆ«‰»ì—p‚ð‰î‚µ‚½•â‘ÌC5a•sŠˆ«‰»‚É‚æ‚茋’°’É‚ð—}§‚·‚éD‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD
23. ’Ø“c^”¿A²X–؉ÔØAShin EunkyungA‰ª‘º—I‘¾A“°–{从ÑAŠÖŒû•x”üŽqA‰ª“c ‘ìÆA–L‰ª ®Ž÷A씨“ÄŽjDButyrate—U‹NŒ‹’°‰ß•q‚ւ̃}ƒNƒƒtƒ@[ƒW‚¨‚æ‚Ñ’°ƒOƒŠƒA×–E—R—ˆHMGB1‚ÌŠÖ—^‚ÆRAGEhR–òazeliragon‚¨‚æ‚уŠƒEƒ}ƒ`E‰ŠÇ«’°Ž¾Š³Ž¡—Öòsulfasalazine‚ÌŒø‰ÊD‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD
24. ŠâªŽDAŠÝ–{Ê–ìAŠÖçç“lA‹{–{•ü‰ÀA“¡ˆä—Ç•½A“c’†‰ëKA‘Å’J˜a‹LA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ““Š—^Œã‚É”F‚ß‚ç‚ê‚鉻Šw—Ö@—U”«––½_ŒoáŠQ‚ɑ΂·‚éRŒŒ¬”–ò‚Ì—\–hŒø‰ÊFŠî‘bŒ¤‹†’mŒ©‚ƃŠƒAƒ‹ƒ[ƒ‹ƒhƒf[ƒ^‰ðÍ‚É‚æ‚éƒqƒg‚Å‚ÌŒŸØD‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD
25. ‹{–{•ü‰ÀAŒj–Ø‘ŽqA–Ø‘ºŒ’A씨“ÄŽjBƒpƒNƒŠƒ^ƒLƒZƒ‹“Š—^‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚鉻Šw—Ö@—U”«––½_ŒoáŠQ‚É‹y‚Ú‚·ŒŒ‰t‹ÃŒÅŠˆ«’ቺ‚ÆŒoŒûR‹ÃŒÅ–ò“Š—^‚̉e‹¿D‘æ143‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2023, 6, 24, –¼ŒÃ‰®iŒû“ªjD
26. Š}”g‰ÃlAŽR–{‘쎑A‹{–{•ü‰ÀA¼–샒jA匴Š²•vAŠâé³GA씨“ÄŽjDƒŒƒZƒvƒgƒf[ƒ^‚ð—p‚¢‚½potentially
inappropriate medications (PIMs)‚ÌŽÀ‘Ô’²¸F‚—î‚Ì“œ”A•aŠ³ŽÒ‚É‚¨‚¢‚Ä“Á‚É’ˆÓ‚ð—v‚·‚éPIMs‚Æ«·‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiŒû“ªjD
27. ŠÖŒû•x”üŽq, ‘“cŠ°Žu, Š}”g‰Ãl, ¬’r”JX, “싽—DŠó, “‡“cNO, ™–{‰Ê•à, ²“¡Žs, ’†‘º‹XŽi, ŽRŒû_–¾, “c糌³ŽO, ŠÛ–{^•ã, ’Ø“c^”¿, 씨“ÄŽjDƒTƒ‹ƒtƒ@ƒCƒh‚É‚æ‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹ˆË‘¶«áu’É‘‹‚Æ—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€Ge-132‚É‚æ‚é—°‰©•ß‘¨‚ð‰î‚µ‚½áu’É—}§D“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiƒ|ƒXƒ^[jD
28. ŠÝ–{Ê–ìA“°–{从ÑAŠÖçç“lA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA—F–ì–õŽqA¼–x³—mA씨“ÄŽjDRŒŒ¬”–ò‚̓IƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQiOIPNj‚ð—}§‚·‚éFOIPN”Ç‚É‚¨‚¯‚錌¬”—R—ˆHMGB1‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiŒû“ªjD
29. •y“cŽDAª–{˜iA‹{–{•ü‰ÀA—Ñ—F“TA“c’†‰ëKA‘Å’J˜a‹LA‘º’†’B–çA¬ò—SˆêA•½“c“ÖŽmA’Ø“c^”¿AŠÖŒû•x”üŽqA’O–ìFˆêA씨“ÄŽjD‚ŒŒˆ³‚ð‡•¹‚·‚é“œ”A•aŠ³ŽÒ‚É‚¨‚¯‚é––½_ŒoáŠQ‚̔ǂɑ΂·‚éƒAƒ“ƒMƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò‚Ü‚½‚ÍŽó—e‘ÌhR–ò‚Ì—}§Œø‰ÊF3•a‰@‚Å‚Ì—Õ°’mŒ©‚ÆŠî‘bŒ¤‹†‚É‚æ‚錟ØD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiŒû“ªjD
30. ’†–ì—yA²‹vŠÔŠC’nA•y“cŽDA’Ø“c^”¿A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD2Œ^“œ”A•aƒ}ƒEƒX‚É‚¨‚¢‚Äthrombomodulin
alfa‚ÍHMGB1‚Æ•â‘ÌC5a‚ð•sŠˆ«‰»‚·‚邱‚Æ‚Å—L’É«––½_ŒoáŠQ‚ð—}§‚·‚éD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiŒû“ªjD
31. –Ø–ìŽuDA‘q‹´ãÄ‘¾˜NAåb“c–¾–çAŽO“ˆŠG”üä»A¼ŽRˆÉ‘ãA“ì–ì仓ßA¼ì—T”VA’Ø“c^”¿AŠÖŒû•x”üŽqA‰ª“c‘ìÆA–L‰ª®Ž÷A씨 “ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹ˆË‘¶«‘~áy‚ɑ΂·‚éV‹Kƒsƒ‚ƒWƒh—U“±‘ÌKTtp‰»‡•¨‚Ì—}§Œø‰ÊD“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiƒ|ƒXƒ^[jD
32. —Ñ —F“T ,
•y“cŽDC‹{–{•ü‰À, •½“c“ÖŽm, ‘º’†’B–çA¬ò—SˆêA씨“ÄŽjD”ñ“]ˆÚ«‘O—§‘BŠà‚Ì‹Ž¨’ïR«Šl“¾‚ƶŠˆKŠµ•a‚ÌŠÖ˜A«D“ú–{–òŠw‰ï‘æ143”N‰ïD2023, 3, 25-28,
ŽD–yiŒû“ªjD
33. 씨“ÄŽjDHMGB1‚ð•W“I‚Æ‚·‚鉻Šw—Ö@—U”«––½_ŒoáŠQ‚Ì—\–hDƒVƒ“ƒ|ƒWƒEƒ€u––½_ŒovA’É‚ÝŒ¤‹†‰ïD2023, 1, 19-20, ‰ªèiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[jD
34. 씨“ÄŽjD‰»Šw—Ö@—U”«––½_ŒoáŠQ‚ÆHMGB1‚ɂ‚¢‚ÄD‘æ38‰ñ‘n–òE–ò—ƒtƒH[ƒ‰ƒ€‰ªŽRD2022, 12, 24, ‰ªŽRizoomji‹³ˆçu‰‰jD
35. 씨“ÄŽjAŠÝ–{Ê–ìA“°–{从ÑA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA‰¤“oä»A¼–x³—mDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”«––½_ŒoáŠQ(OIPN)‚ɑ΂·‚éRŒŒ¬”–ò‚Ì—\–hŒø‰ÊFOPIN‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ44‰ñ“ú–{áu’ÉŠw‰ïD2022, 12, 2-3, Šò•ŒiŒû“ªjD
36. ŠÖŒû•x”üŽq, ‘“cŠ°Žu, Š}”g‰Ãl, ¬’r”JX, “싽—DŠó, “‡“cNO, ™–{‰Ê•à, ²“¡Žs, ’†‘º‹XŽi, ŽRŒû_–¾, “c糌³ŽO, ŠÛ–{^•ã, ’Ø“c^”¿, 씨“ÄŽjDSulfides‚É‚æ‚éCav3.2ƒ`ƒƒƒlƒ‹Šˆ«E’É‚ÝŠ´Žó«˜´i‚Ærepagermanium‚É‚æ‚ésulfide•ß‘¨‚¨‚æ‚ÑCav3.2ˆË‘¶«áu’É—}§D‘æ44‰ñ“ú–{áu’ÉŠw‰ïD2022, 12, 2-3, Šò•ŒiŒû“ªjD
37. 씨“ÄŽjD‘n–ò‚Æ–ò•¨—Ö@“K³‰»‚ÉŒü‚¯‚½—Õ°–òŠw‚Æ–ò—Šw‚Ì“‡“IŒ¤‹†ƒAƒvƒ[ƒ`DƒVƒ“ƒ|ƒWƒEƒ€u–òŠw‚Ì‚È‚©‚Ì–ò—ŠwFˆã–òŒ¤‹†‚Ì‘½—l‚ȃAƒvƒ[ƒ`vD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
38. ŠÝ–{Ê–ìA“°–{从ÑA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA‰¤“oä»A¼–x³—mA씨“ÄŽji”•\ŽÒjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQiOIPNj‚Ö‚ÌŒŒ¬”—R—ˆHMGB1‚ÌŠÖ—^FRŒŒ¬”–ò‚ÌOIPN—\–hŒø‰Ê‚ɂ‚¢‚ÄD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liŒû“ªj
39. ŠÖŒû•x”üŽqAˆÀ’B‹`ŽjA“‡“cNOA’†‘º‹XŽiA씨“ÄŽjDH2S‚¨‚æ‚ÑATP•â‘¨ì—p‚ð—L‚·‚érepagermanium (Ge-132) ‚̓}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚ð—}§‚·‚éD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liƒ|ƒXƒ^[j
40. “c“‡˜aŽ÷Aš¢”öŒ«ŒåA’Ø“c^”¿A‰¤“oä»A¼–x³—mA“ì’B˜YAˆÉ“¡²•qA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é•â‘̃AƒiƒtƒBƒ‰ƒgƒLƒVƒ“C5a—U‹NƒAƒƒfƒBƒjƒA‚Ì”Œ»ƒƒJƒjƒYƒ€‚ɂ‚¢‚ÄD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liƒ|ƒXƒ^[j
41. Š}”g‰Ãl, ‚“‡NG , –Ø–ì‹M”Ž, Îìç_, ’·“ì•S, –L‰ª®Ž÷, ŠÖŒû•x”üŽq, ’Ø“c^”¿, 죓Ďj, ‘å‹v•Û‚‚âŽq, ‹g“c@”É, ‰ª“c‘ìÆ, 씨“ÄŽjD’èŒ^R¸_•a–òpimozide‚Ì\‘¢“WŠJ‚É‚æ‚èŠJ”‚µ‚½V‹KTŒ^Ca‚Q{ƒ`ƒƒƒlƒ‹‘jŠQ–òKTtp38Fƒ`ƒƒƒlƒ‹‘I‘ð«A“d‹C¶—Šw“I“Á’¥A’Á’ÉŠˆ«‚Ì•]‰¿D‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liŒû“ªjD
42. š¢”öŒ«ŒåA’r“c—TÆA’Ø“c^”¿A‰¤“oä»A¼–x³—mA“ì’B˜YAˆÉ“¡²•qA씨“ÄŽjDŠˆ«‰»protein C‚Íproteinases-activated
receptor 1 ‚ð‰î‚µ‚Ä_ŒoáŠQ«áu’É‚ð—}§‚·‚éD‘æ96‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 11, 30 – 12, 2, ‰¡•liŒû“ªjD
43. Š}”g‰Ãl, ¼‘º—³‹M, ŠÖŒû•x”üŽq, ‚“‡NG, –Ø–ì‹M”Ž, ’Ø“c^”¿, Îìç_, ’·“ì•S, –L‰ª®Ž÷, ‰ª“c‘ìÆ, ‘å‹v•Û‚‚âŽq, ‹g“c”É, 씨“ÄŽjDTŒ^Ca2+ƒ`ƒƒƒlƒ‹ (Cav3) ‘jŠQŠˆ«‚ð—L‚·‚éV‹Kpimozide—U“±‘ÌKTtp38‚Ì–ò—Šw“I“Á«‚̉ðÍ‘æ142‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 11, 12, “Œ‘åãiŒû“ªjD
44. ¼–{ˆŸŽÑØA’Ø“c^”¿AŠÑŒËˆ»”TA•½–{Žu‰——¢A—F–ì–õŽqA¼–x³—mA씨“ÄŽjD—‘‘ƒ“EoŒã‚ɃAƒƒ}ƒ^[ƒ[‘jŠQ–ò‚ð“Š—^‚µ‚½ƒ}ƒEƒX‚Å‚Í’´’á—p—ʃpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚艻Šw—Ö@—U”«––½_ŒoáŠQ‚ª”Ç‚·‚éD‘æ142‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 11, 12, “Œ‘åãiŒû“ªjD
45. ¼‘ºÊ‰ÔAŽRãp•à–²A’Ø“c^”¿A씨“ÄŽjDButyrate—U‹NŒ‹’°‰ß•q‚Ö‚Ì•â‘ÌC5a‚ÌŠÖ—^D‘æ72‰ñ@“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2022, 10, 8, –‡•ûiƒ|ƒXƒ^[jD
46. ¼‘º—³‹MAŠ}”g ‰ÃlA‚“‡NGA–Ø–ì‹M”ŽAÎìç_A’·“ì•SA‰ª“c‘ìÆAŠÖŒû•x”üŽqA‹g“c”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨 “ÄŽjD’èŒ^R¸_•a–òPimozide‚Ì\‘¢“WŠJŒ¤‹†‚É‚æ‚èŠJ”‚µ‚½V‹Káu’ÉŽ¡—Öò‚Ì–ò—Šw“I«Ž¿D‘æ72‰ñ@“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2022, 10, 8, –‡•ûiŒû“ªjD
47. •y“cŽDA‹{–{•ü‰ÀA“c’†‰ëKA‘Å’J˜a‹LA¬ò—SˆêA‘º’†’B–çAª–{˜iA’O–ìFˆêA’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒAƒ“ƒMƒIƒeƒ“ƒVƒ“•ÏŠ·y‘f‘jŠQ–ò‚ƃAƒ“ƒMƒIƒeƒ“ƒVƒ“IIŽó—e‘ÌhR–ò‚Í“œ”A•a«––½_ŒoáŠQ‚̔ǂð—}§‚·‚éF—Õ°EŠî‘b—Z‡Œ¤‹†‚É‚æ‚éƒGƒrƒfƒ“ƒXD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2022D2022, 8, 25-26, ɪiƒ|ƒXƒ^[j
48. š¢”öŒ«ŒåA’r“c—TÆA’Ø“c^”¿A‰¤“oä»A¼–x³—mA“ì’B˜YAˆÉ“¡²•qA씨“ÄŽjDŠˆ«‰»ƒvƒƒeƒCƒ“C‚Í_ŒoáŠQ«áu’É‚ð—}§‚·‚éFProteinase-activated receptor-1iPAR1j‚ÌŠÖ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2022D2022, 8, 25-26, ɪiƒ|ƒXƒ^[j
49. ˆäê—S—¢ŽqA–{šêò˜ÐA’Ø“c^”¿A죓ĎjA‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD–F‘°L-ƒAƒ~ƒmŽ_’E’YŽ_y‘f‚ð‘jŠQ‚µ‚È‚¢D-carbidopa‚ÍH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚ð‘jŠQ‚·‚邱‚Æ‚ÅTNBS—U‹NŒ‹’°’É‚ð—}§‚·‚éD‘æ141‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 7, 1, ‚¼ZoomiŒû“ªj
50. ŠÝ–{Ê–ìA“°–{从ÑA¼‰i_–¾A¼–{ˆŸŽÑØA’Ø“c^”¿AŠÖŒû•x”üŽqA‰¤“oä»A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N––½_ŒoáŠQ‚É‚ÍŒŒ¬”—R—ˆHMGB1‚ªŠÖ—^‚·‚éD‘æ141‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2022, 7, 1, ‚¼ZoomiŒû“ªj
51. –ؗt—DˆßA’J’ÃŒ’‘¾A’r“c—TÆAŠÖŒû•x”üŽqA’Ø“c^”¿AWang DengliA¼–x³—mA씨@“ÄŽjDR‚ª‚ñÜvincristine‚¨‚æ‚Ñbortezomib‚É‚æ‚è—U‹N‚³‚ê‚é––½_ŒoáŠQ‚ÉŠÖ—^‚·‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£ƒƒJƒjƒYƒ€‚Ì‘ŠˆáD“ú–{–òŠw‰ï‘æ142”N‰ïD2022, 3, 26-28,
–¼ŒÃ‰®ZoomiŒû“ªj
52. ²X–؉ÔØAShin EunkyungA–ì’†Œ‹A’Ø“c^”¿AWang Dengli
A¼–x³—mA씨“ÄŽjDButyrate—U‹NŒ‹’°‰ß•q‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW‚¨‚æ‚Ñ’°ŠÇƒOƒŠƒA—R—ˆHMGB1‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ142”N‰ïD2022, 3, 26-28,
–¼ŒÃ‰®ZoomiŒû“ªj
53. Š}”g‰ÃlAŽR–{‘쎑A‹{–{•ü‰ÀA¼–샒jA匴Š²•vAŠâé³GA씨“ÄŽjDƒŒƒZƒvƒgƒf[ƒ^‚ð—p‚¢‚½potentially
inappropriate medications (PIMs)‚ÌŽÀ‘Ô’²¸F”F’mÇŠ³ŽÒ‚É‚¨‚¢‚Ä“Á‚É’ˆÓ‚ð—v‚·‚éPIMsˆ•û‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ142”N‰ïD2022, 3, 26-28,
–¼ŒÃ‰®ZoomiŒû“ªj
54. ŠÖŒû•x”üŽqCXŒû°C•Ÿ“‡Žu•àCˆäê—S—¢ŽqC’Ø“c^”¿C•½–{Žu‰——¢C‰ª“c‘ìÆC–L‰ª®Ž÷C“c’†G˜aCˆ°“c—²ŽiC¼‘º“žC씨“ÄŽjD“àˆö«H2SŽY¶‘jŠQ‚É‚æ‚鑽”«œ‘Žî×–E‚̶‘¶—}§: ƒJƒ‹ƒrƒhƒp‚ƃxƒ“ƒZƒ‰ƒWƒh‚Ìcystathionine-ƒÀ-synthase‘jŠQŠˆ«‚ƃ{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«‘½”«œ‘ŽîŽ¡—Âւ̉ž—p‚ɂ‚¢‚ÄD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiƒ|ƒXƒ^[j
55. ŽÅ–ì“Þ”¿AˆÀ’B‹`ŽjA˜e’Jq•½Aó–ìŠG仉ÖAŠÖŒû•x”üŽqA‰ª“c‘ìÆA¼ì—T”VA–L‰ª®Ž÷A씨“ÄŽjDRAGEhR–òazeliragon‚̓qƒg‘O—§‘B‚ª‚ñ—R—ˆLNCaP×–E‚̶‘¶E‘B‚ð—}§‚·‚éF‰e‹¿‚ð‚¤‚¯‚é×–EƒVƒOƒiƒ‹‚̉ðÍD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiƒ|ƒXƒ^[j
56. š¢”öŒ«ŒåA’Ø“c^”¿A“c“‡˜aŽ÷AŠÖŒû•x”üŽqA¼–x³—mA“ì@’B˜YAˆÉ“¡²•qA씨“ÄŽjDThrombomodulin/thrombinŒn‚ÅŽY¶‚³‚ê‚éTAFIa/carboxypeptidase
B‚Í•â‘̬•ªC5a‚ð•sŠˆ«‰»‚·‚邱‚Æ‚Åoxaliplatin—U”«––½_ŒoáŠQ‚ð—}§‚·‚éD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªj
57. Š}”g‰ÃlA“싽—DŠóA‘“cŠ°ŽuAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDƒ|ƒŠƒTƒ‹ƒtƒ@ƒCƒh‚̓Tƒ‹ƒtƒ@ƒCƒh‚ÌCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‹@”\˜´iì—p‚ðÄŒ»‚Å‚«‚È‚¢FˆŸ‰”e˜a«‚Ì‘Šˆá‚ªŠÖ—^‚·‚é‰Â”\«‚ɂ‚¢‚ÄD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªj
58. “°–{从ÑA“c‘º‚ЂȂÌAŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDRƒŠƒEƒ}ƒ`–òsulfasalazine‚ÍToll-like
receptor 4ŽhŒƒ‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ð—}§‚·‚邱‚ƂʼnŠÇ«áu’É‚ðŒyŒ¸‚·‚éD‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªF‰pŒêj
59. •y“cŽDA’†–ì—yA’Ø“c^”¿A“c’†‰ëKA‘Å’J˜a‹LA‘º’†’B–çA씨“ÄŽjD“œ”A•a«––½_ŒoáŠQ‚ÍthrombinˆË‘¶“I‚Éthrombomodulin alfa‚É‚æ‚Á‚Ä—}§‚³‚êR‹ÃŒÅ–ò‚É‚æ‚Á‚Ä‘ˆ«‚·‚éFŠî‘bE—Õ°—Z‡Œ¤‹†‚É‚æ‚éV’mŒ©D‘æ95‰ñ“ú–{–ò—Šw‰ï”N‰ïD2022, 3, 7-9, •Ÿ‰ªiŒû“ªF‰pŒêj
60. ŠÖŒû•x”üŽqA‘“cŠ°ŽuAŠ}”g‰ÃlA¬’r”JXA“싽—DŠóA“‡“cNOA¼–{‰Ê•àA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãA’Ø“c^”¿A씨“ÄŽjDƒTƒ‹ƒtƒ@ƒCƒh‚É‚æ‚éCav3.2ˆË‘¶«áu’É‚Æ—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‚ÌŒø‰ÊD’É‚ÝŒ¤‹†‰ïi2021”N“xjA2022, 1, 31, ‰ªèiƒŠƒ‚[ƒgjiŒû“ªj
61. š¢”öŒ«ŒåA’Ø“c^”¿A“c“‡˜aŽ÷AŠÖŒû•x”üŽqA¼–x³—mA“ì@’B˜YAˆÉ“¡²•qA씨“ÄŽjDThrombomodulin alfa‚Ìoxaliplatin—U”«––½_ŒoáŠQ—}§ì—p”Œ»‚É‚¨‚¯‚éHMGB1•sŠˆ«‰»‚Æprotein C‹y‚ÑTAFIŠˆ«‰»‚Ì‘Š‘ΓId—v«‚Ɖº—¬ƒVƒOƒiƒ‹•ªŽq‚̉ðÍD‘æ140‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 11, 13, “Þ—ÇiŒû“ªj
62. Š}”g‰ÃlA“싽—DŠóA‘“cŠ°ŽuAŠÖŒû•x”ü1A‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì‹@”\‚É‚¨‚æ‚Ú‚·ƒTƒ‹ƒtƒ@ƒCƒh‚ƃ|ƒŠƒTƒ‹ƒtƒ@ƒCƒh‚̈قȂéŒø‰ÊFˆŸ‰”‚̉ʂ½‚·–ðŠ„‚É‚Â‚¢‚ÄD‘æ140‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 11,
13, “Þ—ÇiŒû“ªj
63. “°–{从ÑA“c‘º‚ЂȂÌAŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDRƒŠƒEƒ}ƒ`–òsulfasalazine‚̓}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ð—}§‚·‚邱‚Æ‚Ålipopolysaccharide—U‹NƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éD‘æ140‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 11, 13, “Þ—ÇiŒû“ªj
64. “싽—DŠóA‘“cŠ°ŽuAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDƒTƒ‹ƒtƒ@ƒCƒh‚É‚æ‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‹@”\‘‹ƒƒJƒjƒYƒ€‚̉ðÍFƒ|ƒŠƒTƒ‹ƒtƒ@ƒCƒh‚Ƃ̈Ⴂ‚ƈŸ‰”‚ÌŠÖ—^D‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
65. “c“‡˜aŽ÷Aš¢”öŒ«ŒåA’Ø“c^”¿A¼–x³—mA씨“ÄŽj@ƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚Ö‚Ì•â‘ÌC5a‚ÌŠÖ—^D‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
66. ’†–ì—yA•y“cŽDA’Ø“c^”¿A씨“ÄŽj@ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚Í2Œ^“œ”A•adb/dbƒ}ƒEƒX‚É‚¨‚¯‚é—L’É«––½_ŒoáŠQ‚ðƒgƒƒ“ƒrƒ“ˆË‘¶«‚É—}§‚·‚éFƒXƒgƒŒƒvƒgƒ]ƒVƒ“—U”1Œ^“œ”A•aƒ‚ƒfƒ‹‚Ƃ̈Ⴂ‚ɂ‚¢‚ÄD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
67. –ؗt—DˆßA’r“c—TÆAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽj.@ƒvƒƒeƒAƒ\[ƒ€‘jŠQ–ò‚̓}ƒNƒƒtƒ@[ƒW‚©‚çƒJƒXƒp[ƒ[ˆË‘¶«‚ÉHMGB1‚ð—V—£‚³‚¹‚éF‘½”«œ‘ŽîŽ¡—Öòƒ{ƒ‹ƒeƒ]ƒ~ƒu—U”«––½_ŒoáŠQ‚Ö‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
68. XŒû°AŠÖŒû•x”üŽqA•Ÿ“‡Žu•àA–{šêò˜ÐAˆäê—S—¢ŽqA’Ø“c^”¿A•½–{Žu‰——¢A“c’†G˜aAˆ°“c—²ŽiA¼‘º“žA씨“ÄŽjD–F‘°LƒAƒ~ƒmŽ_’E’YŽ_y‘f‘jŠQ–òƒJƒ‹ƒrƒhƒp‚ƃxƒ“ƒZƒ‰ƒWƒh‚Í‘½”«œ‘Žî×–E‚̶‘¶E‘B‚ð—}§‚·‚éFH2SŽY¶‘jŠQì—p‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
69. ˆäê—S—¢ŽqA–{šêò˜ÐA’Ø“c^”¿A죓ĎjAŠâé³GA씨“ÄŽjD–F‘°LƒAƒ~ƒmŽ_’E’YŽ_y‘f‘jŠQ–òƒJƒ‹ƒrƒhƒp‚ÍH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚ð‘jŠQ‚·‚邱‚Æ‚Å“à‘Ÿ’É‚ð—}§‚·‚éD‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD@
70. ’Ø“c^”¿A씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚̔ǃƒJƒjƒYƒ€‚̉ðÍ\HMGB1‚¨‚æ‚Ñ“àˆö«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“/ƒgƒƒ“ƒrƒ“‚Ì–ðŠ„\D‘æ71‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ïD2021, 10, 9, “Œ‘åãiƒŠƒ‚[ƒgji§—ãÜŽóÜu‰‰jD
71. Š}”g‰ÃlA–Ø–ì‹M”ŽAÎìç_A‚“‡NGA’·“ì•SA‰ª“c‘ìÆAŠÖŒû•x”üŽqA‹g“c ”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚ð—L‚·‚é’èŒ^R¸_•a–òpimozide‚Ì\‘¢“WŠJŒ¤‹†‚É‚æ‚éV‹K“«áu’ÉŽ¡—Öò‚Ì‘n»D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j
72. ŠÑŒËˆ»”TA’Ø“c^”¿A•½–{Žu‰——¢A¼‰i_–¾A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“‚̓}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ÆHMGB1Š´Žó«‚ð’ቺ‚³‚¹‚邱‚ƂŃpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚ð—}§“I‚ɧŒä‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j
73. ²X–؉ÔØAShin
EunkyungA–ì’†Œ‹AŠ’J—œŠGA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹‚É‚¨‚¯‚錋’°‰ß•q‚ւ̃}ƒNƒƒtƒ@[ƒW‚¨‚æ‚Ñ’°ŠÇƒOƒŠƒA×–E—R—ˆHMGB1‚ÌŠÖ—^D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j
74. š¢”öŒ«ŒåA“c“‡˜aŽ÷A’Ø“c^”¿A¼–x³—mA씨“ÄŽjDThrombomodulin alfa‚É‚æ‚éoxaliplatin—U‹N––½_ŒoáŠQ”Ç—}§ì—p‚ÉŠÖ—^‚·‚郃JƒjƒYƒ€‚̉ðÍFHMGB1•sŠˆ«‰»ì—p‚Æprotein C‹y‚ÑTAFIŠˆ«‰»ì—p‚ÌŠñ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒ|ƒXƒ^[j
75. ’Ø“c^”¿A씨“ÄŽjD“à‘Ÿ’ɂ̔ǂɂ¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑHMGB1‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2021D2021, 8, 26, ŽD–yiƒnƒCƒtƒŒƒbƒNƒXjiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
76.–Ø–ì‹M”ŽAŠ}”g‰Ã⼈AÎìç_A‚“‡NGA’·“ì•S⾹A‰ª“c‘ìÆAŠÖŒû•x”üŽqA‹g“c”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjDR¸_•a–òpimozide‚Ì\‘¢“WŠJ‚É‚æ‚éV‹K‘I‘ð“ITŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚Ì‘n»FV‚½‚ȓ«áu’ÉŽ¡—Öò‚ÌŠJ”‚ÉŒü‚¯‚ÄD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[j
77. ‘q‹´ãÄ‘¾˜YA¼ŽRˆÉ‘ãA“ì–ì仓ßA–Ø–ì‹M”ŽA‚“‡NGAŠ}”g‰Ã⼈A–Ø–ìŽuDA¼ì—T”VAÎìç_A‰ª“c‘ìÆAŠÖŒû•x”üŽqA’Ø“c^”¿A–L‰ª®Ž÷A씨 “ÄŽjDH2S‹Ÿ—^‘ÌNa2S‚̃}ƒEƒX–j”ç“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚éCav3.2ˆË‘¶«‘~áy‚¨‚æ‚Ñáu’ɂɑ΂·‚é’èŒ^R¸_•a–òpimozide‚ÆD2Žó—e‘ÌŽÕ’fŠˆ«‚ðŒ¸Žã‚³‚¹‚½V‹Kpimozide—U“±‘ÌKTtp-5‚Ìì⽤D‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[j
78. ŠÖŒû•x”üŽqA•Ÿ“‡Žu•àAXŒû°A•½–{Žu‰——¢A“c’†G˜aAˆ°“c—²ŽiA¼‘º“žA씨“ÄŽjDH2SŽY¶y‘fcystathionine-ƒÀ-synthase‚Ì‘jŠQ–ò‚̓{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«‚ðŠl“¾‚µ‚½‘½”«œ‘Žî×–E‚̶‘¶E‘B‚ð—}§‚·‚éD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiŒû“ªj
79. ŠÑŒËˆ»”TA’Ø“c^”¿A•½–{Žu‰——¢A¼‰i_–¾A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“‚̓}ƒNƒƒtƒ@[ƒW‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U‹NHMGB1—V—£‚ƃ}ƒEƒX‚É‚¨‚¯‚éHMGB1—U‹NƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éFƒGƒXƒgƒƒQƒ“’ቺ‚É‚æ‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQdlj»‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ÄD‘æ139‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2021, 6, 26, –¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[j
80. 씨“ÄŽjD“à‘Ÿ’É‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«DƒVƒ“ƒ|ƒWƒEƒ€u“à‘Ÿ’ÉE“à‘ŸŠ´Šo‚Ì‹@”\Œ`‘ÔŠw“IŠî”Õ‚Æ‚»‚̈Ù킪‚à‚½‚ç‚·•a‘ÔvA‘æ126‰ñ“ú–{‰ð–UŠw‰ï‘‰ïE‘S‘ŠwpW‰ï‚Æ‘æ98‰ñ“ú–{¶—Šw‰ï‘å‰ï‚̇“¯‘å‰ïD2021, 3, 28-30,
–¼ŒÃ‰®iƒŠƒ‚[ƒgjiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[jD
81. ‰Æ“c³ŽqA‹{–{•ü‰ÀA׌©ŒõˆêA‚“c[—²A’|ãŠwA씨“ÄŽjD–òŠw•”¶‚É‚¨‚¯‚éˆê”Ê–¼‚Ƥ•i–¼‚É‚æ‚éˆã–ò•i”FŽ¯‚É‹y‚Ú‚·•a‰@ŽÀ–±ŽÀK‚̉e‹¿D“ú–{–òŠw‰ï@‘æ141”N‰ïA2021, 3, 26-29,
L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
82. “c’†”ŽlA‘åˆäŒMAœA£‰ë˜NA¬ì‹œA‰““¡„AŽRì•x—YA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQÜ‚Ì‘n»Œ¤‹†D“ú–{–òŠw‰ï@‘æ141”N‰ïA2021, 3, 26-29,
L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
83. •½–{Žu‰——¢AŸÇ–씣A‹g”N³GAúå]³ŽkA‹{–{•ü‰ÀA’|ãŠwA씨@“ÄŽjD—«ŠàŠ³ŽÒ‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚Ì”ÇEdlj»‚ÉŠñ—^‚·‚éˆöŽq‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï@‘æ141”N‰ïA2021, 3, 26-29,
L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
84. ŠÑŒËˆ»”TA•½–{Žu‰——¢A’Ø“c^”¿A¼‰i_–¾A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjD—‘‘ƒ“Eoƒ}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚¨‚æ‚ÑHMGB1—U‹NƒAƒƒfƒBƒjƒA‚Ì‘ˆ«D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiŒû“ªjD
85. ŽRãp•à–²A¼ˆä˜aŽ÷A’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒgƒƒ“ƒrƒ“‘jŠQ–ò‚ÍHMGB1‚ªŠÖ—^‚·‚錋’°’É‚ÆäNã÷’ɂ𑈫‚³‚¹‚éF“à‘ ’ɧŒä‚É‚¨‚¯‚é“àˆö«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“^ƒgƒƒ“ƒrƒ“Œn‚Ì–ðŠ„D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiŒû“ªjD
86. ŠÖŒû•x”üŽq, ’†•‚ä‚¢, ’Ø“c^”¿A¼–x³—mA씨“ÄŽjD¿œ_Œo‘¹ƒ}ƒEƒX‚©‚ç“Eo‚µ‚½Œãª_Œoß_Œo×–E‚Ì“Ë‹NL’·‘£i‚ɂ̓}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ªŠÖ—^‚·‚éD‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
87. ¬’r”JXA™–{‰Ê•àA‘“cŠ°ŽuA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c”ÉA씨“ÄŽjDRepagermanium…‰ð•¨‚Ísulfide‚ð•ß‘¨‚·‚邱‚Æ‚ÅH2S‚É‚æ‚éCav3.2ƒ`ƒƒƒlƒ‹Šˆ«ã¸‚Æ“à‘Ÿ’É‚¨‚æ‚Ñ‘Ì«’É‚ð—}§‚·‚éD‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
88. ‘q‹´ãÄ‘¾˜YA¼ŽRˆÉ‘ãA“ì–ì仓ßA¼ì—T”VAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ}ƒEƒX‚¨‚¢‚Ä—°‰»•¨‚Ì–j”ç“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚éáy‚Ý‚Æ’É‚ÝFCav3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹ˆâ“`ŽqŒ‡Ž¸‚̉e‹¿D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
89. “°–{从ÑAŠ˜Œû—ÍA‰Æ‘º–ƒˆßŽqAŠÖŒû•x”üŽqA씨“ÄŽjD_Œo—R—ˆATP‚Ípaclitaxel‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚ð‘£i‚·‚éF‰»Šw—Ö@—U”«––½_ŒoáŠQ‚É‚¨‚¯‚é_Œo|–Ɖu˜AŠÖ”}‰î•¨Ž¿‚Æ‚µ‚Ä‚ÌATP‚Ì–ðŠ„D‘æ94‰ñ“ú–{–ò—Šw‰ï”N‰ïD2021, 3, 8-10, ŽD–yiƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
90. ŠÖŒû•x”üŽqA¬’r”JXA“‡“cNOA™–{‰Ê•àA‘“cŠ°ŽuA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlA’Ø“c^”¿A씨“ÄŽjD—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‰»‡•¨repagermanium‚ÌH2S/Cav3.2‚ð‰î‚µ‚½‘Ì«’É‚¨‚æ‚Ñ“à‘Ÿ’ɂɑ΂·‚é—}§Œø‰ÊDƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢áu’ÉŽ¡—Öò‚ÌŠJ”‚ð–ÚŽw‚µ‚½–ò—ŠwŒ¤‹†vA‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[jD
91. “c’†”ŽlA¬ì‹œA’†‘º‰p¶A’Ø“c^”¿A¬¼—²’jA¡ˆä—˜ˆÀAŽRì•x—YAŠÖŒû•x”üŽqA씨“ÄŽjDV‹KCav3.2‘jŠQÜNCP-1117‚Ì–ò—ƒvƒƒtƒ@ƒCƒ‹D‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD
92. “Œ–{g—Ú”üAã–ìŽR‹ËŽqA¼ì—T”VAŠÖŒû•y”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚ÍRAGE‚ªŠÖ—^‚·‚é’É‚Ý‚ð—}§‚·‚éD‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD
93. •y“cŽDA“c’†‰ëKA‘Å’J˜a‹LA‘º’†’B–çA씨“ÄŽjD“œ”A•aŠ³ŽÒ‚É‚¨‚¢‚ÄR‹ÃŒÅ–ò‚Í––½_ŒoáŠQ‚̔ǂð‘£i‚·‚éFŒã‚ëŒü‚«ƒRƒz[ƒg—Õ°Œ¤‹†‚É‚æ‚éŠî‘bŒ¤‹†’mŒ©‚ÌŒŸØD‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD
94. —Ñ —F“TA‹{–{•ü‰ÀA•½“c“ÖŽmA’·ˆä‹IÍA씨“ÄŽjD‘O—§‘BŠà‚Ì‹Ž¨’ïR«Šl“¾‚ƶŠˆKŠµ•a‚ÌŠÖ˜A«D‘æ138‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2020, 11, 14, “Œ‘åãiƒŠƒ‚[ƒgjiŒû“ªjD
95. ’Ø“c ^”¿A•Ÿ“c —º‘¾˜YA—Ñ —C—ºA‹{è ‹M–çAã“cTAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚É‚¨‚¯‚éHMGB1‚Ì–ðŠ„‚Æƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“/ƒgƒƒ“ƒrƒ“Œn‚É‚æ‚é—}§“I§ŒäD‘æ70‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘å‰ïD2020, 10, 10, ‘’ÃiƒŠƒ‚[ƒgjiŒû“ªjD
96. •y“cŽDA“c’†‰ë”VA‘Å’J˜a‹LA‘º’†’B–çA‰ªè˜aˆêA씨“ÄŽjD“œ”A•a«––½_ŒoáŠQ‚Ì”Œ»‚É‹y‚Ú‚·R‹ÃŒÅ–ò‚̉e‹¿‚ÉŠÖ‚·‚éŒã‚ëŒü‚«ƒRƒz[ƒgŒ¤‹†D‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2020, 9, 20, –¼ŒÃ‰®iƒŠƒ‚[ƒgjD
97. ‹{–{•ü‰ÀA•xŽm’J¹“TA”¨’†dŽA¬ò—SˆêA씨“ÄŽjD•ÂŒoŒã‚Ì“û‚ª‚ñŠ³ŽÒ‚̓pƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚Ì”ÇEdlj»ƒŠƒXƒN‚ª‚‚¢D‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2020, 9, 20, –¼ŒÃ‰®iƒŠƒ‚[ƒgjD
98. —Ñ —F“TA‹{–{•ü‰ÀA•½“c“ÖŽmA’·ˆä‹IÍA씨“ÄŽjD‘O—§‘BŠà‚Ì‹Ž¨’ïR«Šl“¾‚Æ—Õ°ˆöŽq‚ÌŠÖ˜A«‚É‚¨‚¯‚é’T¸Œ¤‹†D‘æ30‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ïD2020, 9, 20, –¼ŒÃ‰®iƒŠƒ‚[ƒgjD
99. Kawabata, A.,
Nishikawa, H. Higashimoto, K., Uenoyama, K., Sekiguchi, F., Tsubota1, M.,
Okada, T., Toyooka, N. Middle molecular weight heparinylphenylalanine
selectively blocks RAGE and reduces HMGB1-dependent neuropathic and visceral
pain in mice. 12th FENS Forum of Neuroscience. 2020, 7, 11-15, Glasgow, UK.
(poster; ƒŠƒ‚[ƒg)
100. Sekiguchi, F.,
Yamashita, R., Yasui, H., Kawabata, A. Schwann cells from neonatal rat sciatic
nerves secrete high mobility group box 1 (HMGB1), a pro-inflammatory and
pro-nociceptive mediator, in response to paclitaxel. 12th FENS Forum of
Neuroscience. 2020, 7, 11-15, Glasgow, UK. (poster; ƒŠƒ‚[ƒg)
101. Kawabata, A. Neuroimmune crosstalk in neuropathic and visceral pain: HMGB1 and ATP as
key mediators. In Symposium gNeuroimmune crosstalk and painh, organized by
Kawabata, A. and Zamponi, G., ‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•liƒŠƒ‚[ƒgjDiSymposium
Organizer & Speakerj
102. ‰Æ“c³ŽqA‹{–{•ü‰ÀA׌©ŒõˆêA‚“c[—²A’|ãŠwA씨“ÄŽjD–òŠw•”¶‚É‚¨‚¯‚éˆê”Ê–¼‚Ƥ•i–¼‚É‚æ‚éˆã–ò•i”FŽ¯‚É‹y‚Ú‚·•a‰@ŽÀ–±ŽÀK‚̉e‹¿D“ú–{–òŠw‰ï‘æ141”N‰ïD2021, 3, 26-29,
L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
103. “c’†”ŽlA‘åˆäŒMAœA£‰ë˜NA¬ì‹œA‰““¡„AŽRì•x—YA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQÜ‚Ì‘n»Œ¤‹†D“ú–{–òŠw‰ï‘æ141”N‰ïD2021, 3, 26-29,
L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
104. •½–{Žu‰——¢AŸÇ–씣A‹g”N³GA–ö]³ŽkA‹{–{•ü‰ÀA’|ãŠwA씨“ÄŽjD—«ŠàŠ³ŽÒ‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚Ì”ÇEdlj»‚ÉŠñ—^‚·‚éˆöŽq‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ141”N‰ïD2021, 3, 26-29,
L“‡iƒŠƒ‚[ƒgjiƒ|ƒXƒ^[jD
105. 씨“ÄŽjDŠî‘b‚Æ—Õ°‚Ì‘o•ûŒü«ƒAƒvƒ[ƒ`‚É‚æ‚é–ò—ŠwŒ¤‹†F‚ª‚ñŠ³ŽÒ‚É‚¨‚¯‚鉻Šw—Ö@‚̃ŠƒXƒNˆöŽq‰ðÍ‚©‚猩‚¦‚Ä‚«‚½‚à‚ÌD”N‰ïŠé‰æƒVƒ“ƒ|ƒWƒEƒ€u–ò—ŠwŒ¤‹†‚É‚¨‚¯‚é—Õ°ƒrƒbƒOƒf[ƒ^‚ÌŠˆ—pF‰¼àŒŸØ‚©‚çƒhƒ‰ƒbƒOƒŠƒ|ƒWƒVƒ‡ƒjƒ“ƒO‚Ü‚ÅvAorganized byÎàVA’†ìD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•liƒŠƒ‚[ƒgjDiƒVƒ“ƒ|ƒWƒEƒ€EƒXƒs[ƒJ[j
106. ŠÖŒû•x”üŽqA•Ÿ“‡Žu•àA•½–{Žu‰——¢A“c’†G˜aAˆ°“c—²ŽiA¼‘º@“žA씨“ÄŽjD—°‰»…‘fŽY¶y‘f‘jŠQ–ò‚̓vƒƒeƒAƒ\[ƒ€‘jŠQ–òƒ{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«‚ðŠl“¾‚µ‚½ƒqƒg‘½”«œ‘ŽîKMS-11×–E‚̶‘¶‚ð—}§‚·‚éD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•liƒŠƒ‚[ƒgjDiƒ|ƒXƒ^[j
107. ¬’r”JXA™–{‰Ê•àA‘“cŠ°ŽuA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlAŠÖŒû•x”üŽqA‘å‹v•Û‚‚âŽqA‹g“c@”ÉA씨“ÄŽjDRepagermanium‚ÍH2S‚Æ’¼Ú”½‰ž‚·‚邱‚Æ‚ÅH2S‚É‚æ‚è—U‹N‚³‚ê‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Šˆ«‚¨‚æ‚Ñ’É‚ÝŠ´Žó«‚Ì‘‘å‚ð—}§‚·‚éD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•lDi‰pŒêŒû“ª”•\j
108. ŠÑŒËˆ»”TA•½–{Žu‰——¢A’Ø“c^”¿A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“Œ‡–R‚É‚æ‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚Ì‘ˆ«FHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïD2020, 3, 14-16, ‰¡•lDiƒ|ƒXƒ^[j
109. “Œ–{‹v—Ú”üAã–ìŽR‹ËŽqA¼ì—T”VAŠÖŒû•x”üŽqA’Ø“c^”¿A–L‰ª®Ž÷A씨“ÄŽjDRAGE‘jŠQŠˆ«‚ð—L‚·‚é’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚̓}ƒEƒX‚É‚¨‚¯‚éoxaliplatin—U”«––½_ŒoáŠQ‚¨‚æ‚Ñbutyrate—U‹NŒ‹’°’É‚ð—}§‚·‚éD‘æ93‰ñ“ú–{–ò—Šw‰ï”N‰ïiƒŠƒ‚[ƒgjD2020, 3, 14-16, ‰¡•lDiƒ|ƒXƒ^[j
110. Kawabata, A. Role of ATP/HMGB1/RAGE and H2S/Cav3.2 axes in
cystitis-related bladder pain. gPain and Survival Strategyh, National Institute
of Physiological Sciences International Workshop on Frontiers in Defensive
Survival Circuit Researchi’É‚ÝŒ¤‹†‰ï2019j2020, 1, 7-8,
Okazaki.iOralj
111. Kamaguchi, R., Domoto, R., Sekiguchi, F., Tsubota, M., Nishibori, M.,
Kawabata, A. Hepatic injury aggravates oxaliplatin-induced peripheral
neuropathy in mice: possible involvement of HMGB1 derived from the liver. gPain
and Survival Strategyh, National Institute of Physiological Sciences
International Workshop on Frontiers in Defensive Survival Circuit Researchi’É‚ÝŒ¤‹†‰ï2019j2020, 1, 7-8, Okazaki. iPosterj
112.
‹{–{•ü‰ÀA•½–{Žu‰——¢AŠÑŒËˆ»”TA•xŽm’J¹“TA”¨’†dŽA’Ø“c^”¿A¬ò—SˆêA씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽq‰ðÍF‚ª‚ñ‚ÌŽí—Þ‚É‚æ‚éˆá‚¢‚ƉÁ—î‚̉e‹¿‚ɂ‚¢‚ÄD‘æ136‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï, 2018, 11, 23, –‡•ûDiŒû“ªj
113.
•½–{Žu‰——¢AŠÑŒËˆ»”TA‹{–{•ü‰ÀA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽq‰ðÍF—‘‘ƒ“Eoƒ}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚Ì‘ˆ«FHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD@‘æ136‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï, 2018, 11, 23, –‡•ûDiŒû“ªj
114.
¬’r”JXA™–{‰Ê•àA‘“cŠ°ŽuA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÛ–{^•ãAŠ}”g‰ÃlAŠÖŒû•x”üŽqA씨“ÄŽjD—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‰»‡•¨repagermanium‚ÍH2S‚É‚æ‚è—U‹N‚³‚ê‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Šˆ«ã¸‚ƃ}ƒEƒX‚É‚¨‚¯‚éƒAƒƒfƒBƒjƒA‚ð’¼Ú“I‚É‘jŠQ‚·‚éD‘æ136‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï, 2018, 11, 23, –‡•ûDiŒû“ªj
115. Kawabata, A. Role
of HMGB1 and PRRs in pain processing. In Symposium gEmerging roles of
DAMPs/alarmins and PRRs in neurological disordersh, organized by Kawabata, A.,
The 6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10,
11-13, Fukuoka. (Symposium speaker)
116. Sekiguchi, F., Yamashita, R., Yasui,
H., Kawabata, A. Paclitaxel, an anti-cancer drug, causes
extracellular release of HMGB1, a pro-inflammatory and pro-nociceptive
mediator, in Schwann cells derived from neonatal rat sciatic nerves. The 6th
Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13,
Fukuoka. (Poster)
117. Tsubota, M., Fukuda, R., Hayashi,
Y., Miyazaki, T., Ueda, S., Nishibori, M., Kawabata, A. Endogenous thrombin plays a preventive role against oxaliplatin-induced
peripheral neuropathy: involvement of thrombomodulin-dependent inactivation of
HMGB1 by thrombin. The 6th Asian College of
Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka. (Poster)
118. Ikeda, Y., Miyazak, T., Tsubota,
M., Tomita, S., Sekiguchi, F., Nishibori, M., Kawabata, A. Involvement
of HMGB1 in bortezomib-induced peripheral neuropathy in mice. The 6th Asian
College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13, Fukuoka.
(Poster)
119. Koike, N., Yasui, H., Sekiguchi,
F., Tanabe, G., Kawabata, A. Role of T-type calcium channels in
methamphetamine-induced hyperlocomotion and neuronal excitation in mice. The
6th Asian College of Neuropsychopharmacology (AsCNP) Congress, 2019, 10, 11-13,
Fukuoka. (Poster)
120. “Œ–{g—Ú”üAã–ìŽR‹ËŽqA¼ì—T”VAŠÖŒû•x”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚ÌRAGE‘jŠQŠˆ«‚ƃ}ƒEƒX‚É‚¨‚¯‚éoxaliplatin—U”«––½_ŒoáŠQ‚¨‚æ‚Ñbutyrate—U‹NŒ‹’°’ɂɑ΂·‚é—}§ì—pD‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019,
10, 12, _ŒËDiƒ|ƒXƒ^[j
121.
Š˜Œû@—ÍA“°–{从ÑA¼‘ºä»AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDŠÌáŠQ‚É‚æ‚éƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”«––½_ŒoáŠQ‚Ì‘ˆ«F
•aŒ´ˆöŽqHMGB1‚ð—V—£‚·‚éŠÌ“à×–E‚Ì’TõD‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019,
10, 12, _ŒËDiƒ|ƒXƒ^[j
122.
ŽRãp•à–²A¼ˆä˜aŽ÷A’Ø“c^”¿A씨“ÄŽjD¶‘Ì“à‚É‚¨‚¢‚ăgƒƒ“ƒrƒ“Eƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“Œn‚Í“à‘Ÿ’É‚ð—}§“I‚ɧŒä‚µ‚Ä‚¢‚éD‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019,
10, 12, _ŒËDiƒ|ƒXƒ^[j
123.
•Ÿ“‡Žu•àA•½–{Žu‰——¢AŠÖŒû•x”üŽqA“c’†G˜aAˆ°“c—²ŽiA¼‘º@“žA씨“ÄŽjDƒqƒg‘½”«œ‘Žî—R—ˆKMS-11×–E‚̃{ƒ‹ƒeƒ]ƒ~ƒu‘Ï«Šl“¾‚É‚¨‚¯‚é“àˆö«—°‰»…‘f‚Ì–ðŠ„D‘æ69‰ñ“ú–{–òŠw‰ïŠÖ¼Žx•”‘‰ïE‘å‰ï, 2019,
10, 12, _ŒËDiƒ|ƒXƒ^[j
124. Kawabata, A., Tsubota, M., Uebo,
K., Miki, K., Sekiguchi, F., Ishigami, A. Dietary
ascorbic acid restriction in GNL/SMP30-knockout mice unveils the role of
ascorbic acid in regulation of Cav3.2-dependent pain. 11th
Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9,
4-7, Valencia, Spain. (Poster)
125. Sekiguchi, F., Kasanami, Y.,
Onishi, R., Tsubota, M., Miyazaki, T., Hiramoto, S., Okazaki, K., Nguyen, H.D.,
Okada, T., Toyooka, N., Yoshida, S., Ohkubo, T., Kawabata, A. 6-Prenylnaringenin and its derivative, KTt45, are mixed
T-type Ca2+ channel inhibitors/CB2 receptor agonists:
antinociceptive activity in neuropathic and visceral pain models. 11th
Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019,
9, 4-7, Valencia, Spain. (Poster)
126. Matsui, K., Fukushi, S., Koike,
N., Yamagata, A., Tsubota, M., Mukai, Y., Oita, A., Takada, M., Kawabata, A. Critical role
of Cav3.2 T-type calcium channels in H2S-dependent
somatic and visceral pain signaling in mice. 11th Congress of the
European Pain Federation EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia,
Spain. (Poster)
127. Domoto, R., Fukuda, R., Sekiguchi,
F., Tsubota, M., Nishibori, M., Kawabata, A. Hepatic injury
aggravates oxaliplatin-induced peripheral neuropathy in mice: possible
involvement of HMGB1. 11th Congress of the European Pain Federation
EFIC (2019 Pain in Europe XI), 2019, 9, 4-7, Valencia, Spain. (Poster)
128. Hiramoto, S., Tsubota, M.,
Yamaguchi, K., Okazaki, K., Tanaka, J., Sekiguchi, F., Ishikura, H., Nishibori,
M., Kawabata, A. Crosstalk between the HMGB1/RAGE and CSE/H2S/Cav3.2
pathways involved in cystitis-related bladder pain in mice. 11th
Congress of the European Pain Federation EFIC (2019 Pain in Europe XI), 2019,
9, 4-7, Valencia, Spain. (Poster)
129.
’Ø“c^”¿A•Ÿ“c—º‘¾˜YA—Ñ —C—ºA‹{è‹M–çAã“c TAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚É‚¨‚¯‚éHMGB1Œn‚ƃgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“/ƒgƒƒ“ƒrƒ“Œn‚Ì‘Š”½“I–ðŠ„DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2019@@2019, 8, 31, “Œ‹žDiŒû“ªj
130.
¬’r”JXA™–{‰Ê•àA“‡“cNOA²“¡ŽsA’†‘ºéŽiAŽRŒû_–¾A“c糌³ŽOAŠÖŒû•x”üŽqA씨“ÄŽjD—L‹@ƒQƒ‹ƒ}ƒjƒEƒ€‰»‡•¨repagermanium…‰ð•¨‚Í‹C‘̃ƒfƒBƒG[ƒ^[H2S‚ð•ß‘¨‚·‚邱‚ƂŃAƒƒfƒBƒjƒA‚ð—}§‚·‚éDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2019@@2019, 8, 31, “Œ‹žDiŒû“ªj
131. 씨“ÄŽjD‰»Šw—Ö@—U”«––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽq‰ðÍ‚ÆHMGB1‚ð•W“I‚Æ‚·‚é—\–hí—ªFŠî‘bŒ¤‹†‚Æ—Õ°Œ¤‹†‚Ì—Z‡‚É‚æ‚éV’mŒ©‚ƃCƒmƒx[ƒVƒ‡ƒ“DƒVƒ“ƒ|ƒWƒEƒ€uŠî‘b‚Æ—Õ°‚Ì—Z‡‚©‚ç‚Ìáu’ÉŒ¤‹†viƒI[ƒKƒiƒCƒU[F씨“ÄŽjA’O–ìFˆêjA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019A2019, 8, 29-30,
“Œ‹žDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
132. ¬’r”JXAˆÀˆä—mŽ÷AŠÖŒû•x”üŽqA“c糌³ŽOA씨“ÄŽjDŠoÁ܃ƒ^ƒ“ƒtƒFƒ^ƒ~ƒ“‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒX‚Ìs“®—Ê‘‰Á‚Æ”]“àcFos”Œ»‚É‚¨‚¯‚éTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019@2019, 8, 29-30, “Œ‹žDiƒ|ƒXƒ^[j
133. ™–{‰Ê•àA¬’r”JXA“‡“cNOA²“¡ŽsA’†‘º‹XŽiAŽRŒû_–¾A“c糌³ŽOAŠÖŒû•x”üŽqA씨“ÄŽjDRepagermanium…‰ð•¨3-(trihydroxygermyl)propanoic
acid (THGP)‚ÍH2S‚É’¼Úì—p‚µŠOˆö«‚¨‚æ‚Ñ“àˆö«H2S‚É‚æ‚éƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019@2019, 8, 29-30, “Œ‹žDiƒ|ƒXƒ^[j
134. ŠÑŒËˆ»”TA•½–{Žu‰——¢A‹{–{•ü‰ÀA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒGƒXƒgƒƒQƒ“‚̓pƒNƒŠƒ^ƒLƒZƒ‹—U”«––½_ŒoáŠQ‚ɑ΂µ‚Ä—}§“I‚Éì—p‚·‚éFƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2019@2019, 8, 29-30, “Œ‹žDiƒ|ƒXƒ^[j
135. Kawabata, A. Role of peripheral HMGB1 and thrombomodulin/thrombin
in neuropathic pain. In Symposium gImpact of new advances in the DAMPs/alarmins
and neuroinflammation researches on diverse neuronal diseasesh organized by
Kawabata, A. and Okazawa, H., ‘æ42‰ñ“ú–{_Œo‰ÈŠw‰ï@2019, 7, 25-28, VŠƒDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
136. ‹{–{•ü‰ÀA•xŽm’J¹“TA“°–{从ÑA”¨’†dŽA•ŸŽRhŠîAŠÖŒû•x”üŽqA¬ò—Sˆê@씨“ÄŽjDŠÌáŠQ‚̓{ƒ‹ƒeƒ]ƒ~ƒu—U”«––½_ŒoáŠQ‚̔ǃŠƒXƒN‚ð‘‘傳‚¹‚éD‘æ135‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2019, 6, 21, Šò•Œ.iŒû“ª”•\j
137. “°–{从ÑA‹{–{•ü‰ÀAŠÖŒû•x”üŽqA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄŠÌáŠQ‚É‚æ‚è•úo‚³‚ê‚éHMGB1‚̓{ƒ‹ƒeƒ]ƒ~ƒu—U”«––½_ŒoáŠQ‚𑈫‚³‚¹‚éD‘æ135‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2019, 6, 21, Šò•Œ.iŒû“ª”•\j
138. ’r“c—TÆA‹{è‹M–çA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚ébortezomib—U”«––½_ŒoáŠQ‚̔ǂ¨‚æ‚шێ‚É‚¨‚¯‚éHMGB1‚Ì–ðŠ„‚Æ‚»‚Ì‹NŒ¹D‘æ135‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2019, 6, 21, Šò•Œ.iŒû“ª”•\j
139. Kawabata, A. Distinct effects of
T-type Ca2+ channel blockers and genetic deletion of Cav3.2
on somatic and visceral hypersensitivity. International Calcium Channel Meeting
2019, 2019, 3, 31-4, 5, Penang, Malaysia. (Invited speaker)
140. 씨“ÄŽjDHMGB1‚ð•W“I‚Æ‚·‚鉻Šw—Ö@—U”«––½_ŒoáŠQ‚̔Ǘ\–hDƒVƒ“ƒ|ƒWƒEƒ€u‰»Šw—Ö@—U”«––½_ŒoáŠQ‚̔Nj@˜‚Æ‘ÎôFÅV‚ÌŒ¤‹†“®ŒüvA‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
141. ŠÖŒû•x”üŽqA씨“ÄŽjD‘O—§‘B‚ª‚ñ×–E‚É‚¨‚¯‚é’á“dˆÊŠˆ«‰»Cav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„DƒVƒ“ƒ|ƒWƒEƒ€uƒCƒIƒ“ƒ`ƒƒƒlƒ‹Eƒgƒ‰ƒ“ƒXƒ|[ƒ^[‚ð•W“I‚Æ‚µ‚½‚ª‚ñ‘n–òŒ¤‹†‚ÌV“WŠJvA‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
142. ’Ø“c^”¿A씨“ÄŽjD—°‰»…‘f‚É‚æ‚éCav3.2‚ð‰î‚·‚éáu’ɃVƒOƒiƒ‹‚Ì’²ßDƒVƒ“ƒ|ƒWƒEƒ€u—°‰»…‘f‚ð‚Í‚¶‚ß‚Æ‚µ‚½¶—Šˆ«ƒCƒIƒEŒ¤‹†‚ÌV“WŠJvA‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
143. “°–{从ÑA‹{–{•ü‰ÀA¼‘ºä»A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA’Ø“c^”¿A¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒqƒg‚¨‚æ‚у}ƒEƒX‚É‚¨‚¢‚ÄŠÌáŠQ‚̓IƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”«––½_ŒoáŠQ‚Ì‘ˆ«ˆöŽq‚Å‚ ‚éFHMGB1‚ªŠÖ—^‚·‚é‰Â”\«‚ɂ‚¢‚ÄD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiŒû“ª”•\j
144. •½–{Žu‰——¢A’¹ŽR—SŠóAžÄ–ØÊAŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄäNã÷‰Š‚É”º‚¤áu’ɃVƒOƒiƒ‹”¶‚ÉŠÖ—^‚·‚éHMGB1/RAGEŒn‚ÆCSE/H2S/Cav3.2Œn‚̃NƒƒXƒg[ƒNFATP‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒWŠˆ«‰»‚Ì–ðŠ„D‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒ|ƒXƒ^[”•\jD
145. Š}”g‰ÃlA‘å¼—à‰ÀA–Ø–ì‹M”ŽAŠÖŒû•x”üŽqA’Ø“c^”¿A‹{è‹M–çA•½–{Žu‰——¢A‰ªèˆÇŽqANguyen Huy DuA‰ª“c‘ìÆA–L‰ª®Ž÷A‹g“c@”ÉA‘å‹v•Û‚‚âŽqA씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹AƒJƒ“ƒiƒrƒmƒCƒhŽó—e‘Ì‚¨‚æ‚ѓ«áu’É‚É‹y‚Ú‚·ƒzƒbƒv¬•ª6-prenylnaringenin‚Æ‚»‚Ì—U“±‘ÌKTt45‚ÌŒø‰ÊD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒ|ƒXƒ^[”•\jD
146. ŽRŒûˆêŽ÷A“°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDPaclitaxel‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚É‚¨‚¯‚écystathionine
ƒÁ-lyase/H2SŒn‚Ì–ðŠ„‚Æ––½_ŒoáŠQ‚Ö‚ÌŠÖ—^D‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒ|ƒXƒ^[”•\jD
147. ¬’r”JXAˆÀˆä—mŽ÷AŠÖŒû•x”üŽqA“c糌³ŽOA씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚̓}ƒEƒX‚É‚¨‚¢‚ăƒ^ƒ“ƒtƒFƒ^ƒ~ƒ“‚É‚æ‚è—U‹N‚³‚ê‚és“®—Ê‘‰Á‚¨‚æ‚Ñ”]“à“Á’è•”ˆÊ‚É‚¨‚¯‚écFos”Œ»‚ÉŠÖ—^‚·‚éD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒ|ƒXƒ^[”•\jD
148. ’r“c—TÆA‹{è‹M–çA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚ébortezomib—U”«––½_ŒoáŠQ‚ÉŠÖ—^‚·‚éHMGB1‚Ì‹NŒ¹‚Æ•W“I•ªŽqF”ÇŠú‚ƈێŠú‚É‚¨‚¯‚éˆá‚¢‚ɂ‚¢‚ÄD‘æ92‰ñ“ú–{–ò—Šw‰ï”N‰ïD2019, 3, 14-16,
‘åãDiƒ|ƒXƒ^[”•\jD
149. 씨“ÄŽjD‰»Šw—Ö@—U”«––½_ŒoáŠQ‚ÌŒ´ˆö•¨Ž¿‚Æ‚µ‚Ä‚ÌHMGB1‚Ì–ðŠ„F—Õ°ƒf[ƒ^‰ðÍ‚ÆŠî‘bŒ¤‹†‚ð‹ìŽg‚µ‚½ƒAƒvƒ[ƒ`D’É‚ÝŒ¤‹†‰ï2018D2018,
12, 13-14, ‰ªèDiŒû‰‰j
150. “°–{从ÑAŽRŒûˆêŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW‚É‚¨‚¢‚ăpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚è—U”‚³‚ê‚é“àˆö«H2S‚Ɉˑ¶‚µ‚½HMGB1—V—£F‰»Šw—Ö@—U”«––½_ŒoáŠQ‚Ö‚ÌŠÖ—^D’É‚ÝŒ¤‹†‰ï2018D2018,
12, 13-14, ‰ªèDiƒ|ƒXƒ^[j
151. 씨“ÄŽjDCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹@|@‚Ç‚±‚ʼn½‚ð‚µ‚Ä‚¢‚é‚Ì‚©H@‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[D‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiµ‘Òu‰‰j
152. ‹{–{•ü‰ÀA•ŸŽRhŠîA”¨’†dŽA•xŽm’J¹“TA“°–{从ÑAŠÖŒû•x”üŽqA¬ò—Sˆê@씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”––½_ŒoáŠQ‚̃ŠƒXƒNˆöŽqFŠÌ‹@”\áŠQ‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ÄD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”•\j
153. “°–{从ÑA¼‘ºä»AŠÖŒû•x”üŽqA’Ø“c^”¿A‹{–{•ü‰ÀA¬ò—SˆêA¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ăIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”«––½_ŒoáŠQ‚ÍŠÌáŠQ‚É‚æ‚Á‚Ä‘ˆ«‚·‚éD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”•\j
154. —Ñ@—C—ºA’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA¼–x³—mA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“^ƒgƒƒ“ƒrƒ“Œn‚ÍHMGB1‚ð•sŠˆ«‰»‚·‚邱‚ƂŃIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U”«––½_ŒoáŠQ‚̔ǂð—}§“I‚ɧŒä‚µ‚Ä‚¢‚éD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”•\j
155. ¬’r”JXAˆÀˆä—mŽ÷AŠÖŒû•x”üŽqA“c糌³ŽOA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄŠoÁ܃ƒ^ƒ“ƒtƒFƒ^ƒ~ƒ“‚É‚æ‚è—U‹N‚³‚ê‚és“®—Ê‘‰Á‚Æ”]“àcFos”Œ»‚É‹y‚Ú‚·TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚ÌŒø‰ÊD‘æ134‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 11, 23, _ŒËDiŒû“ª”•\j
156. ’Ø“c^”¿A씨“ÄŽjD“à‘Ÿ’É”Œ»‚É‚¨‚¯‚é—°‰»…‘f‚¨‚æ‚щߗ°‰»•¨‚Ì–ðŠ„D‘æ91‰ñ“ú–{¶‰»Šw‰ï‘å‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uŠˆ«—°‰©Ží‚ÌV“WŠJ|—°‰»…‘f‚©‚ç‰ß—°‰»•¨‚Ü‚Å|vD9, 24-26, ‹ž“sDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
157. Kawabata, A.,
Nishikawa, H., Uenoyama, K., Sekiguchi, F., Tsubota, M., Okada, T., Toyooka, N.
Middle Molecular Weight Heparinylphenylalanine Prevents the Development of
Chemotherapy-Induced Peripheral Neuropathy in Mice. 17th World
Congress on Pain. 2018, 9, 12-16, Boston. (Poster)
158. Matsui, K.,
Nakano, M., Tomochika, K., Tsubota, M., Kawabata, A. Pharmacological blockade
and genetic deletion of Cav3.2 T-type Ca2+ channels
abolish butyrate-induced colonic hypersensitivity in mice. 17th
World Congress on Pain. 2018, 9, 12-16, Boston. (Poster)
159. Wakitani, K.,
Sekiguchi, F., Tsubota, M., Nakamura, S., Nakanishi, I., Kawabata, A.
Azelastine attenuates RAGE-dependent allodynia in mice: a discovery by a drug
reprofiling/repositioning approach. 17th World Congress on Pain.
2018, 9, 12-16, Boston. (Poster)
160. 씨“ÄŽjDDAMPs‚Æ’É‚ÝD‘æ40‰ñ“ú–{¶•¨Šw“I¸_ˆãŠw‰ïE‘æ61‰ñ“ú–{_Œo‰»Šw‘å‰ï‡“¯”N‰ï@ƒVƒ“ƒ|ƒWƒEƒ€u_ŒoŽ¾Š³‚Ì‘•‚ƧŒä‚É‚¨‚¯‚éDAMPs‚Ì–ðŠ„vD2018, 9, 6-8,
_ŒËDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
161. “°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDPaclitaxel‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1•úo‚̓jƒ…[ƒƒ“—R—ˆATP‚É‚æ‚Á‚Ä‘£i‚³‚ê‚éF‰»Šw—Ö@—U‹N––½_ŒoáŠQ‚É‚¨‚¯‚é_ŒoŒn|–ƉuŒnƒNƒƒXƒg[ƒN‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2018D2018, 8, 23-24, •Ÿ‰ªBiƒ|ƒXƒ^[j
162. •½–{Žu‰——¢A’¹ŽR—SŠóAžÄ–Ø ÊA’Ø“c^”¿AŽRŒû@ŒOA“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¢‚ÄATP/HMGB1/RAGEŒn‚ÍCSE/H2S/Cav3.2Œn‚Ìã—¬ƒVƒOƒiƒ‹‚Æ‚µ‚ÄäNã÷’ɂ̔ǂɊ֗^‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2018D2018, 8, 23-24, •Ÿ‰ªBiƒ|ƒXƒ^[j
163. —Ñ@—C—ºA’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚ɑ΂·‚éƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚Ì—\–hŒø‰Ê‚É‹y‚Ú‚·R‹ÃŒÅ–ò‚̉e‹¿D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2018D2018, 8, 23-24, •Ÿ‰ªBiƒ|ƒXƒ^[jD
164. Kawabata, A.,
Tomita, S., Miyazaki, T., Deguchi, T., Sekiguchi, F., Tsubota, M., Nguyen,
H.D., Okada, T., Yoshida, S.,
Toyooka, N. Cav3.2 T-type calcium channels as
therapeutic targets for bortezomib-induced peripheral neuropathy in mice. 11th
FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)
165. Sekiguchi, F.,
Noda, S., Kasanami, Y., Onishi, R., Ono, S., Murata, K., Matsuda, H., Nguyen,
H.D., Toyooka, N., Harada, N., Kawabata, A. Agonistic
activity of 6-prenylnaringenin, a novel T-type Ca2+ channel
inhibitor, toward cannabinoid CB1 receptors in neural
progenitor-like NG108-15 cells and CB1-transfected HEK293 cells. 11th
FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin. (Poster)
166. Domoto, R., Yamasoba, D., Sekiguchi, F., Tsubota,
M., Nishibori, M., Kawabata, A. Molecular mechanisms for the HMGB1-dependent mechanical
allodynia following intraplantar administration of lipopolysaccharide in mice. 11th FENS Forum of Neuroscience. 2018, 7,
7-11, Berlin. (Poster)
167. Hiramoto, S., Tsubota, M., Yamaguchi, K., Toriyama,
Y., Tanaka, J., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A. ATP
and HMGB1 mediate H2S-dependent bladder pain in mice with
cyclophosphamide-induced cystitis. 11th FENS Forum of
Neuroscience. 2018, 7, 7-11, Berlin. (Poster)
168. Nakatake, Y., Sekiguchi, F., Tsubota, M., Tsujita,
R., Honda, G., Kawabata, A. Effect of extracellular HMGB1 on
neuritogenesis in mouse dorsal root ganglion neurons and its inhibition by
thrombomodulin alfa. 11th FENS Forum of Neuroscience. 2018, 7, 7-11, Berlin.
(Poster)
169. Sekiguchi, F., Yagura, A., Kawabata, A. High
mobility group box 1 suppresses smooth muscle tension in rat aorta via
Toll-like receptor 4-dependent upregulation of iNOS. 18th
World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiPosterj
170. Nishikawa, H., Uenoyama, K., Sekiguchi, F.,
Tsubota, M., Kawabata, A. Middle molecular weight heparinylphenylalanine is an
analgesic with reduced risk of hemorrhage. 18th
World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiPosterj
171. Domoto, R, Yamasoba, D., Yamanishi, H., Sekiguchi,
F., Tsubota, M., Nishibori, M., Kawabata, A. Macrophage-derived HMGB1 is a
key molecule in paclitaxel-induced peripheral neuropathy in
mice: involvement of ROS generation and NF-ƒÈB activation. 18th
World Congress of Basic and Clinical Pharmacology / ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiOralj
172. Hayashi, Y., Tsubota, M., Tsujita, R., Honda, G.,
Kawabata, A. Molecular mechanisms for the recombinant
soluble thrombomodulin-induced
suppression of HMGB1-dependent allodynia in mice: Roles of the N-terminal
domains of thrombomodulin. 18th World Congress of Basic and Clinical Pharmacology
/ ‘æ91‰ñ“ú–{–ò—Šw‰ï”N‰ïD2018, 7, 1-6, ‹ž“sDiPosterj
173.
Tsubota,
M., Matsui, K., Nakano, M. Tomochika, K., Sekiguchi, F., Kawabata, A. Role of
Cav3.2 T-type calcium channels in the butyrate-induced colonic hypersensitivity
in the mouse, a model for irritable bowel syndrome. 10th
International Symposium on Cell/Tissue Injury and
Cytoprotection/Organoprotection. 2018, 6, 28-30, ‹ž“sD
174. 씨“ÄŽjD“à‘Ÿ’É‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW—R—ˆ HMGB1‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D‘æ40‰ñ“ú–{áu’ÉŠw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€u“à‘Ÿ’É‚Ì•ªŽqƒƒJƒjƒYƒ€\“Á‚É_ŒoŒn‚ƖƉuŒn‚̃NƒƒXƒg[ƒN‚ɂ‚¢‚ÄvD2018, 6, 15-16, ’·èDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
175. ¼ì—T”VAã–ìŽR‹ËŽqAŠÖŒû•x”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚͉»Šw—Ö@—U‹N––½_ŒoáŠQ‚ð—}§‚·‚éD‘æ40‰ñ“ú–{áu’ÉŠw‰ïD2018, 6, 15-16, ’·èDiƒ|ƒXƒ^[j
176. ì’[—MŠóA—ш¤—¹A’Ø“c^”¿A’†•‚ä‚¢A’Ò“c—²ˆêAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjD‹}«‚¨‚æ‚Ñ–«pŒã’É‚É‚¨‚¯‚éHMGB1‚Ì–ðŠ„D‘æ40‰ñ“ú–{áu’ÉŠw‰ïD2018, 6, 15-16, ’·èDiŒû“ª”•\j
177. ˜e’Jq•½, ŠÖŒû•x”üŽq, ’Ø“c^”¿, ’†‘º^–ç, ’‡¼Œ÷, 씨“ÄŽjDRAGE‚ð•W“I‚Æ‚µ‚½‰»Šw—Ö@—U‹N––½_ŒoáŠQŽ¡—Öò‚Ì’TõF In silicoƒhƒ‰ƒbƒOEƒŠƒvƒƒtƒ@ƒCƒŠƒ“ƒO/ƒŠƒ|ƒWƒVƒ‡ƒjƒ“ƒO‚©‚ç‚̃Aƒvƒ[ƒ`D‘æ40‰ñ“ú–{áu’ÉŠw‰ïD2018, 6, 15-16, ’·èDiƒ|ƒXƒ^[j
178.
¼ì—T”VAã–ìŽR‹ËŽqAŠÖŒû•x”üŽqA’Ø“c^”¿A‰ª“c‘ìÆA–L‰ª®Ž÷A씨“ÄŽjD‚ª‚ñ‰»Šw—Ö@—U‹N––½_ŒoáŠQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚é’†•ªŽqƒwƒpƒŠƒjƒ‹ƒtƒFƒjƒ‹ƒAƒ‰ƒjƒ“‚ÌRƒAƒƒfƒBƒjƒAì—pD‘æ133‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 6, 1, L“‡DiŒû“ª”•\j
179.
’Ø“c^”¿A¼ˆä˜aŽ÷A’†–ì^ŠóA—F‹ßŒAŠÖŒû•x”üŽqA씨“ÄŽjDTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚ð—L‚·‚éƒzƒbƒv¬•ª6-prenylnaringenin‚ÍŒ‹’°’É‚ð—}§‚·‚éD‘æ133‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 6, 1, L“‡DiŒû“ª”•\jD
180.
˜e’Jq•½, ŠÖŒû•x”üŽq, ’Ø“c^”¿, ’†‘º^–ç, ’‡¼Œ÷, 씨“ÄŽjDAzelastine‚ÍRAGE‚ªŠÖ—^‚·‚鉻Šw—Ö@—U‹N––½_ŒoáŠQ‚̔ǂð—}§‚·‚é | ƒhƒ‰ƒbƒOEƒŠƒvƒƒtƒ@ƒCƒŠƒ“ƒO^ƒŠƒ|ƒWƒVƒ‡ƒjƒ“ƒOŒ¤‹†‚©‚ç‚Ì’mŒ©D‘æ133‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2018, 6, 1, L“‡DiŒû“ª”•\j
181. 씨“ÄŽjD–«áu’É‚É‚¨‚¯‚éCav3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D‘æ61‰ñ“ú–{“œ”A•aŠw‰ï”NŽŸŠwpW‰ï@ƒVƒ“ƒ|ƒWƒEƒ€u_ŒoáŠQ‚Ì•a‘Ô‚ÆŽ¡—à | ’É‚Ý‚ð‰ÈŠw‚·‚évD2018, 5, 24-26, “Œ‹žDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
182. ’Ò“c—²ˆêA’Ø“c^”¿A—Ñ—C—ºA²”Œ°A–{“c„ˆêA씨“ÄŽjD’É‚ÝŒ¤‹†‰ï2017i’É‚Ý‚ð’†S‚Æ‚·‚é—LŠQ󋵓K‰ž‚Ì_Œoí—ªƒoƒCƒIƒƒW[jD2017, 12, 14-15, ‰ªèDiŒû“ª”•\j
183. 씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð•W“I‚Æ‚·‚é“«áu’É‚ÌŽ¡—ÃDƒ[ƒNƒVƒ‡ƒbƒvuƒJƒ‹ƒVƒEƒ€ƒVƒOƒiƒ‹“®‘Ô§Œä‚Ì•ªŽqŠî”Õ‚ÆŽ¾Š³Ž¡—Ãí—ªD2017”N“x¶–½‰ÈŠwŒnŠw‰ï‡“¯”NŽŸ‘å‰ïiConBio2017jD2017, 12,
6-9, _ŒËDiƒ[ƒNƒVƒ‡ƒbƒvƒXƒs[ƒJ[j.
184.
”öè—FA¼‰ª‡‹IA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA“ì•ŽuA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éH2S/Cav3.2Œn‚ð‰î‚·‚éäNã÷’É‚Ì”Œ»FNF-ƒÈBŒn‚Ì–ðŠ„‚ÆˆŸ‰”‚É‚æ‚駌äD‘æ132‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï 2017, 11, 24,@–L’†DiŒû“ª”•\j
185. ŠÖŒû•x”üŽqA–ì“cŽÑ—F—A“´Œû‘å˜aAŽR‰ª@÷AŠ}”g‰ÃlA‘å–ì@ä¿ANguyen Huy DuA–L‰ª®Ž÷A‘º“c˜a–çA¼“cGHA‹g“c@”ÉAŒ´“c¬MAˆÉ“¡—R—¢A‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚Æ‚»‚Ì—U“±‘̂̓Jƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘Ì‚ð‰î‚µ‚Ä_Œo‘O‹ìNG108-15×–E‚Ì_Œo—l“Ë‹NL’·‚ð—U‹N‚·‚éD‘æ132‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï
2017, 11, 24,@–L’†DiŒû“ª”•\j
186. ’Ø“c^”¿A씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚Ì’mŠo_Œo‰ß•q‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D‘æ45‰ñ“ú–{’×ᇊw‰ïD2017, 11, 20-21, ‹ž“sDiŒû“ª”•\j
187. Kawabata, A., Tomita, S., Deguchi, T., Sekiguchi,
F., Tsubota, M., Yoshida, S. The critical role of Cav3.2 T-type calcium channels in the
peripheral neuropathy induced by bortezomib, a proteasome-inhibiting
chemotherapy agent, in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC.
(Poster)
188. Sekiguchi,
F., Tomita, S., Shikimi, S., Tsubota, M., Kawabata, A. Involvement of Cav3.2 T-type calcium channels in
zinc deficiency-induced mechanical allodynia in mice. Neuroscience 2017. 2017, 11, 11-15, Washington DC.
(Poster)
189. Matsui, K., Terada, Y., Tsubota, M., Kawabata, A.
Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in
mice. Neuroscience 2017.
2017, 11, 11-15, Washington DC. (Poster)
190. Domoto, R., Nakashima, K., Tsubota, M., Sekiguchi,
F., Kawabata, A. Macrophages and NF-ƒÈB signaling
mediate peripheral HMGB1-induced mechanical allodynia in mice. Neuroscience
2017. 2017, 11, 11-15, Washington DC. (Poster)
191. Nakatake, Y., Sekiguchi, F., Tsubota, M., Tsujita,
R., Honda, G., Kawabata, A. HMGB1-induced neurite outgrowth in mouse dorsal
root ganglion neurons and its inhibition by thrombomodulin. Neuroscience 2017. 2017, 11,
11-15, Washington DC. (Poster)
192. Hayashi, Y., Tsubota, M., Tsujita, R., Honda, G.,
Kawabata, A. Thrombin-dependent
inhibition of HMGB1-induced mechanical allodynia by thrombomodulin in mice. Neuroscience 2017. 2017, 11, 11-15,
Washington DC. (Poster)
193. Kawabata, Y., Tsubota, M., Tsujita, R, Nishibori,
M., Kawabata, A. Involvement of HMGB1 in postoperative pain. Neuroscience 2017. 2017, 11,
11-15, Washington DC. (Poster)
194. Nguyen, H.D., Okada, T., Kitamura, S., Yamaoka, S.,
Horaguchi, Y., Kasanami, Y., Sekiguchi, F., Tsubota, M., Yoshida, S., Kawabata,
A., Toyooka, N. ‘æ35‰ñƒƒfƒBƒVƒiƒ‹ƒPƒ~ƒXƒgƒŠ[ƒVƒ“ƒ|ƒWƒEƒ€D2017, 10,
25-27, –¼ŒÃ‰®iƒ|ƒXƒ^[”•\j
195. ”öè—FA¼‰ª‡‹IA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA“ì•ŽuA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚鈟‰”Œ‡–R‚É‚æ‚éäNã÷’É‘‹ƒƒJƒjƒYƒ€@\Cav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì‹@”\‘‹‚Æ”Œ»‘‰Á‚ÌŠÖ—^\D‘æ67‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïD2017, 10, 14, _ŒËiŒû“ª”•\j
196. –î‘qˆ»”TAŠÖŒû•x”üŽqA씨“ÄŽjDŠj“àƒ^ƒ“ƒpƒNhigh mobility
group box 1‚̓‰ƒbƒg‹¹•”‘å“®–¬‚É‚¨‚¢‚ÄiNOS”Œ»—U“±‚ð‘£i‚·‚邱‚ƂŃtƒFƒjƒŒƒtƒŠƒ“Žûk‚ð—}§‚·‚éD‘æ67‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïD2017, 10, 14, _ŒËiƒ|ƒXƒ^[”•\j
197. ŠÖŒû•x”üŽqA•y“cŽDAoŒû’q‘ãA’Ø“c^”¿A‹g“c”ÉA씨“ÄŽjDƒvƒƒeƒAƒ\[ƒ€‘jŠQì—p‚ð—L‚·‚鑽”«œ‘ŽîŽ¡—Öòbortezomib‚É‚æ‚Á‚Ä—U‹N‚³‚ê‚éƒ}ƒEƒX‚Ì_ŒoáŠQ«áu’ɂɂ͈ꎟ’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì”Œ»—Ê‘‰Á‚ªŠÖ—^‚·‚éD‘æ39‰ñ“ú–{¶•¨Šw“I¸_ˆãŠw‰ïE‘æ47‰ñ“ú–{_Œo¸_–ò—Šw‰ï@‡“¯”N‰ïD2017, 9, 28, ŽD–yDiƒ|ƒXƒ^[”•\j
198.
’Ø“c^”¿AŠ’J—œŠGA–ì’†Œ‹AΈä—DŽqAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽj. Butyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÌŠÖ—^ioralj. ŽŸ¢‘ãƒVƒ“ƒ|ƒWƒEƒ€2017.
2017, 8, 26, ‹ž“siŒû“ª”•\j
199. “°–{@从ÑA’†“‡‰Ä“ÞAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚ÄHMGB1‘«’ê“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚é‹@ŠB“IƒAƒƒfƒBƒjƒA‚É‚ÍNF-ƒÈBƒVƒOƒiƒ‹‚ƃ}ƒNƒƒtƒ@[ƒW‚ªŠÖ—^‚·‚éDŽŸ¢‘ãƒVƒ“ƒ|ƒWƒEƒ€2017.
2017, 8, 26, ‹ž“siŒû“ª”•\j
200. ‹{è‹M–çA’Ø“c^”¿A•y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDBortezomib—U‹N_ŒoáŠQ«áu’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÌŠÖ—^DŽŸ¢‘ãƒVƒ“ƒ|ƒWƒEƒ€2017. 2017, 8, 26, ‹ž“siŒû“ª”•\j
201. —Ñ —C—ºA²”Œ°A’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚̓gƒƒ“ƒrƒ“ˆË‘¶“I‚ÉHMGB1‚ð•ª‰ð‚µ‰ŠÇ«áu’É‚ð—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j
202. ’†•‚ä‚¢AŠÖŒû•x”üŽqA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¢‚Äthrombomodulin
alfa‚ÍŠÒŒ³Œ^HMGB1‚É‚æ‚è—U‹N‚³‚ê‚é_Œo“Ë‹NL’·‚ðƒgƒƒ“ƒrƒ“ˆË‘¶“I‚¨‚æ‚Ñ”ñˆË‘¶“I‚É—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j
203. ’†“‡‰Ä“ÞA“°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒŒƒhƒbƒNƒXó‘Ԃ̈قȂéHMGB1‚É‚æ‚é‹@ŠB“IƒAƒƒfƒBƒjƒA‚Ì”Œ»ƒƒJƒjƒYƒ€‚̉ðÍFToll-like
receptor 5ANMDAŽó—e‘Ì‚¨‚æ‚ÑNF-ƒÈB‚ÌŠÖ—^‚ƃ}ƒNƒƒtƒ@[ƒW‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j
204. ì’[—MŠóA’Ø“c^”¿A’Ò“c—²ˆêA¼–x³—mA씨“ÄŽjDpŒã’É‚É‚¨‚¯‚éHMGB1ƒVƒOƒiƒ‹‚Ì–ðŠ„‚ÆŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j
205. ¼ˆä˜aŽ÷A’†–ì^ŠóA—F‹ßŒA’Ø“c^”¿A씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°‚Ì’mŠo_Œo‰ß•q‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2017.@2017, 8, 24-25, ‹ž“sDiƒ|ƒXƒ^[j
206. Kawabata, A. HMGB1 and pain. Symposium gMolecular
Mechanisms of pain – implications for pain therapeuticsh ‘æ40‰ñ“ú–{_Œo‰ÈŠw‘å‰ïD2017, 7, 20-23, ç—tDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
207. ŠÖŒû•x”üŽqA–ì“cŽÑ—F—A‘å–ì@ä¿A“´Œû‘å˜aAŠ}”g‰ÃlANguyen
Huy Du A–L‰ª®Ž÷A‘º“c˜a–çA¼“cGHAŒ´“c¬MAˆÉ“¡—R—¢A씨“ÄŽjD6-prenylnaringenin‚Í_Œo‘O‹ì—lNG108-15×–E‚É‚¨‚¢‚ÄTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚ƃJƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘̃AƒSƒjƒXƒgŠˆ«‚ðŽ¦‚·D‘æ40‰ñ“ú–{_Œo‰ÈŠw‘å‰ïD2017, 7, 20-23, ç—tDiƒ|ƒXƒ^[j
208. ’Ø“c ^”¿A•Ÿ“c —º‘¾˜YA‹{è ‹M–çA씨 “ÄŽjDCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð•W“I‚Æ‚·‚éƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N––½_ŒoáŠQ‚ÌŽ¡—ÃD‘æ40‰ñ“ú–{_Œo‰ÈŠw‘å‰ïD2017, 7, 20-23, ç—tDiƒ|ƒXƒ^[j
209. ‹{è‹M–çA’Ø“c^”¿A•y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box1‚Íbortezomib—U‹N_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éD‘æ131‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2017, 6, 30, –¼ŒÃ‰®DiŒû“ª”•\j
210. ’†“‡‰Ä“ÞA“°–{从ÑAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD––½‘gD’†‚̃`ƒI[ƒ‹Œ^‚¨‚æ‚уWƒXƒ‹ƒtƒBƒhŒ^high mobility group box 1‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‘‹‚ւ̃}ƒNƒƒtƒ@[ƒW‚ÌŠÖ—^D‘æ131‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2017, 6, 30, –¼ŒÃ‰®DiŒû“ª”•\j
211.
’†•‚ä‚¢AŠÖŒû•x”üŽqA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß×–E‚É‚¨‚¯‚éHMGB1—U‹N_Œo“Ë‹NL’·‚Æ‚»‚ê‚ɑ΂·‚éˆâ“`Žq‘g‚ÝŠ·‚¦ƒqƒg‰Â—n«thrombomodulin‚ÌŒø‰ÊD‘æ131‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2017, 6, 30, –¼ŒÃ‰®DiŒû“ª”•\j
212.
’Ø“c^”¿A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹{è‹M–çA“°–{从ÑAˆÀˆä—mŽ÷AŽR‰ºä»‰ÁAã“cTA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N_ŒoáŠQ«áu’ɂ̔ǃƒJƒjƒYƒ€‚̉ðÍFCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÆHMGB1‚ÌŠÖ—^D‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiŒû“ª”•\j
213. •½–{ Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NŠÔŽ¿«äNã÷‰Š—lƒ}ƒEƒXƒ‚ƒfƒ‹‚É‚¨‚¯‚éäNã÷’É‚ÍATP/HMGB1/H2SƒVƒOƒiƒ‹‚ð‰î‚µ‚Ä”Œ»‚·‚éD‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiŒû“ª”•\j
214. ŠÖŒû•x”üŽqA•y“cŽDAoŒû’q‘ãA’Ø“c^”¿A‹g“c”ÉA씨“ÄŽjDƒvƒƒeƒAƒ\[ƒ€‘jŠQ–òbortezomib—U‹N_ŒoáŠQ«áu’ɂɂ͈ꎟ’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚̃^ƒ“ƒpƒN—Ê‘‰Á‚ªŠÖ—^‚·‚éD‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiƒ|ƒXƒ^[”•\j
215. ’Ò“c—²ˆêA—Ñ—C—ºA’Ø“c^”¿A–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚̓gƒƒ“ƒrƒ“ˆË‘¶«‚ÉHMGB1—U‹N’ÉŠo‰ß•q‚ð—}§‚·‚éD‘æ39‰ñ“ú–{áu’ÉŠw‰ïD2017, 6, 16, _ŒËDiƒ|ƒXƒ^[”•\j
216. ’Ø“c^”¿A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹{è‹M–çA“°–{从ÑAˆÀˆä—mŽ÷A¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚É‚¨‚¯‚éHMGB1‚Æ‚»‚Ì•W“I•ªŽq‚Ì–ðŠ„Fƒ}ƒNƒƒtƒ@[ƒW”ñˆË‘¶“I‹@˜‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiŒû“ª”•\j
217. •y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDR‚ª‚ñ–òƒ{ƒ‹ƒeƒ]ƒ~ƒu‚É‚æ‚è—U‹N‚³‚ê‚é_ŒoáŠQ«áu’É‚É‚ÍCav3.2
TŒ^ƒJƒ‹ƒVƒ€ƒ`ƒƒƒlƒ‹‚Ì”Œ»‘‰Á‚ªŠÖ—^‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3, 15-17, ’·èDiŒû“ª”•\j
218.
ì’[—MŠóA’Ø“c^”¿A’Ò“c—²ˆêA¼–x³—mA씨“ÄŽjDHMGB1‚ÍpŒã’É‚ÉŠÖ—^‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3,
15-17, ’·èDiŒû“ª”•\j
219.
—Ñ—C—ºA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚ÌHMGB1—U‹N’ÉŠo‰ß•q‚ɑ΂·‚é—}§Œø‰Ê‚̓gƒƒ“ƒrƒ“‚Ɉˑ¶‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3,
15-17, ’·èDiŒû“ª”•\j
220.
¼ˆä˜aŽ÷A’†–ì^ŠóAΈä—DŽqAŽ›“c˜Ð‰ÁA’Ø“c^”¿A씨“ÄŽjDŒ‹’°’ɔǃƒJƒjƒYƒ€‚̉ðÍFNŠQŽó—eƒjƒ…[ƒƒ“”Œ»•ªŽqTRPV1APAR2‚¨‚æ‚ÑCav3.2‚Ì–ðŠ„D‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3,
15-17, ’·èDiƒ|ƒXƒ^[j
221.
‹{–{•ü‰À, ’Ø“c^”¿, ’‹”n²‹I, 씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚éƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰ŠEäNã÷’É‚Í”½•œŠ¦—âƒXƒgƒŒƒX‚É‚æ‚èŒyŒ¸‚³‚ê‚éFƒXƒgƒŒƒX‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‹@”\’ቺ‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3,
15-17, ’·èDiƒ|ƒXƒ^[j
222.
“°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒpƒNƒŠƒ^ƒLƒZƒ‹‚É‚æ‚éƒ}ƒNƒƒtƒ@[ƒW‚©‚ç‚ÌHMGB1—V—£‚Ì•ªŽqƒƒJƒjƒYƒ€F‰»Šw—Ö@—U‹N––½_ŒoáŠQ‚̔ǂɂ¨‚¯‚é–ðŠ„D‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3,
15-17, ’·èDiƒ|ƒXƒ^[j
223.
ŠÖŒû•x”üŽqA–ì“cŽÑ—F—A‘å–ì@ä¿A‘º“c˜a–çA¼“cGHANguyen, H.D.A–L‰ª®Ž÷A씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚̓Jƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘Ì‚ð‰î‚µ‚Ä_Œo‘O‹ì—lNG108-15×–E‚Ì_Œo“Ë‹NL’£‚ð‘£i‚·‚éD‘æ90‰ñ“ú–{–ò—Šw‰ï”N‰ïD2017, 3,
15-17, ’·èDiƒ|ƒXƒ^[j
224.
’Ø“c^”¿A•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹{è‹M–çA“°–{从ÑAˆÀˆä—mŽ÷AŽR‰ºä»‰ÁA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDR‚ª‚ñ–òƒIƒLƒTƒŠƒvƒ‰ƒ`ƒ“—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÆHMGB1‚ÌŠÖ—^‚ɂ‚¢‚ÄD’É‚ÝŒ¤‹†‰ï2016u’É‚Ý‚Ì—‰ð‚ð–ÚŽw‚µ‚½æ’[“IƒAƒvƒ[ƒ`vD2017, 1, 30-31, ‰ªèDiŒû“ª”•\j
225.
“°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDPaclitaxel—U‹N’ÉŠo‰ß•q‚ւ̃}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚ÌŠÖ—^’É‚ÝŒ¤‹†‰ï2016u’É‚Ý‚Ì—‰ð‚ð–ÚŽw‚µ‚½æ’[“IƒAƒvƒ[ƒ`vD2017, 1, 30-31, ‰ªèDiŒû“ª”•\j
226.
‹{è‹M–çA’Ø“c^”¿A•y“cŽDAoŒû’q‘ãAŠÖŒû•x”üŽqAŽR‘Z‘å’qA¼–x³—mA씨“ÄŽjDBortezomib—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌŠj“àƒ^ƒ“ƒpƒNhigh mobility
group box1‚ÌŠÖ—^D‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19,
‹ž“sDiƒ|ƒXƒ^[j
227.
ã“c•‘A[ŠC˜aŽ÷Aó–ìŠG仉ÖAŠÖŒû•x”üŽqA‹g“c”ÉA씨“ÄŽjDƒqƒg‘O—§‘BŠà×–E‚É‚¨‚¯‚éinterleukin-6—U‹N_Œo“à•ª”å—l•ª‰»‚É”º‚¤Cav3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”Œ»‘‰Á‚ÉŠÖ—^‚·‚é×–EƒVƒOƒiƒ‹‚̉ðÍD‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19,
‹ž“sDiŒû“ª”•\j
228.
•½–{Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷’É‚Ì”Œ»ƒƒJƒjƒYƒ€‚̉ðÍFƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚É‚æ‚éRAGEŠˆ«‰»‚ð‰î‚·‚éH2SŽY¶y‘f‚Ì”Œ»—U“±‚ÌŠÖ—^D‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19,
‹ž“sDiŒû“ª”•\j
229.
—Ñ—C—ºA’Ø“c^”¿A’Ò“c—²ˆêA–{“c„ˆêA씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚ÌHMGB1—U‹N’ÉŠo‰ß•q‚ɑ΂·‚é—}§ì—p‚Ì•ªŽqƒƒJƒjƒYƒ€‚ƃgƒƒ“ƒrƒ“ˆË‘¶«‚̉ðÍD‘æ130‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2016, 11, 19,
‹ž“sDiŒû“ª”•\j
230.
Tsubota,
M., Fukuda, R., Miyazaki, T., Domoto, R., Kamitani, N., Nishida, T., Sekiguchi,
F., Ishikura, H., Nishibori, M., Kawabata, A. Targeting HMGB1 and its downstream
molecules for treatment of oxaliplatin-induced peripheral neuropathy. The 12th International
Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Oral)
231.
Tomita,
S., Sekiguchi, F., Tsubota, M., Kawabata, A. Molecular mechanisms for the
upregulation of Cav3.2 T-type calcium channels in the neuropathic
pain. The 12th
International Conference on Protein Phosphatase. 2016, 10, 27-30,
Higashi-Osaka. (Oral)
232.
Miyazaki,
T., Fukuda, R., Tsubota, M., Kawabata, A. Cav3.2 T-type calcium channels
as therapeutic targets for the oxaliplatin-induced peripheral neuropathy. The 12th International
Conference on Protein Phosphatase. 2016, 10, 27-30, Higashi-Osaka. (Poster)
233.
Fukami,
K., Ueda, M., Asano, E., Sekiguchi, F., Yoshida, S., Kawabata, A. Interleukin-6-induced neuroendocrine-like differentiation of human
prostate cancer cells: cell signaling and upregulation of Cav3.2
T-type calcium channels. The 12th
International Conference on Protein Phosphatase. 2016, 10, 27-30,
Higashi-Osaka. (Poster)
234.
Domoto,
R., Yamasoba, D., Yamanishi, H., Sekiguchi, F., Tsubota, M., Nishibori, M.,
Kawabata, A. A role of macrophage-derived
HMGB1 in paclitaxel-induced peripheral neuropathy in mice. The 12th
International Conference on Protein Phosphatase. 2016, 10, 27-30,
Higashi-Osaka. (Poster)
235.
ŽR‰ª÷A“´Œû‘å˜aANguyen, H.D.A–k‘º@xA‰ª“c‘ìÆA‘å–ì@ä¿AŠÖŒû•x”üŽqA¼ì—T”VA‹g“c@”ÉA‘º“c˜a–çA¼“cGHA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjD6-Prenylnaringenin‚ðƒŠ[ƒh‰»‡•¨‚Æ‚µ‚½V‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚Ì’TõF“d‹C¶—Šw“IŒŸ“¢D‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j
236.
Ž®Œ©Žd—EA•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿AŠÝ‰ªŽj˜YA씨@“ÄŽjDƒ}ƒEƒX‚Ì¿œ_Œo•”•ªŒ‹ãF—U‹N_ŒoáŠQ«áu’É‚É‚Í’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”Œ»‘‰Á‚ªŠÖ—^‚·‚éF“]ŽÊˆöŽqEgr-1‚¨‚æ‚Ñ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚Ì–ðŠ„D‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10, 15,
‚’ÎDiƒ|ƒXƒ^[j
237.
’†–ì^ŠóA¼ˆä˜aŽ÷AΈä—DŽqA’Ø“c^”¿A씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°’ÉŠo‰ß•q‚Ö‚ÌCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j
238.
“´Œû‘å˜aAŽR‰ª@÷A‘å–ì@ä¿AŠÖŒû•x”üŽqANguyen, H.D.A“¡“c—F‘ãA‘º“c˜a–çA¼“cGHA‹g“c@”ÉA‘å‹v•Û‚‚âŽqA–L‰ª®Ž÷A씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚̃CƒIƒ“ƒ`ƒƒƒlƒ‹‘I‘ð«‚ÉŠÖ‚·‚錟“¢F2S‘̂ƃ‰ƒZƒ~‘Ì‚Ì”äŠrD‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j
239.
–ì“cŽÑ—F—A‘å–ìä¿AŠÖŒû•x”üŽqA‘º“c˜a–çA¼“cGHANguyen, H.D.A–L‰ª®Ž÷A씨“ÄŽjD_Œo‘O‹ì—lNG108-15×–E‚É‚¨‚¢‚ÄV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò6-prenylnaringenin‚̓Jƒ“ƒiƒrƒmƒCƒhCB1Žó—e‘Ì‚ð‰î‚µ‚Ä_Œo“Ë‹NL’·‚ð‘£i‚·‚éD‘æ66‰ñ “ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïD2016, 10,15, ‚’ÎDiƒ|ƒXƒ^[j
240.
Kawabata,
A. Impact of zinc or ascorbic acid
deficiency on Cav3.2-dependent pain. 2016 International Calcium channel
Meeting. 2016, 10, 2-7, Hoi An, Vietnam. (Invited)
241.
Tsubota,
M. Involvement of Cav3.2 T-type Ca2+channels
in the oxaliplatin-induced neuropathic pain. . 2016 International Calcium channel Meeting. 2016, 10, 2-7, Hoi
An, Vietnam. (oral)
242.
Tomita,
S. Mechanisms of Cav3.2 upregulation in
neuropathic pain models. . 2016
International Calcium channel Meeting. 2016, 10, 2-7, Hoi An, Vietnam. (oral)
243.
Kawabata,
A. Roles of TLR4 and RAGE targeted by high mobility group box 1 in inflammatory
and chemotherapy-induced peripheral neuropathy. Topical Workshop gToll-Like
Receptor Pain Mechanismsh in 16th World Congress on Pain. 2016, 9,
26-30, Yokohama, Japan. (Invited speaker)
244.
Terada,
Y., Tsubota, M., Sekiguchi, F., Wada, K., Kuwahara, T., Takada, M., Kawabata,
A. Tacrolimus causes relapse of pancreatic pain through TRPV1 activation during
the recovery from cerulein-induced pancreatitis in mice. 16th World
Congress on Pain. 2016, 9, 26-30, Yokohama, Japan.
245.
Miyazaki,
T., Fukuda, R., Tsubota, M., Kawabata, A. Cav3.2 T-type calcium
channels contribute to oxaliplatin-induced neuropathic pain in mice. 16th
World Congress on Pain. 2016, 9, 26-30, Yokohama, Japan.
246.
Domoto,
R., Yamasoba, D., Yamanishi, H., Sekiguchi, F., Tsubota, M., Nishibori, M.,
Kawabata, A. Macrophage-derived HMGB1 participates in lipopolysaccharide-induced
inflammatory hyperalgesia and paclitaxel-induced neuropathic pain in mice. 16th
World Congress on Pain. 2016, 9, 26-30, Yokohama, Japan.
247.
씨“ÄŽjDHMGB1Œ¤‹†‚ÌV“WŠJ@`–ƉuŒn‚Æ_ŒoŒn‚̃NƒƒXƒg[ƒN‚É‚¨‚¯‚é–ðŠ„`D‘æ31‰ñ“ú–{‹~–½ˆã—Êw‰ï‘‰ïEŠwpW‰ï@ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[D2016, 9, 16-17, •Ÿ‰ªDiµ‘Òu‰‰j
248.
씨“ÄŽjDƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“ƒAƒ‹ƒtƒ@‚Ì“à‘Ÿ’ÉŽ¡—Âւ̉ž—pD‘æ44‰ñ“ú–{’×ᇊw‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uˆã–ò•i‚ÌÁ‰»Ší•a‚Ö‚Ì“K—pŠg‘å‚É‚¨‚¯‚é—˜_\’z@`@‚±‚ꂼÁ‰»Ší–ò—‚Ì—ÍvD2016, 9, 2-3, ˆ®ìDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
249. ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA“°–{从ÑAã’J‰Ä¶A¼“c•ŽiAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ì”Œ»ƒƒJƒjƒYƒ€‚̉ðÍFHMGB1‚Æ‚»‚Ì•W“I•ªŽq‚ÌŠÖ—^‚ɂ‚¢‚ÄD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2016A2016, 8,
25-26, å‘äDiŒû“ª”•\j
250.
•½–{Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷’ɂɂ̓}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚É‚æ‚éRAGE‚ð‰î‚·‚éH2SŽY¶y‘f‚Ì”Œ»—U“±‚ªŠÖ—^‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2016A2016, 8,
25-26, å‘äDiƒ|ƒXƒ^[j
251.
’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2016A2016, 8,
25-26, å‘äDiƒ|ƒXƒ^[j
252.
•½–{Žu‰——¢AŽRŒûŒOA’Ø“c^”¿A“c’†ˆêAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NŠÔŽ¿«äNã÷‰Š—lƒ}ƒEƒX‚É‚¨‚¯‚éäNã÷’É‚ÉŠÖ—^‚·‚éHMGB1/RAGEŒn‚ÆH2S/Cav3.2Œn‚Ì‘ŠŒÝŠÖŒWDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2016A2016A2016, 8, 24, å‘äDiŒû“ª”•\j
253.
’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ö‚ÌHMGB1‚ÌŠÖ—^F‚»‚Ì—R—ˆ‚Æ•W“I•ªŽq‚ɂ‚¢‚ÄDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2016A2016A2016, 8, 24, å‘äDiŒû“ª”•\j
254.
Kawabata, A., Irie, Y., Tsubota, M., Sekiguchi, F., Ishikura, H.,
Nishibori, M. High mobility group box 1 mediates pancreatic pain in mice. Physiology 2016, 2016, 7, 28-31,
Dublin. (Poster)
255.
Sekiguchi, F., Sugimoto, R., Imanishi, M., Ueda, N., Kawabata, A. Macrophage-derived high mobility group box 1 enhances neuritogenesis via
NMDA receptors in neuron-like NG108-15 cells. Physiology 2016, 2016, 7, 28-31, Dublin.
(Poster)
256.
Domoto, R., Yamasoba, D., Yamanishi, H.,
Sekiguchi, F., Tsubota, M., Nishibori, M., Kawabata, A. Involvement
of macrophage-derived high mobility group box 1 in paclitaxel-induced
neuropathic pain in mice. Physiology
2016, 2016, 7, 28-31, Dublin. (Poster)
257.
Hiramoto, S., Tsubota, M., Yamguchi, K.,
Tanaka, J., Sekiguchi, F., Ishikura, H., Nishibori, M., Kawabata, A.
Macrophage-derived high mobility group box 1 mediates H2S-dependent
bladder pain in mice with cyclophosphamide-induced cystitis. Physiology 2016, 2016, 7, 28-31,
Dublin. (Poster)
258.
Maeda,
M., Irie, Y., Tsubota, M., Kubo, L., Sekiguchi, F., Ishikura, H., Nishibori,
M., Kawabata, A. High mobility group box 1 mediates
substance P-induced bladder pain in mice, a model for bladder pain syndrome.
Physiology 2016, 2016, 7, 28-31, Dublin. (Poster)
259. •y“cŽDCŽ®Œ©Žu—ECŠÖŒû•x”üŽqC’Ø“c^”¿C씨“ÄŽjDƒ‰ƒbƒg‚ ‚é‚¢‚̓}ƒEƒX‚Ì_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éˆêŽŸ’mŠo_Œo‚É‚¨‚¯‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì”Œ»—U“±ƒƒJƒjƒYƒ€D‘æ38‰ñ“ú–{áu’ÉŠw‰ïA2016, 6, 24-25, ŽD–yDiŒû“ª”•\j
260. “°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Ílipopolysaccharide—U‹N‰ŠÇ«áu’É‚Æpaclitaxel—U‹N_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éD‘æ38‰ñ“ú–{áu’ÉŠw‰ïA2016, 6, 24-25, ŽD–yDiŒû“ª”•\j
261. ’Ø“c^”¿A•Ÿ“c—º‘¾˜YA‹{è‹M–çA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDOxaliplatin—U‹N_ŒoáŠQ«áu’ɂɂ̓}ƒNƒƒtƒ@[ƒWˆÈŠO‚Ì×–E‚É—R—ˆ‚·‚éHMGB1‚ªŠÖ—^‚·‚éD‘æ129‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2016, 6, 24, L“‡DiŒû“ª”•\j
262. “V‰Hˆê‹RA‘å–ìä¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¢‚Ä—°‰»…‘fƒhƒi[‚¨‚æ‚Ñ–Œ“§‰ß«cyclic AMPƒAƒiƒƒO‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚Ä_Œo“Ë‹NL’·‚ð—U‹N‚·‚éF×–EƒTƒCƒY‚É‚æ‚éŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚ÄD‘æ129‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2016, 6, 24, L“‡DiŒû“ª”•\j
263. ¼ˆä˜aŽ÷A’†–ì^ŠóAΈä—DŽqAŽ›“c˜Ð‰ÁA’Ø“c^”¿A씨“ÄŽjDŒ‹’°’ɂ̔ǂɂ¨‚¯‚éNŠQŽó—eƒjƒ…[ƒƒ“”Œ»•ªŽqTRPV1APAR2‚¨‚æ‚ÑCav3.2‚Ì–ðŠ„‚É‚Â‚¢‚ÄD‘æ129‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2016, 6, 24, L“‡DiŒû“ª”•\j
264. Kawabata, A. T-type calcium channels and
neuropathic/visceral pain. Symposium entitled gIon channels and pain: current
research trendsh organized by Kawabata, Tanabe and Zamponi, “ú–{–òŠw‰ï‘æ136”N‰ïA2016,3,27-29,
‰¡•lDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
265. ”öè—FA’Ø“c^”¿A씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰ŠEäNã÷’Ƀ}ƒEƒX‚É‚¨‚¯‚é—°‰»…‘f/TŒ^Ca2+ƒ`ƒƒƒlƒ‹Œn‚Ì–ðŠ„-‰º•””A˜H‹@”\áŠQ‚ɑ΂·‚éV‚½‚ÈŽ¡—ÕW“I•ªŽq‚Æ‚µ‚Ẳ”\«D‰@¶ƒVƒ“ƒ|ƒWƒEƒ€uŽŸ¢‘ãŽáŽèŒ¤‹†ŽÒ‚Ì’§íI`“«Ž¾Š³‚ɑ΂·‚éV‚½‚È‘n–òƒXƒgƒŒƒeƒW[`viƒI[ƒKƒiƒCƒU[F•ŸdE”öèj“ú–{–òŠw‰ï‘æ136”N‰ïA2016,3,27-29, ‰¡•lDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
266. “ü]—I•½A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjD‹}«äX‰Š‚É”º‚¤äX‘Ÿ’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆHMGB 1‚ÌŠÖ—^FRAGE‚¨‚æ‚ÑCXCR4‚Ì•W“I•ªŽq‚Æ‚µ‚Ä‚Ì–ðŠ„D‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3,
9-11, ‰¡•lDiŒû“ª”•\F‰pŒêj
267. •y“cŽDAŽ®Œ©Žd—EAŠÖŒû•x”üŽqA’Ø“c^”¿A”’ˆä—º—mA¼–x³—mA씨“ÄŽjDˆŸ‰”Œ‡–R‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒX’ÉŠo‰ß•qFCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Æhigh mobility group box 1‚ÌŠÖ—^D‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3,
9-11, ‰¡•lDiŒû“ª”•\F‰pŒêj
268. ‘å–ì@ä¿AŽR‰ª@÷AŠÖŒû•x”üŽqAŽsˆä^‹MA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A¼ì—T”VA‹g“c@”ÉA‘º“c˜a–çA¼“cGHA–L‰ª®Ž÷A‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone G‚Æ6-prenylnaringenin‚Ì–ò—ì—p‰ðÍF“d‹C¶—Šw“I«Ž¿‚̈Ⴂ‚ƃ}ƒEƒX‚É‚¨‚¯‚é’ÉŠo‰ß•q—}§ì—pD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3, 9-11,
‰¡•lDiŒû“ª”•\j
269. ‘O“c^—ŽqA“ü]—I•½A’Ø“c^”¿A‹v•Û—¢ŽÑAŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDSubstance P—U‹NŠÔŽ¿«äNã÷‰Š^äNã÷’ÉÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚Ì–ðŠ„D‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3,
9-11, ‰¡•lDiŒû“ª”•\j
270. ŠÖŒû•x”üŽqA™–{@—ËA¡¼–¢ŒÈA씨“ÄŽjD_Œo‚¨‚æ‚у}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÍNMDAŽó—e‘Ì‚ð‰î‚µ‚Ä_Œo‘O‹ì—lNG108-15×–E‚Ì_Œo“Ë‹NL’£‚ð‘£i‚·‚éD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3,
9-11, ‰¡•lDiƒ|ƒXƒ^[j
271. ’Ø“c^”¿AŽR‘Z‘å’qA“°–{从ÑAŠÖŒû•x”üŽqA¼–x³—mA씨“ÄŽjD––½‘gD’†‚É‚¨‚¢‚ăŒƒhƒbƒNƒXó‘Ԃ̈قȂéHMGB1‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‰ß•qƒƒJƒjƒYƒ€‚Ì‘ŠˆáD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3,
9-11, ‰¡•lDiƒ|ƒXƒ^[j
272. ¼‰ª‡‹IA”öè—FA’Ø“c^”¿A씨“ÄŽjDˆŸ‰”ƒLƒŒ[ƒ^[‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì‹@”\‘‹‚É‚æ‚ècyclophosphamide—U‹NäNã÷‰Š‚É”º‚¤äNã÷’É‚ð‘‹‚·‚éD‘æ89‰ñ“ú–{–ò—Šw‰ï”N‰ïD2016, 3,
9-11, ‰¡•lDiƒ|ƒXƒ^[j
273. •y“cŽDCŽ®Œ©Žu—ECŠÖŒû•x”üŽqC’Ø“c^”¿C씨“ÄŽjD_ŒoáŠQ«áu’Ƀ‚ƒfƒ‹“®•¨‚ÌŒãª_Œoß‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”Œ»—U“±ƒƒJƒjƒYƒ€‚̉ðÍD’É‚ÝŒ¤‹†‰ï2015.@2015, 12, 17-18, ‰ªèDiŒû“ª”•\j
274.
“ü]—I•½A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility group box 1‚̓Zƒ‹ƒŒƒCƒ“—U‹N‹}«äX‰Š‚¨‚æ‚уTƒuƒXƒ^ƒ“ƒXP—U‹NŠÔŽ¿«äNã÷‰Š/äNã÷’ÉÇŒóŒQƒ‚ƒfƒ‹‚É‚¨‚¯‚é“à‘Ÿ’É‚ÉŠÖ—^‚·‚éD’É‚ÝŒ¤‹†‰ï2015.@2015, 12, 17-18, ‰ªèDiŒû“ª”•\j
275.
“°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆhigh
mobility group box 1‚̓}ƒEƒX‚É‚¨‚¯‚élipopolysaccharide—U‹N‰ŠÇ«’ÉŠo‰ß•q‹y‚ÑRŠàÜpaclitaxel—U‹N_ŒoáŠQ«áu’É‚ÉŠÖ—^‚·‚éD‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015,
11, 20, –L’†BiŒû“ª”•\j
276.
“ü]—I•½A‘O“c^—ŽqA‹v•Û—¹A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDHigh
mobility group box 1‚Ísubstance
P—U‹NäNã÷’ÉÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠÖ˜A’ÉŠo‰ß•q‚Ì”Œ»EˆÛŽ‚ÉŠÖ—^‚·‚éD‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015,
11, 20, –L’†BiŒû“ª”•\j
277.
”öè—FA¼‰ª‡‹IA’Ø“c^”¿A•y“cŽDAŠÖŒû•x”üŽqA“ì•ŽuA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éäNã÷’ɂ͈Ÿ‰”Œ‡–R‚É‚æ‚è‘‹‚³‚ê‚éFTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015,
11, 20, –L’†BiŒû“ª”•\j
278.
‘å–ìä¿AŽR‰ª÷AŠÖŒû•x”üŽqAŽsˆä^‹MA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A¼ì_”VA‹g“c”ÉA‘º“c˜a–çA¼“cGHA–L‰ª®Ž÷A‘å‹v•Û‚‚âŽqA씨“ÄŽjDSophoraflavanone
G‚Æ‚»‚Ì—Þ‰‘Ì6-prenylnaringenin‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQì—p‚Ì“d‹C¶—Šw“I“Á’¥‚ÆŠeŽíáu’Ƀ‚ƒfƒ‹‚Å‚Ì—LŒø«D‘æ128‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2015,
11, 20, –L’†BiŒû“ª”•\j
279.
Kawabata, A., Tsubota, M., Yamaguchi,
K., Hiramoto, S., Sekiguchi, F., Tanaka, J., Ishikura, H., Nishibori, M. Bladder pain accompanying cyclophosphamide-induced
mouse cystitis involves HMGB1 release upstream of the
cystathionine-gamma-lyase/H2S/Cav3.2 pathway in the bladder tissue. Neuroscience 2015,
2015, 10, 17-21, Chicago. (Poster)
280.
Sekiguchi, F., Amo, I., Ono, S., Kawabata, A.
Hydrogen sulfide and intracellular cyclic AMP
enhance T-type calcium channel-dependent neurite outgrowth in distinct
subpopulations of isolated and dissociated mouse dorsal root ganglion neurons. Neuroscience 2015, 2015, 10, 17-21,
Chicago. (Poster)
281.
Irie, Y., Tsubota, M., Sekiguchi, F.,
Ishikura, H., Nishibori, M., Kawabata, A. Macrophage-derived high mobility group box 1 participates in the
development and maintenance of pancreatic pain through the activation of RAGE
and CXCR4 in mice with cerulein-induced acute pancreatitis. Neuroscience 2015, 2015, 10, 17-21,
Chicago. (Poster)
282.
Ozaki, T., Matsuoka, J., Tsubota, M., Tomita,
S., Sekiguchi, F., Minami, T., Kawabata, A. Zinc
deficiency aggravates bladder pain accompanying cyclophosphamide-induced
cystitis through the enhanced activity of Cav3.2 T-type Ca2+ channels
in mice. Neuroscience
2015, 2015, 10, 17-21, Chicago. (Poster)
283.
Miyamoto, T., Funakami, Y., Kawasita, E.,
Nomura, A., Sugimoto, N., Ichida, S., Kawabata, A. Chronic stress enhances the hyperthermia in
response to acute restraint stress. Neuroscience 2015, 2015, 10, 17-21,
Chicago. (Poster)
284.
Ono, S., Ichii, M., Yamaoka, S., Sekiguchi,
F., Fujita, T., Deguchi, T., Tsubota, M., Nishikawa, H., Yoshida, S., Murata,
K., Matsuda, H., Toyooka, N., Ohkubo, T., Kawabata, A. The electrophysiological property and
antihyperalgesic activity of sophoraflavanone G and 6prenylnaringenin, novel
T-type calcium channel blockers. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)
285.
Tomita, S., Sekiguchi, F., Tsubota, M.,
Kawabata, A. Molecular
mechanisms for the upregulation of Cav3.2 T-type calcium channels in the dorsal
root ganglion of rats with spinal nerve injury-induced neuropathy: involvement
of Egr-1 and USP5. Neuroscience 2015, 2015, 10, 17-21, Chicago. (Poster)
286.
ã’J‰Ä¶A¼“c•ŽiAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDVincristine—U‹N_ŒoáŠQ«áu’É‚Ì”Œ»‚¨‚æ‚шێ‚É‚¨‚¯‚éŠj“àƒ^ƒ“ƒpƒNHMGB1‚Ì–ðŠ„D‘æ65‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï@2015, 10, 17, •x“c—ÑDiƒ|ƒXƒ^[j
287.
ŽR‰ª÷A‘å–ìä¿AŽsˆä^‹MAŠÖŒû•x”üŽqA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A‹g“c”ÉA‘º“c˜a–çA¼“cGHA‘å‹v•Û‚‚âŽqA씨“ÄŽjD‹êŽQ—R—ˆV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone
G‚¨‚æ‚Ñ‚»‚Ì—Þ‰‘Ì‚Ì–ò—ì—p‰ðÍD‘æ65‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï@2015, 10, 17, •x“c—ÑDiƒ|ƒXƒ^[j
288.
Œ´“c¬MAˆÉ“¡—R—¢A‚“ˆˆê•½A‰¤Žq“c²•vA씨“ÄŽjD—°‰»…‘f‚É‚æ‚Á‚ÄŽä‹N‚³‚ꂽŠO—L–Ñ×–E‚ÌTRPV4Žó—e‘Ì‚ð‰î‚µ‚½ƒXƒgƒAì“®«ƒJƒ‹ƒVƒEƒ€—¬“üD‘æ25‰ñ“ú–{Ž¨‰ÈŠw‰ï‘‰ïD2015, 10, 7-10,
’·èDiƒ|ƒXƒ^[j
289.
Kawabata, A, Tsubota, M., Uebo, K., Miki, K.,
Sekiguchi, F., Fukuda, R., Kondo, Y., Takahashi, K., Masutomi, H., Ishigami, A.
Vitamin C deficiency aggravates hydrogen sulfide-induced pain/hyperalgesia and
chemotherapy-induced neuropathy in mice: possible involvement of T-type calcium
channels. 9th Congress of the European Pain Federation EFIC. 2015,
9, 2-5, Vienna. (Poster)
290.
’Ø“c^”¿Aã–VŒ’‘¾AŽO–ØD‹PA•Ÿ“c—º‘¾˜YAŠÖŒû•x”üŽqA‹ß“¡‰Ã‚A‚‹´Œo‘¾A‘•x—T•¶AÎ_ºlA씨“ÄŽjDAscorbic acidŒ‡–R‚ÍACav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é’É‚Ý‚ð‘‹‚·‚éDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8,
29, “Œ‹žDiŒû“ª”•\j
291.
•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD‘æ5˜_ŒoØ’f—U‹N_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚ÌŒãª_Œoß‚É‚¨‚¯‚éCav3.2‚Ì”Œ»—Ê‘‰Á‹@˜‚̉ðÍF“]ŽÊ‘£iˆöŽqEgr-1‚É‚æ‚锌»—U“±‚Æ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚É‚æ‚éƒvƒƒeƒAƒ\[ƒ€•ª‰ð—}§DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8,
29, “Œ‹žDiŒû“ª”•\j
292.
‘å–ì@ä¿A“V‰Hˆê‹RAŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß×–E‚É‚¨‚¯‚é—°‰»…‘fƒhƒi[Na2S‚ÌTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚½_Œo“Ë‹NL’·‘£iŒø‰ÊF×–E‚Ì‘å‚«‚³‚É‚æ‚éŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚ÄDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8,
29, “Œ‹žDiƒ|ƒXƒ^[j
293.
“°–{从ÑAŽR‘Z‘å’qAŽR¼LŽ÷AŠÖŒû•x”üŽqA’Ø“c^”¿A¼–x³—mA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚élipopolysaccharide—U‹N‰ŠÇ«’ÉŠo‰ß•q‚¨‚æ‚ÑRŠàÜpaclitaxel—U‹N_ŒoáŠQ«áu’ɂւ̃}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility
group box 1‚ÌŠÖ—^DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8,
29, “Œ‹žDiƒ|ƒXƒ^[j
294.
Ž®Œ©Žd—EA•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿AŠÝ‰ªŽj˜YA씨“ÄŽjDƒ}ƒEƒX‚Ì¿œ_Œo•”•ªŒ‹ãF—U‹N_ŒoáŠQ«áu’É‚É‚¨‚¯‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„DŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€ 2015. 2015, 8,
29, “Œ‹žDiƒ|ƒXƒ^[j
295.
씨“ÄŽjD“à‘Ÿ’É‚ÌV‚µ‚¢Ž¡—ÕW“I•ªŽqFTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÆHMGB1D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2015D2015, 8, 27-28, ‘D‹´DiƒVƒ“ƒ|ƒWƒEƒ€EƒXƒs[ƒJ[j
296.
‘å–ì@ä¿AŽsˆä^‹MAŽR‰ª@÷AŠÖŒû•x”üŽqA“¡“c—F‘ãAoŒû‹M_A’Ø“c^”¿A¼ì—T”VA‹g“c@”ÉA‘º“c˜a–çA¼“cGHA–L‰ª®Ž÷A‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone
G‚¨‚æ‚Ñ6-prenylnaringenin‚Ì“d‹C¶—Šw“I«Ž¿‚Æ’ÉŠo‰ß•q—}§Œø‰ÊD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2015D2015, 8, 27-28, ‘D‹´Diƒ|ƒXƒ^[j
297.
•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDƒ‰ƒbƒg‘æ5˜_ŒoØ’f‚É‚æ‚è—U‹N‚³‚ê‚é_ŒoáŠQ«áu’É‚¨‚æ‚ÑÒ‘Œãª_Œoß‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹”Œ»‘‰Á‚Ö‚Ì“]ŽÊ’²ßˆöŽqEgr-1‚Æ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚ÌŠÖ—^D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2015D2015, 8, 27-28, ‘D‹´Diƒ|ƒXƒ^[j
298.
씨“ÄŽjDPAR2‚Æ’É‚ÝD“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ï‘æ49‰ñ‘å‰ïD2015, 7, 24-25,
‘åãDiµ‘ÒFµ¿u‰‰j
299.
’Ø“c^”¿AΈä—DŽqA’†–ì^ŠóAŠ’J—œŠGA¼–x³—mA씨“ÄŽjDButyrate—U‹N‰ß•q«’°ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚錋’°’ÉŠo‰ß•q‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑHMGB1‚ÌŠÖ—^D‘æ127‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2015, 6, 26, Šò•ŒDiŒû“ª”•\j
300.
“ü]—I•½A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDCerulein—U‹Nƒ}ƒEƒX‹}«äX‰Šƒ‚ƒfƒ‹‚É‚¨‚¯‚éäX‘Ÿ’É‚Ì”Œ»EˆÛŽ‚ɂ̓}ƒNƒƒtƒ@[ƒW—R—ˆhigh mobility
group box 1‚É‚æ‚éRAGE‚¨‚æ‚ÑCXCR4‚ÌŠˆ«‰»‚ªŠÖ—^‚·‚éD‘æ127‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2015, 6, 26, Šò•ŒDiŒû“ª”•\j
301.
Ž›“c˜Ð‰ÁA’Ø“c^”¿AŠÖŒû•x”üŽqA˜a“c‹±ˆêAú㌴Œ’A‚“c[—²A씨“ÄŽjD‹}«äX‰ŠEäX‘Ÿ’É“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½•a‘Ô‰ðÍFTŒ^ Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑTRPƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ135”N‰ï@u‘åŠw‰@¶ƒVƒ“ƒ|ƒWƒEƒ€vA2015, 3, 26-28,
_ŒËDiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
302.
“V‰Hˆê‹RA‘å–ì@ä¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¢‚Ä—°‰»…‘fƒhƒi[Na2S‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚Ä_Œo“Ë‹NL’·‚ð‘£i‚·‚éF×–E‚Ì‘å‚«‚³‚É‚æ‚éŒø‰Ê‚̈Ⴂ‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3,
26-28, _ŒËDiƒ|ƒXƒ^[”•\j
303.
•Ÿ“c—º‘¾˜YAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽjDHMGB1‚Íoxaliplatin—U‹N_ŒoáŠQ«áu’É‚Ì”Œ»‚¨‚æ‚шێ‚ÉŠÖ—^‚·‚éD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3,
26-28, _ŒËDiƒ|ƒXƒ^[”•\j
304.
ó–ìŠG仉ÖC[ŠC˜aŽ÷CŠÖŒû•x”üŽqC‘×ì–¢—ˆAŠ}¼—²“ñA‹g“c”ÉA씨“ÄŽjD‚ƒOƒ‹ƒR[ƒXðŒ‰º‚Å”|—{‚µ‚½_Œo“à•ª”å—l•ª‰»ƒqƒg‘O—§‘BŠàLNCaP×–E‚É‚¨‚¯‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Ì“œ½Cü‚É‚æ‚é‹@”\‘‹‚Æ•ª”å‹@”\˜´iD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3,
26-28, _ŒËDiƒ|ƒXƒ^[”•\j
305.
‘ºãi’†ŽRj‰ë—TA’‹”n²‹IA’Ø“c^”¿AŠÖŒû•x”üŽqA¼ŽRŒ«Ž¡3A–Ø‘ºŒ’4AXŽR‰ëO2A씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚Ì—\–hEŽ¡—ÃŒø‰ÊD“ú–{–òŠw‰ï‘æ135”N‰ïD2015, 3,
26-28, _ŒËDiƒ|ƒXƒ^[”•\jD
306.
’Ø“c^”¿A씨“ÄŽjDHMGB1‚ð•W“I‚Æ‚·‚é“à‘Ÿ’ÉŽ¡—ÃD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uHMGB1‚ð•W“I‚Æ‚·‚鎡—ÂÌV‹K“WŠJvA‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3,
18-20, –¼ŒÃ‰®DiƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[j
307.
[ŠC˜aŽ÷Aó–ìŠG仉ÖAŠÖŒû•x”üŽqA‘×ì–¢—ˆAŠ}¼—²“ñA‹g“c”ÉA씨“ÄŽjD_Œo“à•ª”å—l•ª‰»‚µ‚½‘O—§‘BŠàLNCaP×–E‚É‚¨‚¢‚Ä‚ƒOƒ‹ƒR[ƒXðŒ‰º‚Å‚ÌCav3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌN-Œ‹‡Œ^ƒOƒŠƒRƒVƒ‹‰»‚É‚æ‚蕪”å‹@”\‚ª˜´i‚·‚éD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3,
18-20, –¼ŒÃ‰®DiŒû“ª”•\j
308.
ŽR‘Z‘å’qAŠÖ—R‰Á—¢AŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA”ª–ØGŽ÷A‰vŽq@‚A¼–x³—mA씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚ÍNF-kBŒn‚ð‰î‚µ‚ĉŠÇ«’ÉŠo‰ß•q‚ÉŠñ—^‚·‚éD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3,
18-20, –¼ŒÃ‰®DiŒû“ª”•\E‰pŒêj
309.
•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚Ì’mŠo_Œo‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹”Œ»—U“±‚É‚Í“]ŽÊˆöŽqEgr-1‚¨‚æ‚Ñ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚ªŠÖ—^‚·‚éD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3,
18-20, –¼ŒÃ‰®DiŒû“ª”•\E‰pŒêj
310.
’‹”n²‹IA‘ºãi’†ŽRj‰ë—TA’Ø“c^”¿AŠÖŒû•x”üŽqA¼ŽRŒ«Ž¡A–Ø‘ºŒ’AXŽR‰ëOA씨“ÄŽjD@ˆŸ‰”ŠÜ—L»Üƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚Ìcyclophosphamide—U‹NäNã÷‰ŠEäNã÷’ɂɑ΂·‚é—\–h‚¨‚æ‚ÑŽ¡—ÃŒø‰ÊD‘æ88‰ñ“ú–{–ò—Šw‰ï”N‰ïD2015, 3,
18-20, –¼ŒÃ‰®DiŒû“ª”•\j
311.
Kawabata, A., Kawaishi, Y., Nishida, T., Yamanishi, H.,
Kamitani, N., Tsubota, M., Sekiguchi, F., Ishikura, H., Nishibori, M. High
mobility group box 1 as a target for prevention and therapeutic treatment of
chemotherapy-induced neuropathic pain. Pharmacology 2014. 2014, 12, 16-28,
London. (Oral)
312.
Terada, Y., Tsubota, M., Sekiguchi, F., Wada, K., Kuwahara, T.,
Takada, M., Kawabata, K. Effect of tacrolimus on caerulein-induced
pancreatitis-related pain in mice. Pharmacology 2014. 2014, 12, 16-28, London.
(Poster)
313.
Ozaki, T., Tsubota, M., Kawabata, A. The NK1 receptor antagonist
prevents the cyclophosphamide-induced cystitis-related bladder pain and
upregulation of cystathionine-ƒÁ-lyase, an H2S-generating enzyme, in
mice. Pharmacology 2014. 2014, 12, 16-28, London. (Poster)
314.
Ohno, S., Kanaoka, D., Ide, H., Sekiguchi, F., Yoshida, S.,
Fukunaga, K., Kawabata, A. The novel cognitive enhancer ST101 induces neurite
outgrowth in NG108-15 cells and hyperalgesia in mice through T-type Ca2+
channels. Pharmacology 2014. 2014, 12, 16-28, London. (Poster)
315.
Irie, Y., Kubo, L., Tsubota, M., Sekiguchi, F., Ishimura, H.,
Nishibori, M., Kawabata, A. Involvement of high mobility group box 1 in
substance P-induced cystitis-related bladder pain in mice. Pharmacology 2014.
2014, 12, 16-28, London. (Poster)
316.
Ž›“c˜Ð‰ÁA¼ˆä˜aŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA˜a“c‹±ˆêAú㌴@Œ’Aûü“c[—²A씨“ÄŽjDCalcineurin‘jŠQ–òtacrolimus‚Ícapsaicin—U‹NŒ‹’°’É‚¨‚æ‚Ñcerulein—U‹N‹}«äX‰ŠŠÖ˜A’É‚ð‘‹‚·‚éD‘æ126‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2014, 10,
24, ˜a‰ÌŽRDioralj
317.
•y“cŽDAŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjD‘æ5˜_ŒoØ’f_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚É‚¨‚¯‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹”Œ»‘‰Á‹@˜‚̉ðÍF“]ŽÊ’²ßˆöŽqEgr-1‚Æ’Eƒ†ƒrƒLƒ`ƒ“‰»y‘fUSP5‚Ì‹““®‚ɂ‚¢‚ÄD‘æ126‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2014, 10,
24, ˜a‰ÌŽRDioralj
318.
ŽR‘Z‘å’qAŠÖ—R‰Á—¢AŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA”ª–ØGŽ÷A‰vŽq@‚A¼–x³—mA 씨“ÄŽjDƒ}ƒNƒƒtƒ@[ƒW—R—ˆHMGB1‚̉ŠÇ«’ÉŠo‰ß•q‚Ö‚ÌŠÖ—^‚Æ•ªŽqì—pƒƒJƒjƒYƒ€‚̉ðÍD‘æ126‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2014, 10,
24, ˜a‰ÌŽRDioralj
319.
Kawabata, A. Hydrogen sulfide: Importance of T-type calcium
channels as the molecular target. International Symposium gGasotransmitters:
Physiology and Pathophysiologyh. 2014, 9, 21-23, Kazan, Russia. (Invited
lecture)
320.
Ozaki, T., Tsubota, M., Kawabata, A. Mechanims for upregulation
of cystathionine-gamma-lyase, a hydrogen sulfide-generating enzyme, in mice
with cyclophosphamide-induced cystititis: Involvement of substance P/NK1
pathway and NF-kappaB signals. International Symposium gGasotransmitters:
Physiology and Pathophysiologyh. 2014, 9, 21-23, Kazan, Russia. (Poster)
321.
•y“cŽDAŠ¢˜Ð”nAŠÖŒû•x”üŽqAìΗY‘åA’Ø“c^”¿A‹g“c@”ÉA‘å‹v•Û‚‚âŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚Ì“d‹C¶—Šw“I«Ž¿‚¨‚æ‚Ñ_ŒoáŠQ«áu’ɂɑ΂·‚é—}§Œø‰ÊDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2014.
2014, 8, 30, “Œ‘åãD(Poster)
322.
™–{—ËAã“cضAŠÖŒû•x”üŽqA씨“ÄŽj. . Histone deacetylase‘jŠQ–ò‚Í“àˆö«high
mobility group box 1—V—£‚ð‰î‚µ‚Ä_Œo‘O‹ì×–EŠ”NG108-15×–E‚Ì_Œo“Ë‹NL’·‚ð—U‹N‚·‚éDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2014.
2014, 8, 30, “Œ‘åãD(Poster)
323.
¼ˆä˜aŽ÷AŽ›“c˜Ð‰ÁA’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDCapsaicin—U‹NŒ‹’°’ɂɑ΂·‚écalcineurin‘jŠQ–òFK506‚Ì‘‹Œø‰ÊDŽŸ¢‘ã‚ð’S‚¤‘n–òEˆã—Öò—ƒVƒ“ƒ|ƒWƒEƒ€2014.
2014, 8, 30, “Œ‘åãD(Poster)
324.
Sekiguchi, F., Kawabata, ADExploration
of novel T-type Ca2+ channel inhibitors for treatment of intractable
painDƒVƒ“ƒ|ƒWƒEƒ€5uNovel therapeutic strategy for treatment of painvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014.
2014, 8, 28-29, “Œ‘åãD(ƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[)
325.
’Ø“c^”¿A씨“ÄŽjDƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ð—p‚¢‚½’É‚Ý‚ÌŽ¡—ÃFHMGB1‹z’…E•ª‰ð‘£iì—p‚ÌŠÖ—^DƒVƒ“ƒ|ƒWƒEƒ€4uŒŒ‰t‹ÃŒÅEü—nŒnŠÖ˜AˆöŽq‚ð•W“I‚Æ‚µ‚½‘n–òŒ¤‹†‚ÌV“WŠJvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014.
2014, 8, 28-29, “Œ‘åãD(ƒVƒ“ƒ|ƒWƒEƒ€ƒXƒs[ƒJ[)
326.
Ž›“c˜Ð‰ÁA’Ø“c^”¿AŠÖŒû•x”üŽqA˜a“c‹±ˆêAú㌴@Œ’Aûü“c[—²A씨“ÄŽj.@Calcineurin‘jŠQ–òtacrolimus‚ÍTRPV1‚ð‰î‚µ‚Äcerulein—U‹N‹}«äX‰ŠŠÖ˜A’É‚ð‘‹‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014.
2014, 8, 28-29, “Œ‘åãD(Poster)
327.
’‹”n²‹IA’†ŽR‰ë—TA’Ø“c^”¿AŠÖŒû•x”üŽqA¼ŽRŒ«Ž¡A–Ø‘ºŒ’AXŽR‰ëOA씨“ÄŽj.@ƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚Ícyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚鉊ÇÇ󂨂æ‚ÑäNã÷’É‚ð—}§‚·‚éD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014, 8,
28-29, “Œ‘åãD(Poster)
328.
’†ŽR‰ë—TA’†‘º‹ŽuA“Œ@„ŽjA¼ŽRŒ«Ž¡AXŽR‰ëOA–Ø‘º@Œ’A씨“ÄŽjDƒ|ƒ‰ƒvƒŒƒWƒ“ƒN‚ðŽg—p‚µ‚½ŠÜšu‰t‚̈À’è«‚Æ•úŽËü«Œûo”S–Œ‰Š‚ɑ΂·‚é—Õ°•]‰¿. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,
8, 28-29, “Œ‘åãD(Poster)
329.
“c•Ó
q,
¼‰º ãÄŽq, ¼–{ ‰ÄŠC, ’·ˆä ‹IÍ, ˆÉ“¡ ‹g›’, ¼ì —T”V, 씨 “ÄŽjDƒiƒm‰»‹Zp‚ð—p‚¢‚½V‹K’ŽË—p»Ü‚ÌŠJ”‚Æ‚»‚Ì—L—p«•]‰¿@|ƒVƒƒXƒ^ƒ][ƒ‹Ã–¬“à“Š—^‚É‚æ‚é”][ÇŽ¡—Ã|D@¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2014. 2014,
8, 28-29, “Œ‘åãD(Poster)
330. Kawabata,
A., Kawaishi, Y., Nishida, T., Yamanishi, H., Kamitani, N., Tsubota, M.,
Ishikura, H., Sekiguchi, F., Nishibori, M. Prevention and reversal of
chemotherapy-induced neuropathic pain by HMGB1 neutralization in rodents. 9th
FENS Forum of European Neuroscience, 2014, 7, 5-9, Milan, Italy. (Poster)
331. Sekiguchi,
F., Fujita, T., Deguchi, T., Ichii, M., Yamaoka, S., Nishikawa, H., Yoshida,
S., Murata, K., Matsuda, M., Ohkubo, T., Kawabata, A. Sophoraflavanone G as a
novel T-type Ca2+ channel inhibitor: electrophysiological evidence
in Cav3.2-expressing HEK293 cells and anti-hyperalgesic activity in
mice. 9th FENS Forum of European Neuroscience, 2014, 7, 5-9, Milan,
Italy. (Poster)
332. ŠÖŒû•x”üŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òsophoraflavanone
G‚Ì–ò—Šw“I“Á’¥‚Æ’ÉŠo‰ß•q—}§Œø‰ÊD‘æ36‰ñ“ú–{áu’ÉŠw‰ïD2014, 6, 20-21, ‘åãDiOralj
333. ‹v•Û—¢ŽÑA’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjD‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚¨‚æ‚ÑRHMGB1’†˜aR‘Ì‚Ílipopolysaccharide‚ ‚é‚¢‚Ísubstance PäNã÷“à’“ü‚É‚æ‚è—U‹N‚³‚ê‚éäNã÷’É‚ð—}§‚·‚éD‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6,
20, ‰ªŽRDiOralj
334. ŽRŒûŒOA“c’†ˆêA’Ø“c^”¿AŠÖŒû•x”üŽqAŠÖ—R‰Á—¢AΑqG‹±A¼–x³—mA씨“ÄŽjDCyclophosphamide—U‹Nƒ}ƒEƒXäNã÷‰Šƒ‚ƒfƒ‹‚É‚¨‚¯‚éäNã÷’ɔǃƒJƒjƒYƒ€‚̉ðÍFŠj“à’`”’HMGB1‚Æ“àˆö«H2S‚Ì–ðŠ„D‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6,
20, ‰ªŽRDiOralj
335. ã–VŒ’‘¾AŽO–ØD‹PA’Ø“c^”¿AŠÖŒû•x”üŽqA‹ß“¡‰Ã‚A‚‹´Œo‘¾A‘•x—T•¶AÎ_ºlA씨“ÄŽjDCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‘jŠQ‚·‚éascorbic
acid‚ÌŒ‡–R‚Í—°‰»…‘f‚É‚æ‚é‘Ì«’ÉE“à‘Ÿ’É‚¨‚æ‚Ñpaclitaxel—U‹N_ŒoáŠQ«áu’É‚ð‘‹‚·‚éD‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6,
20, ‰ªŽRDiOralj
336.
¬–¸Ê‰ÁAŠÖ–{WŒÈAŠÖŒû•x”üŽqA씨“ÄŽjDƒqƒgˆÝŠà—R—ˆAGS×–E‚É‚¨‚¯‚é“àˆö«—°‰»…‘f‚Ì×–E‘B‚Ö‚ÌŠÖ—^‚Æ‚»‚̉º—¬ƒVƒOƒiƒ‹‚̉ðÍD‘æ125‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2014, 6,
20, ‰ªŽRDiPosterj
337. Fukami,
K., Kawabata, A. Roles of hydrogen sulfide and T-type calcium channels in
neuroendocrine-differentiated prostate cancer cells at androgen-independent
stage. Anti-Aging International Mini-Symposium 2014: Cell Signaling and
Therapeutic Targets for Geriatric and Inflammatory Diseases. 2014, 6, 7,
Higashi-Osaka. (Oral)
338. Kawabata,
A. Roles of the hydrogen sulfide-Cav3.2 T-type calcium channel
pathway in neuronal and neuroendocrine differentiation. Third International
Conference on Hydrogen Sulfide in Biology and Medicine, 2014, 6, 4-6, Kyoto.
(Invited lecture).
339. Sekiguchi,
F., Takeda, Y., Kanaoka, D., Yoshida, S., Kawabata, A. Involvement of
endogenous hydrogen sulfide and T-type calcium channels in cyclic AMP-induced
neuronal differentiation in NG108-15 cells. Third International Conference on
Hydrogen Sulfide in Biology and Medicine, 2014, 6, 4-6, Kyoto. (Poster)
340. Tsubota,
M., Uebo, K., Miki, K., Sekiguchi, F., Kondo, Y., Takahashi, K., Masutomi, H.,
Ishigami, A., Kawabata, A. Ascorbic acid deficiency augments hyperalgesia
induced by hydrogen sulfide in mice. Third International Conference on Hydrogen
Sulfide in Biology and Medicine, 2014, 6, 4-6, Kyoto. (Poster)
341. ’Ø“c^”¿A씨“ÄŽjDŒ‹’°‚Ìáu’É‚¨‚æ‚щŠÇ‚É‚¨‚¯‚éƒKƒXóî•ñ“`’B•¨Ž¿—°‰»…‘f‚Ì–ðŠ„D“ú–{–òŠw‰ï‘æ134”N‰ï@ƒVƒ“ƒ|ƒWƒEƒ€uŽáŽè–ò—ŠwŽÒ‚ªŠJ‘ñ‚·‚é“«Ž¾Š³‚ÌŽ•ž‚ð–ÚŽw‚µ‚½ŽŸ¢‘ã‘n–òEˆç–òŒ¤‹†v2014, 3, 27-30,
ŒF–{iƒVƒ“ƒ|ƒWƒEƒ€j
342. Kawabata,
A. Roles
of Cav3.2 T-type Ca2+ channels in prostate cancer cells:
impact on an androgen-independent stage. Symposium gNovel aspects of voltage-gated@Ca2+
channels: emerging trends for drug developmenth organized by
Kawabata, A. and Mochida, S., ‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiƒVƒ“ƒ|ƒWƒEƒ€F‰pŒêj
343. ¼“c•ŽiAìΗY‘åAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽjDƒrƒ“ƒNƒŠƒXƒ`ƒ“—U‹N_ŒoáŠQ«áu’Ƀ‰ƒbƒg‚É‚¨‚¯‚éRHMGB1’†˜aR‘̂ƈâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚Ì—\–hEŽ¡—ÃŒø‰ÊD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äioralj
344. ŠÖŒû•x”üŽq, “¡“c—F‘ã, oŒû‹M_, Žsˆä^‹M, ¼ì—T”V, ‹g“c@”É, ‘º“c˜a–ç, ¼“cGH,‘å‹v•Û‚‚âŽq, 씨“ÄŽjD‹êŽQ—R—ˆsophoraflavanone
G‚¨‚æ‚Ñ‚»‚Ì—Þ‰‘Ì‚ÌTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQŠˆ«‚Æ’ÉŠo‰ß•q—}§Œø‰ÊD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj
345. Ž›“c˜Ð‰Á, ’Ø“c^”¿, ŠÖŒû•x”üŽq, ˜a“c‹±ˆê, ú㌴@Œ’, ûü“c[—², 씨“ÄŽjDƒJƒ‹ƒVƒjƒ…[ƒŠƒ“‘jŠQ–òƒ^ƒNƒƒŠƒ€ƒX‚̓JƒvƒTƒCƒVƒ“—U‹NŒ‹’°’É‚ð‘‹‚·‚éD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj
346. ‘å–ì@ä¿A‹à‰ª‘åŽ÷AˆäŽè—mŽ÷AŠÖŒû•x”üŽqA‹g“c@”ÉA•Ÿ‰i_ŽiA씨“ÄŽjDV‹K”F’m‹@”\‰ü‘P–òST101‚É‚æ‚è—U‹N‚³‚ê‚éNG108-15×–E‚É‚¨‚¯‚é_Œo“Ë‹NL’·‘£iì—p‚ƃ}ƒEƒX‚É‚¨‚¯‚é’ÉŠo‰ß•q‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj
347. ìΗY‘åAŽR¼LŽ÷A’Ø“c^”¿AŠÖŒû•x”üŽqA¼“c•ŽiAΑqG‹±A¼–x³—mA씨“ÄŽji”•\ŽÒjD’†˜aR‘̂ƈâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚É‚æ‚éHMGB1•sŠˆ‰»‚̓‰ƒbƒg‚¨‚æ‚у}ƒEƒX‚É‚¨‚¯‚éƒpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_ŒoáŠQ«áu’É‚ð—}§‚·‚éD‘æ87‰ñ“ú–{–ò—Šw‰ï”N‰ï@2014”N3ŒŽ19-21“úAå‘äiposterj
348. Kawabata,
A., Tanaka, J., Yamaguchi, K., Ishikura, H., Tsubota, M. Involvement
of high mobility group box 1 in cyclophosphamide-induced cystitis-related
bladder pain in mice. Pharmacology 2013, 2013, 12, 17-19, London.
349. Kawabata,
A., Miyamoto, Y., Sekiguchi, F., Kanaoka, D., Yoshida, S., Ohkubo, T. Facilitation
of T-type calcium currents by endogenous and exogenous hydrogen sulfide in Cav3.2-expressing
HEK293 cells. Neuroscience 2013, 2013, 11, 9-13, San Diego, USA. (poster)
350. Sekiguchi,
F., Kawara, Y., Kanaoka, D., Kawaishi, Y., Tsubota, M., Kawakami, E., Ozaki,
T., Yoshida, S., Okubo, T., Kawabata, A. RQ-00311651, a
novel T-type Ca2+ channel blocker: electrophysiological
characterization and anti-hyperalgesic/anti-allodynic activity in somatic and
visceral pain models. Neuroscience 2013, 2013, 11, 9-13, San Diego, USA.
(poster)
351. Terada,
Y., Fujimura, M., Nishimukra, S., Tsubota, M., Kawabata, A. Roles
of TRPA1 channels in addition to Cav3.2 or TRPV1 as the downstream
signal of hydrogen sulfide or proteinase-activated receptor-2 in the
development of pancreatic pain. Neuroscience 2013, 2013, 11, 9-13, San Diego,
USA. (poster)
352. Tanaka,
J., Ishikura, H., Yamaguchi, K., Tsubota, M., Sekiguchi, F., Seki, Y.,
Kawabata, A. Recombinant human soluble thrombomodulin abolishes bladder pain
accompanying cyclophosphamide-induced cystitis in mice. Neuroscience 2013,
2013, 11, 9-13, San Diego, USA. (poster)
353. ŠÖŒû•x”üŽq, ‹{–{—z‰î, ‹à‰ª‘åŽ÷, ˆäŽè—mŽ÷, ‹g“c@”É, ‘å‹v•Û‚‚âŽqC씨“ÄŽjDCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹”Œ»HEK293×–E‚É‚¨‚¢‚Ä“àˆö«‚¨‚æ‚ÑŠOˆö«—°‰»…‘f‚̓`ƒƒƒlƒ‹‹@”\‚ð‘‹‚·‚éD‘æ124‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N11ŒŽ1“úA‹ž“s. (oral)
354. ’|’†GA’†‘º‘DA’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚Äprostaglandin E2‚É‚æ‚è—U‹N‚³‚ê‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é‹@ŠB“I’ÉŠo‰ß•q‚Ì“Á’¥FEP2/PKAŒo˜H‚É‚¨‚¯‚é‘«êƒ^ƒ“ƒpƒNAKAP150‚Ìd—v«‚ÆEP1/PKCŒo˜H‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ124‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N11ŒŽ1“úA‹ž“s. (poster)
355. Ž›“c˜Ð‰ÁA“¡‘ºä—RŽqA¼‘ºK—eA’Ø“c^”¿A씨“ÄŽj. TRPA1‚ÍPAR2‚̉º—¬ƒVƒOƒiƒ‹•ªŽq‚Æ‚µ‚ÄTRPV1‚Æ‚Æ‚à‚ÉäX‰ŠŠÖ˜A’ÉŠo‰ß•q‚Ì”ÇEˆÛŽ‚ÉŠñ—^‚·‚é. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
356. Ž›“c˜Ð‰ÁA“¡‘ºä—RŽqA¼‘ºK—eA’Ø“c^”¿A씨“ÄŽj. äX‘Ÿ’É”Œ»‚É‚¨‚¯‚éH2S‰º—¬ƒVƒOƒiƒ‹•ªŽq‚Æ‚µ‚Ä‚ÌCav3.2‚¨‚æ‚ÑTRPA1‚Ì–ðŠ„FŒ’펞‚Æ‹}«äX‰Š”ÇŽž‚̈Ⴂ. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
357. ã–VŒ’‘¾AŽO–ØD‹PA’Ø“c^”¿AŠÖŒû•x”üŽqA‹ß“¡‰Ã‚A‚‹´Œo‘¾A‘•x—T•¶AÎ_ºlA씨“ÄŽj. ƒ}ƒEƒX‚É‚¨‚¯‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é—°‰»…‘f‚Ì’É‚Ý‘£iŒø‰Ê‚̓AƒXƒRƒ‹ƒrƒ“Ž_Œ‡–R‚É‚æ‚è‘‘å‚·‚éF
SMP30/GNLƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
358. ‹v•Û—¢ŽÑA’Ø“c^”¿AŠÖŒû•x”üŽqAΑqG‹±A¼–x³—mA씨“ÄŽj. LipopolysaccharideäNã÷“à’“ü‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒXäNã÷‰ŠEäNã÷’ɂɑ΂·‚é‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÌŒø‰ÊF“Š—^—Ê‚É‚æ‚éˆá‚¢. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
359. ’|“c—DŠóA‹à‰ª‘åŽ÷AŠÖŒû•x”üŽqA‹g“c”ÉA씨“ÄŽj.
NG108-15×–E‚É‚¨‚¯‚édibutyryl cyclic AMP—U‹N_Œo•ª‰»‚Ö‚Ì“àˆö«—°‰»…‘f‚ÆCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
360. ŠÖ—R‰Á—¢A“c’†ˆêAŽRŒûŒOAΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽj. ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÍHMGB1ƒVƒOƒiƒ‹‚ð—}§‚·‚邱‚ƂʼnŠÇ«áu’É‚ð—}§‚·‚é. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
361. ŽRŒûŒOA“c’†ˆêAŠÖ—R‰Á—¢AΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽj. ƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÌäNã÷’É—}§Œø‰ÊFHMGB1‹z’…E•sŠˆ‰»ì—p‚ÌŠÖ—^. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
362. ‘å–ì@ä¿A‹à‰ª‘åŽ÷AˆäŽè—mŽ÷AŠÖŒû•x”üŽqA‹g“c@”ÉA•Ÿ‰i_ŽiA씨“ÄŽj.
V‹K”F’m‹@”\‰ü‘P–òST101‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚ÄNG108-15×–E‚É‚¨‚¯‚é_Œo“Ë‹NL’·‚ƃ}ƒEƒX‚É‚¨‚¯‚é’ÉŠo‰ß•q‚ð—U‹N‚·‚é. ¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2013@2013”N8ŒŽ29-30“úA•Ÿ‰ªiposterj
363. 씨“ÄŽjA’Ø“c^”¿AŠÖŒû•x”üŽqDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̉ŠÇ«áu’É‚¨‚æ‚ÑŠà‰»Šw—Ö@—U‹N_ŒoáŠQ«áu’ɂɑ΂·‚é—\–hEŽ¡—ÃŒø‰ÊFHMGB1‹z’…E•sŠˆ‰»ì—p‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ35‰ñ“ú–{áu’ÉŠw‰ï@2013”N7ŒŽ12-13“úA‚³‚¢‚½‚Üioralj
364. ŠÖŒû•x”üŽqA’Ø“c^”¿A씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚Ì“d‹C¶—Šw“I“Á’¥‚Æ‘Ì«’ÉE“à‘Ÿ’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚é’Á’ÉŒø—ÍD‘æ35‰ñ“ú–{áu’ÉŠw‰ï@2013”N7ŒŽ12-13“úA‚³‚¢‚½‚Üioralj
365. ìΗY‘åAŽR¼LŽ÷A’Ø“c^”¿A¼–x³—mAΑqG‹±A씨“ÄŽjDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚ÍHMGB1ƒVƒOƒiƒ‹‚ð—}§‚·‚邱‚ƂŃpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_ŒoáŠQ«áu’Ƀ‚ƒfƒ‹‚É‚¨‚¢‚Ä—\–h‚¨‚æ‚ÑŽ¡—ÃŒø‰Ê‚ðŽ¦‚·D‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj
366. ‘×ì–¢—ˆA[ŠC˜aŽ÷AŠ}¼—²“ñAŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjDƒqƒg‘O—§‘BŠà—R—ˆLNCaP×–E‚É‚¨‚¯‚écyclic
AMP—U‹N_Œo“à•ª”å—l•ª‰»‚É”º‚¤H2S/Cav3.2Œn‚Ì‹@”\‘‹‚Æ‚»‚Ì•ªŽqƒƒJƒjƒYƒ€D‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj
367. “¡“c—F‘ãAŠÖŒû•x”üŽqAoŒû‹M_A‹g“c@”ÉA‘º“c˜a–çA¼“cGHA‘å‹v•Û‚‚âŽqA씨“ÄŽjD‹êŽQ—R—ˆTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ•¨Ž¿‚ÌŒŸõFƒqƒgCav3.2”Œ»HEK293×–E‚É‚¨‚¯‚é“d‹C¶—Šw“IŒŸ“¢‚ƃ}ƒEƒX‚É‚¨‚¯‚é—°‰»…‘f—U‹N’ÉŠo‰ß•q‚ɑ΂·‚é—}§Œø‰Ê‚Ì•]‰¿D‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj
368. ”öè—FA’Ø“c^”¿A¼‰Y‰À“ߌbA씨“ÄŽjDƒVƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰ŠEäNã÷’ɂɑ΂·‚éNK1Žó—e‘ÌhR–ò‚¨‚æ‚Ñcurcumin‚ÌŒø‰ÊF—°‰»…‘f / TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Œn‚Ìã—¬ƒVƒOƒiƒ‹‚̉ðÍD‘æ123‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2013”N7ŒŽ12“úA–¼ŒÃ‰®ioralj
369. Kawabata,
A. Modulation of Cav3.2 T-type calcium channels by endogenous
mediators: impact on pain signals and others. 3rd International
Calcium Channel Conference, 2013, 3, 24-29, Krabi, Thailand. (Symposium
Speaker)
370. ’Ø“c^”¿A씨“ÄŽjD—°‰»…‘f‚̶—‹@”\‚Æ•a‘Ô‚Ö‚ÌŠÖ—^F“Á‚É“à‘Ÿ’É‚¨‚æ‚Ñ“à‘Ÿ‰ŠÇ‚É‚¨‚¯‚é–ðŠ„D‘æ90‰ñ“ú–{¶—Šw‰ï‘å‰ï ƒVƒ“ƒ|ƒWƒEƒ€u‹C‘Ì•ªŽq‚̃Zƒ“ƒVƒ“ƒO‚ƶ—‹@”\vA•½¬24”N3ŒŽ27-29“úA“Œ‹žDiƒVƒ“ƒ|ƒWƒXƒgj
371. Š¢@˜Ð”n, ŠÖŒû•x”üŽq , ‹à‰ª‘åŽ÷, ìΗY‘å, ’Ø“c^”¿, ‹g“c@”É, ‘å‹v•Û‚‚âŽq, ŽRàV”ü, ‰äŽÓ“¿ˆêA‘å锎s,
ˆäã@‹`, 씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651F–Œ“d—¬‚¨‚æ‚уJƒ‹ƒVƒEƒ€—¬“ü‚ɑ΂·‚é—}§Œø‰Ê‚Æ’Á’ÉŒø—ÍD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)
372. ìãŠG—A’Ø“c^”¿A”öè—FAŠÖŒû•x”üŽqAˆäã‹`A‰œ‘º‹MŽqA씨“ÄŽjDV‹KTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚ÌŠeŽí“à‘Ÿ’ɂɑ΂·‚鎡—ÃŒø‰ÊD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)
373. ŠÖ—R‰Á—¢A“c’†ˆêAŽRŒûŒOAΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̓‰ƒbƒg‚É‚¨‚¢‚ÄHMGB1ˆË‘¶‰ŠÇ«áu’É‚ð—}§‚·‚éD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)
374. ŽRŒûŒOA“c’†ˆêAŠÖ—R‰Á—¢AΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘gŠ·‚¦ƒqƒg‰Â—n«ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̓VƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¯‚éäNã÷’É‚ð—}§‚·‚éD‘æ86‰ñ“ú–{–ò—Šw‰ï”N‰ï 2013”N3ŒŽ21-23“úA•Ÿ‰ªD(poster)
375. ŠÖŒû•x”üŽq, Š¢@˜Ð”n, ‹à‰ª‘åŽ÷, ìΗY‘å, ’Ø“c^”¿, ‹g“c@”É, ‘å‹v•Û‚‚âŽq, ŽRàV”ü, ‰äŽÓ“¿ˆê, ‘å锎s, ˆäã@‹`, 씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚̃`ƒƒƒlƒ‹‘jŠQŒø‰Ê‚Ì“Á’¥‚¨‚æ‚Ñ‘Ì«’ÉŠo‰ß•q‚ɑ΂·‚é—}§Œø‰ÊD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj
376. ’Ø“c^”¿AìãŠG—A”öè—FAŠÖŒû•x”üŽqAˆäã@‹`A‰œ‘º‹MŽqA씨“ÄŽjDV‹KTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–òRQ-00311651‚ÍŠeŽí“à‘Ÿ’É‚ð—}§‚·‚éD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj
377. “c’†ˆêAŽRŒû ŒOAŠÖ—R‰Á—¢AΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘g‚ÝŠ·‚¦‰Â—n«ƒqƒgEƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“‚̃}ƒEƒXŠÔŽ¿«äNã÷‰Šƒ‚ƒfƒ‹‚É‚¨‚¯‚éäNã÷’É—}§Œø‰ÊD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj
378. ‹à‰ª‘åŽ÷AŽR’†—Ú”üAŠÖŒû•x”üŽqA‹g“c ”ÉA씨“ÄŽjDNG108-15×–E‚ƃ‰ƒbƒgŒãª_Œoß×–E‚É‚¨‚¯‚éCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‹@”\‚Ìcyclic AMPˆË‘¶«‘‹ƒƒJƒjƒYƒ€‚̉ðÍD‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj
379. ‘O“c‹MŽjAŽRãp—º‰îAŽO’JŒ’Ž¡A“c’†—F—¢AŠÖŒû•x”üŽqA씨“ÄŽjD’mŠo_Œo×–E‚É‚¨‚¯‚écyclic
AMP—U‹N_Œo“Ë‹NL’·‚ɑ΂·‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑK+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ122‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ï@2012”N11ŒŽ16“úA–L’†Dioralj
380. Kawabata,
A., Nishikawa, H., Matsuda, S., Fukatsu, A., Kurokawa, Y., Tsubota-Matsunami,
M., Tokuyama, S. Blocking T-type calcium channels
protects against the brain injury induced by middle cerebral artery occlusion
and reperfusion in mice. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA.
(poster)
381. Tanaka, J.,
Seki, Y., Yamaguchi, K., Ishikura, H., Tsubota, M., Sekiguchi, F., Kawabata, A.
Recombinant soluble human
thrombomodulin abolishes inflammatory hyperalgesia in
rats. Neuroscience
2012, 2012, 10, 13-27, New Orleans, USA. (poster)
382. Maeda,
T., Mitani, K., Yamagata, R., Sekiguchi, F., Kawabata, A. Molecular mechanisms
for the neurite outgrowth caused by prostaglandin E2 in mouse dorsal
root ganglion cells. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA.
(poster)
383. Kanaoka,
D., Takeda, Y., Sekiguchi, F., Yoshida, S., Kawabata, A. Roles of endogenous
hydrogen sulfide in the cyclic AMP-induced neuronal differentiation in NG108-15
cells. Neuroscience 2012, 2012, 10, 13-27, New Orleans, USA. (poster)
384. Kawabata,
A. Roles of Cav3.2 and TRPA1 channels targeted by hydrogen sulfide
in processing of visceral pain signals in the colon, pancreas and bladder. 7th
International Symposium on Cell/Tissue Injury and
Cyotoprotection/Organoprotection, 2012, 9, 9-11, Honolulu, Hawaii, USA.
(overview)
385. Sekiguchi,
F., Sekimoto, T., Ogura, A., Kawabata, A. Roles of endogenous hydrogen sulfide
in proliferation of gastric cancer cells. 7th International
Symposium on Cell/Tissue Injury and Cyotoprotection/Organoprotection, 2012, 9,
9-11, Honolulu, Hawaii, USA. (oral)
386. Sekiguchi,
F., Matsumoto, Y., Maeda, Y., Tsubota-Matsunami, M., Nishikawa, H., Kawabata,
A. Biological activities of Helicobacter
pylori extracts in various cells: no evidence for involvement of
proteinase-activated receptors? 7th International Symposium on Cell/Tissue
Injury and Cyotoprotection/Organoprotection, 2012, 9, 9-11, Honolulu, Hawaii,
USA. (poster)
387. ŽRãp—º‰îC‘O“c‹MŽjCŽO’JŒ’Ž¡CŠÖŒû•x”üŽqC씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß”|—{×–E‚̃vƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2/cyclic
AMPŒn‚ð‰î‚·‚é_Œo“Ë‹NL’·‚É‚¨‚¯‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑK+ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2012A2012, 8,
30-31, _ŒËD(poster)
388. [’ÈǓÞA¼ì—T”VA¼“cŽÑ’mA•‰Í—SŽqA’Ø“c^”¿A“¿ŽR®ŒáA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é’†‘å”]“®–¬•ÂÇ/ÄŸó—¬—U‹N_ŒoáŠQ‚ɑ΂·‚éTŒ^Ca2+ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚Ì•ÛŒìŒø‰ÊF‹•ŒŒ‘O‚¨‚æ‚Ñğ󗬑O‘¤”]Žº“à“Š—^‚É‚æ‚éŒø‰Ê‚Ì”äŠrD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2012A2012, 8,
30-31, _ŒËD(poster)
389. 씨“ÄŽjD’É‚Ý‚Ìî•ñ“`’B§Œä‚É‚¨‚¯‚é—°‰»…‘fATŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑPAR2‚Ì–ðŠ„DƒVƒ“ƒ|ƒWƒEƒ€u’ɂݧŒä‚ÉŠÖ‚í‚镪Žq‚Æ_Œo‰ñ˜Hv‘æ34‰ñ“ú–{áu’ÉŠw‰ïA2012, 7,
20-21, ŒF–{DiƒVƒ“ƒ|ƒWƒXƒgj@
390. Kawabata,
A. T-type Ca2+ channels and visceral pain: a novel therapeutic
target for treatment of colonic, pancreatic and bladder pain. A Satellite
Symposium of IUPHAR-GI Section, International Ulcer Week 2012, 2012, 7, 12,
Tokyo. (Overview).
391. Kanaoka, D.,
Sekiguchi, F., Nakagawa, M., Aoki Y., Nishimoto Y., Yoshida, S.,
Tsubota-Matsunami, M, Kawabata, A. Prostaglandin E2-induced
sensitization of T-type Ca2+ channels: a mechanism for mechanical
hyperalgesia. A Satellite Symposium of IUPHAR-GI Section, International Ulcer
Week 2012, 2012, 7, 12, Tokyo. (oral).
392. Fukami,
K., Kasamatsu, R., Yasukawa, M., Yoshida, S., Sekiguchi, F., Kawabata, A.
Endogenous H2S formed by cystathionine-ƒÁ-lyase promotes secretory
functions via the activation of Cav3.2 T-type Ca2+ channels
in neuroendocrine-differentiated prostate cancer cells. A Satellite Symposium
of IUPHAR-GI Section, International Ulcer Week 2012, 2012, 7, 12, Tokyo.
(oral).
393. “c’†ˆêAŠÖ—R‰Á—¢AŽRŒûŒOAΑqG‹±A’Ø“c^”¿AŠÖŒû•x”üŽqA씨“ÄŽjDˆâ“`Žq‘g‚ÝŠ·‚¦‰Â—n«ƒqƒgEƒgƒƒ“ƒ{ƒ‚ƒfƒ…ƒŠƒ“‚̃‰ƒbƒg‚É‚¨‚¯‚鉊ǫáu’É—}§Œø‰ÊD‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6,
29, “¿“‡Dioralj
394. ‹à‰ª@‘åŽ÷A’|“c@—DŠóAŠÖŒû@•x”üŽqA‹g“c@”ÉA씨@“ÄŽjDNG108-15×–E‚Ìcyclic
AMP‚ð‰î‚µ‚½_Œo•ª‰»‚Ö‚Ì“àˆö«—°‰»…‘f‚Ì–ðŠ„D‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6, 29, “¿“‡Dioralj
395. Ž›“c˜Ð‰ÁA“¡‘ºä—RŽqA•Ê•{K—eA’Ø“c^”¿A씨“ÄŽjDTRPA1ƒ`ƒƒƒlƒ‹‚Í—°‰»…‘f‚¨‚æ‚ÑPAR2‚̉º—¬ƒVƒOƒiƒ‹•ªŽq‚Æ‚µ‚ÄäX‘Ÿ’É‚Ìî•ñ“`’B‚ÉŠñ—^‚·‚éD‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6,
29, “¿“‡Dioralj
396. ’†‘º‘DA’Ø“c^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚éprostaglandin
E2—U‹N‹@ŠB“I’ÉŠo‰ß•q‚Ì”Œ»‚É‚ÍCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹Šˆ«‰»‚ªŠÖ—^‚·‚é@`ƒvƒƒeƒCƒ“ƒLƒi[ƒ[A‚¨‚æ‚ÑC‚Ì–ðŠ„`D‘æ121‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2012, 6,
29, “¿“‡Dioralj
397. Kawabata,
A, Matsunami, M. Hydrogen sulfide and bladder pain. First European Conference
on the Biology of Hydrogen Sulfide, 2012, 6, 15-18, Smolenice, Slovakia.
(overview)
398. ‘å싱¹A¼”g^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¢‚Äsubstance
PäNã÷“à“Š—^‚Í—°‰»…‘f‡¬y‘f‚Ì”Œ»—U“±‚ÆCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠˆ«‰»‚ð‰î‚µ‚ÄäNã÷’É^ŠÖ˜A’ÉŠo‰ß•q‚ð—U‹N‚·‚éD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3,
28-31, ŽD–yDioralj
399. ’‡¼hŠóA‘å‹v•ÛŽõA¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽjD‘æ‚T˜_ŒoØ’f—U‹N_ŒoáŠQ«áu’ɂɑ΂·‚é—¼e”}«ƒAƒXƒRƒ‹ƒrƒ“Ž_—U“±‘Ìdisodium
isostearyl 2-O-l-ascorbyl phosphateiDI-VCPj‚Ì‹ÇŠ“K—p‚É‚æ‚鎡—ÃŒø‰ÊD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3,
28-31, ŽD–yDioralj
400. ŠÖ–{WŒÈAŠÖŒû•x”üŽqA씨“ÄŽjDˆÝŠà×–E‚É‚¨‚¯‚é“àˆö«—°‰»…‘f‚Ì×–E‘B‘£iì—p‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3,
28-31, ŽD–yDiposterj
401. Š}¼—²“ñA[ŠC˜aŽ÷A‘×ì–¢—ˆAŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjD_Œo“à•ª”å—l•ª‰»‚µ‚½‘O—§‘BŠà—R—ˆLNCaP×–E‚É‚¨‚¯‚é“àˆö«—°‰»…‘f^TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Œn‚ÌŠˆ«˜´i‚Æ•ª”å‹@”\‘‹‚ɂ‚¢‚ÄD“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3,
28-31, ŽD–yDiposterj
402. ŽR’†—Ú”üA‘O“c—D–AŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXœ‰è×–E—lMC3T3-E1×–E‚É‚¨‚¯‚éproteinase-activated
receptor-1‚ð‰î‚µ‚½prostaglandin E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ÌŒŸ“¢D“ú–{–òŠw‰ï‘æ132”N‰ïA2012, 3,
28-31, ŽD–yDiposterj
403. 씨“ÄŽjDCav3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð•W“I‚Æ‚µ‚½Šà‰»Šw—Ö@—U‹N_ŒoáŠQ«áu’É‚ÌŽ¡—Ãí—ªDƒVƒ“ƒ|ƒWƒEƒ€uŠà‰»Šw—Ö@‚É”º‚¤_ŒoáŠQ«áu’É\Å‹ß‚ÌŒ¤‹†“®ŒüviƒI[ƒKƒiƒCƒU[F씨“ÄŽjA‘åΗ¹ŽOj‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3,
14-16, ‹ž“sDiƒVƒ“ƒ|ƒWƒXƒgj
404. ŠÖŒû•x”üŽqAŠÖ–{WŒÈA씨“ÄŽjDˆÝŠà×–E‚É‚¨‚¢‚Ä“àˆö«‚ÉŽY¶‚³‚ê‚é—°‰»…‘f‚ÍŠà×–E‘B‚ÉŠÖ—^‚·‚éD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3,
14-16, ‹ž“sDioralj
405. ‘å‹v•ÛŽõA’‡¼hŠóA¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽjD‘æ5˜_ŒoØ’f_ŒoáŠQ«áu’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚éV‹K—¼e”}«ƒAƒXƒRƒ‹ƒrƒ“Ž_—U“±‘Ìdisodium
isostearyl 2-O-L-ascorbyl phosphate“îp‚Ì’Á’ÉŒø‰ÊD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3,
14-16, ‹ž“sDioralj
406. ¼”g^”¿A‘å싱¹A‘å‹v•ÛŽõAŠÖŒû•x”üŽqA씨“ÄŽjDƒTƒuƒXƒ^ƒ“ƒXP—U‹N’x”«äNã÷’Ƀ}ƒEƒXƒ‚ƒfƒ‹‚ð—p‚¢‚½ŠÔŽ¿«äNã÷‰Š‚Ì•ªŽq•a‘Ô‰ðÍF“àˆö«—°‰»…‘f‚ÆCav3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì–ðŠ„‚É‚Â‚¢‚ÄD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3, 14-16, ‹ž“sDiposterj
407. ¼ì—T”VA¼“cŽÑ’mA[’ÈǓÞA•‰Í—SŽqA¼”g^”¿A“¿ŽR®ŒáA씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQÜ‚Ì‹•ŒŒ«”]áŠQŽ¡—Âւ̉ž—pD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3,
14-16, ‹ž“sDiposterj
408. ‘O“c‹MŽjAŽO’JŒ’Ž¡AŽRãp—º‰îAŠÖŒû•x”üŽqA씨“ÄŽjDƒ}ƒEƒXŒãª_Œoß×–E‚É‚¨‚¯‚éprostaglandin
E2/cyclic AMPŒn‚ð‰î‚µ‚½_Œo“Ë‹NL’·‚Ì•ªŽqƒƒJƒjƒYƒ€‚̉ðÍD‘æ85‰ñ“ú–{–ò—Šw‰ï”N‰ïA2012, 3,
14-16, ‹ž“sDiposterj
409. Kawabata,
A., Matsunami, M., Miki, T., Nishiura, K., Hayashi, Y., Okawa, Y., Sekiguchi,
F. Impact of Cav3.2 T-type calcium channels targeted by hydrogen sulfide on
bladder nociception. Neuroscience 2011, 2011, 11, 12-16,
Washington, DC. (poster)
410. Okubo, K.,
Matsumura, M., Kawaishi, Y., Matsunami, M., Kawabata, A. Involvement
of Cav3.2 T-type calcium channels and TRPA1 channels in mechanical
hyperalgesia induced by hydrogen sulfide in mice. Neuroscience 2011, 2011, 11,
12-16, Washington, DC. (poster)
411. Sekiguchi,
F., Kanaoka, D., Nakagawa, M., Aoki, Y., Nishimoto, Y., Yoshida, S., Matsunami,
M., Kawabata, A. AKAP-dependent modulation of phosphorylation levels of Cav3.2
T-type calcium channels by protein kinase A and calcineurin: implications for mechanical
pain sensitivity. Neuroscience 2011, 2011, 11, 12-16, Washington, DC. (poster)
412. Kanaoka,
D., Sekiguchi, F., Nakagawa, M., Aoki, Y., Nishimoto, Y., Yoshida, S.,
Matsunami, M., Kawabata, A. Sensitization of T-type calcium channels by
prostaglandin E2 via the EP4 receptor/cyclic AMP/protein kinase A
pathway: a possible mechanism for mechanical hyperalgesia. Neuroscience 2011,
2011, 11, 12-16, Washington, DC. (poster)
413. Maeda,
T., Mitani, K., Yamagata, R., Sekiguchi, F., Kawabata, A. Molecular
mechanisms for the morphine-sensitive neurite outgrowth caused by prostaglandin
E2 in sensory neuron-like ND7/23 cells. Neuroscience 2011, 2011, 11,
12-16, Washington, DC. (poster)
414. ¼”g^”¿A‘å싱¹A씨“ÄŽjDƒTƒuƒXƒ^ƒ“ƒX‚o‚ÌäNã÷“à“Š—^‚É‚æ‚è—U‹N‚³‚ê‚éäNã÷ŠÖ˜A’ÉŠo‰ß•q‚É‚Í—°‰»…‘f‡¬y‘f‚Ì”Œ»—U“±‚ÆCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ªŠÖ—^‚·‚éD‘æ120‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 11, 11, ‹ž“sD
415. Kawabata,
A. Roles of the hydrogen sulfixde/T-type calcium channel system in somatic and
visceral pain processing. 6th International Symposium on cell/tissue
injury and cytoprotection/organoprotection – Focus on GI tract. 2011, 10,
12-14, St. Petersburg, Russia (invited lecture).
416. 씨“ÄŽjD—°‰»…‘f‚Æ“à‘Ÿ’ÉD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2011uÁ‰»ŠÇŽ¾Š³‚Ì•a‘Ô¶—‚ÆŽ¡—Öò‚ÌŠJ”vA2011, 9,
1-2,“Œ‹žDiƒVƒ“ƒ|ƒWƒXƒgj
417. 씨“ÄŽjDProteinase-activated receptor (PAR)‚̶—“IE•a‘Ô¶—Šw“I–ðŠ„D‘æ16‰ñ“ú–{•a‘ÔƒvƒƒeƒA[ƒ[Šw‰ïŠwpW‰ï@ƒ[ƒNƒVƒ‡ƒbƒvA2011, 8, 27, –L’†Diµ‘Òj
418. ŠÖŒû•x”üŽqA¼”g^”¿A씨“ÄŽjDPGE2—U‹N‹@ŠB“I’ÉŠo‰ß•q‚É‚ÍEP4Žó—e‘Ì^PKAŒn‚É‚æ‚éCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌAKAPˆË‘¶«ƒŠƒ“Ž_‰»‚ªŠñ—^‚·‚éD‘æ33‰ñ“ú–{áu’ÉŠw‰ïA2011, 7,
22-23, ¼ŽRD
419. ‘å‹v•ÛŽõA¼”g^”¿A씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é—°‰»…‘f—U‹N’ÉŠo‰ß•q‚É‚ÍCav3.2
TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÆTRPA1ƒ`ƒƒƒlƒ‹‚Ì—¼•û‚ªŠÖ—^‚·‚éD‘æ33‰ñ“ú–{áu’ÉŠw‰ïA2011, 7,
22-23, ¼ŽRD
420. ¼”g^”¿A씨“ÄŽjDŒ‹’°“à‚̈Ÿ‰”‚Í—°‰»…‘f^TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚½Œ‹’°’É”Œ»‚ð§Œä‚·‚éD‘æ33‰ñ“ú–{áu’ÉŠw‰ïA2011, 7,
22-23, ¼ŽRD
421. ¼“cŽÑ’mA¼ì—T”VA[’ÈǓÞA•‰Í—SŽqA¼”g^”¿A“¿ŽR®ŒáA씨“ÄŽjDƒ}ƒEƒX‚É‚¨‚¯‚é’†‘å”]“®–¬•ÂÇ^ÄŠÒ—¬—U‹N_ŒoáŠQ‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ119‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 7,
8, –¼ŒÃ‰®D
422. ‘O“c‹MŽjAŽO’JŒ’Ž¡AŽRãp—º‰îAŠÖŒû•x”üŽqA씨“ÄŽjD’mŠo_ŒoŒn×–E‚É‚¨‚¯‚éprostaglandin
E2/cyclic AMPŒn‚ð‰î‚µ‚½morphineŠ´Žó«_Œo“Ë‹NL’·D‘æ119‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 7,
8, –¼ŒÃ‰®D
423. ¼–{—S‘¾A–ؗD‰ÀA¼”g^”¿A씨“ÄŽjDƒTƒCƒNƒŠƒbƒNAMPˆË‘¶«TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Š´Žó«‘‘å‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‰ß•q‚ÉŠÖ—^‚·‚é’mŠo_ŒoüˆÛ‚Ì“¯’èFˆÙ”g’·ƒTƒCƒ“”gŽhŒƒ‚ɑ΂·‚锽‰ž‚ðŽw•W‚Æ‚µ‚½ŒŸ“¢D‘æ119‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2011, 7,
8, –¼ŒÃ‰®D
424. ¼”g@^”¿A‘åì@‹±¹A씨@“ÄŽjDƒTƒuƒXƒ^ƒ“ƒXPäNã÷“à’“ü‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒXäNã÷‰Š‚¨‚æ‚ÑŠÖ˜A’ÉŠo‰ß•q‚Ö‚Ì“àˆö«—°‰»…‘f‚ÆTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3,
22-24, ‰¡•lD
425. [ŠC˜aŽ÷AŠ}¼—²“ñA‹g“c@”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD_Œo“à•ª”啪‰»‚µ‚½‘O—§‘BŠà×–E‚É‚¨‚¢‚Ä“àˆö«H2S‚ÍCav3.2 TŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠˆ«‰»‚ð‰î‚µ‚Ä•ª”å‹@”\‚ð‘‹‚·‚éD‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3,
22-24, ‰¡•lD
426. ‘å‹v•ÛŽõA¼‘º@—ÎA¼”g^”¿A씨“ÄŽjD—°‰»…‘f‚É‚æ‚éƒ}ƒEƒX‚Ì‹@ŠB“I’ÉŠo‘‹‚É‚¨‚¯‚éTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑTRPA1ƒ`ƒƒƒlƒ‹‚̈قȂé–ðŠ„D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3,
22-24, ‰¡•lD
427. ‘O“c—D–AŽR’†—Ú”üAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒ}ƒEƒXœ‰è‘O‹ì×–E‚É‚¨‚¯‚éproteinase-activated receptor-1—U‹NƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3,
22-24, ‰¡•lD
428. ¼‰Y‰À“ߌbA¼”g^”¿AŽO–Ø’—TA씨“ÄŽjDCyclophosphamide—U‹NäNã÷‰Š‚É”º‚¤äNã÷’É‚Ì•ÛŽ‚É‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÍŠÖ—^‚·‚邪TRPA1ƒ`ƒƒƒlƒ‹‚ÍŠÖ—^‚µ‚È‚¢D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3,
22-24, ‰¡•lD
429. ØŽm‘ŽqA¼”g^”¿A‰œˆä‹M‘åA씨“ÄŽjDTNBS—U‹NŒ‹’°‰Šƒ‰ƒbƒg‚É‚¨‚¯‚é—°‰»…‘f‚Ì”S–Œ•ÛŒìƒƒJƒjƒYƒ€F’mŠo_Œo‚¨‚æ‚ÑTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ84‰ñ“ú–{–ò—Šw‰ï”N‰ïA2011, 3,
22-24, ‰¡•lD
430. ¼”g^”¿AØŽm‘ŽqA‰œˆä‹M‘åA씨“ÄŽjDŽÀŒ±“IŒ‹’°‰Šƒ‰ƒbƒg‚É‚¨‚¢‚Ä—°‰»…‘f‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚Ä’mŠo_Œo‚ð‹»•±‚³‚¹‚邱‚Æ‚É‚æ‚è•ÛŒìì—p‚ðŽ¦‚·D‘æ118‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 11,
19, ‘åãD
431. ¼‰Y‰À“ߌbA¼”g^”¿AŽO–Ø’—TA씨“ÄŽjD—°‰»…‘f‚ÍTŒ^Ca2+ƒ`ƒƒƒlƒ‹Šˆ«‰»‚ð‰î‚µ‚ÄäNã÷‰Š‚¨‚æ‚ÑäNã÷’É‚ð—U‹N‚·‚éD‘æ118‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 11,
19, ‘åãD
432. ‘O“c—D–AŽR’†—Ú”üAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒ}ƒEƒXœ‰è×–E‘O‹ì×–E‚É‚¨‚¯‚éƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR1Šˆ«‰»‚É‚æ‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹D‘æ118‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 11,
19, ‘åãD
433. [ŠC˜aŽ÷AŠ}¼—²“ñA‹g“c@”ÉAŠÖŒû•x”üŽqA씨“ÄŽjDƒAƒ“ƒhƒƒQƒ“Š´Žó«‘O—§‘BŠà×–E‚Ì_Œo“à•ª”å—l×–E‚Ö‚Ì•ª‰»‚É”º‚¤—°‰»…‘fŽY¶y‘f‚¨‚æ‚ÑTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì”Œ»—U“±F•ª”å‹@”\’²ß‚É‚¨‚¯‚é–ðŠ„D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2010‹ž“sA2010, 9, 9-1, ‹ž“sD
434. ‘O“c‹MŽjCŽO’JŒ’Ž¡CŠÖŒû•x”üŽqC씨“ÄŽjDƒ}ƒEƒXÒ‘Œãª_Œoß”|—{×–E‚É‚¨‚¯‚éprostaglandin
E2—U”_Œo“Ë‹NL’·ƒƒJƒjƒYƒ€‚̉ðÍD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2010‹ž“sA2010, 9, 9-1, ‹ž“sD
435. ‹à‰ª‘åŽ÷CŠÖŒû•x”üŽqC’†ì•‘ŽqC–ؗD‰ÀC¼–{—S‘¾C‹g“c@”ÉC¼”g^”¿C씨“ÄŽjDProstaglandin
E2/cyclic AMP/protein kinase AŒn‚ð‰î‚µ‚½TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì‹@”\‘‹|“d‹C¶—Šw“I‚¨‚æ‚Ñs“®–ò—Šw“IŽè–@‚ð—p‚¢‚½ŒŸ“¢D¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2010‹ž“sA2010, 9, 9-1, ‹ž“sD
436. Kawabata,
A., Okubo, K., Takahashi, T., Matsunami, M., Shibayama, H. Therapeutic
application of a skin-permeable ascorbic derivative as an ointment to treatment
of paclitaxel-induced neuropathic hyperalgesia in rats. 13th World
Congress of Pain (IASP2010), 2010, 8, 29 – 9, 2, Montreal, Canada.
437. Matsunami,
M., Kirishi, S., Okui, T., Kawabata, A. Luminal zinc chelators induce colonic
pain through activation of T-type calcium channels: A mechanism for hydrogen
sulfide-induced visceral pain? 13th World Congress of Pain
(IASP2010), 2010, 8, 29 – 9, 2, Montreal, Canada.
438. Nishiura,
K., Matsunami, M., Miki, T., Kawabata, A. T-type calcium channels targeted by
hydrogen sulfide are involved in cystitis-related bladder pain and neurogenic
inflammation in mice. 13th World Congress of Pain (IASP2010), 2010,
8, 29 – 9, 2, Montreal, Canada.
439. Kawabata,
A., Aoki, Y., Sekiguchi, F., Nakagawa, M., Kanaoka, D., Yoshida, S. Peripheral hyperalgesia via the cyclic
AMP/protein kinase A pathway involves activation of T-type calcium channels in
rats. 16th World Congress on Basic and Clinical Pharmacology
(WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.@
440. Sekiguchi,
F., Maeda, Y., Matsumoto, Y., Matsunami, M., Nishikawa, H., Kawabata, A. Analysis of various biological responses
induced by Helicobacter pylori extract: independent of proteinase-activated
receptors? 16th World Congress on Basic
and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen,
Denmark.
441. Okubo,
K., Takahashi, T., Matsunami, M., Shibayama, H., Kawabata, A. Topical application of disodium
isostearyl 2-O-l-ascorbyl phosphate, a skin-permeable amphiphilic ascorbic
derivative, attenuates chemotherapy-induced neuropathic hyperalgesia in rats. 16th World Congress on Basic
and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen,
Denmark.
442. Maeda,
Y., Yamanaka, R., Sekiguchi, F., Kawabata, A. Analysis of cellular signaling for epidermal growth
factor-mediated suppression of androgen-induced expression of prostate-specific
antigen gene in human prostate cancer LNCaP cells. 16th World Congress on Basic and Clinical Pharmacology
(WorldPharma2010), 2010, 7, 17-23, Copenhagen, Denmark.
443. Fukami,
K., Kasamatsu, R., Yoshida, S., Sekiguchi, F., Kawabata, A. Hydrogen sulfide promotes function of
T-type calcium channels and secretion of prostatic acid phosphatase in
neuroendocrine-like prostate cancer cells from the androgen-sensitive LNCaP
cell line. 16th World Congress on Basic
and Clinical Pharmacology (WorldPharma2010), 2010, 7, 17-23, Copenhagen,
Denmark.
444. ’†ì•‘ŽqA–ؗD‰ÀA‹à‰ª‘åŽ÷AŠÖŒû•x”üŽqA‹g“c@”ÉA¼”g^”¿A씨“ÄŽjDProstaglandin
E2‚É‚æ‚è—U‹N‚³‚ê‚é‹@ŠB“I’ÉŠo‰ß•q‚Ö‚ÌTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^D‘æ117‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 7,
8, “¿“‡D
445. ‘å‹v•ÛŽõA¼‘º@—ÎA¼”g^”¿A씨“ÄŽjD—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚éƒ}ƒEƒX‚Ì‹@ŠB“I’ÉŠo‰ß•q‚ƃAƒƒfƒBƒjƒAFTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚¨‚æ‚ÑTRPA1ƒ`ƒƒƒlƒ‹‚̈قȂé–ðŠ„D‘æ117‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2010, 7,
8, “¿“‡D
446. ‘å‹v•ÛŽõA‚‹´’mŽqA[ŠC˜aŽ÷A¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽjD”畆“§‰ß«V‹KƒAƒXƒRƒ‹ƒrƒ“Ž_ƒvƒƒhƒ‰ƒbƒOdisodium
isostearyl 2-O-l-ascorbyl phosphate“îp‚Ì_ŒoáŠQ«áu’ÉŽ¡—Âւ̉ž—pD‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
447. ‘å‹v•ÛŽõA‚‹´’mŽqA[ŠC˜aŽ÷A¼”g^”¿AŽÄŽR—TŽ¡A씨“ÄŽj. ƒAƒXƒRƒ‹ƒrƒ“Ž_‚¨‚æ‚ÑV‹K—¼e”}«ƒAƒXƒRƒ‹ƒrƒ“Ž_—U“±‘Ì‚Ì—°‰»…‘f—U‹N’ÉŠo‰ß•q‚¨‚æ‚уpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_ŒoáŠQ«áu’ɂɑ΂·‚éŒø‰ÊD‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
448. ¼‘ºK—eAΑqG‹±A¼”g^”¿AŽÂè@Œ‹AŠÖŒû•x”üŽqA¬£Œõ‰hAŠì‘½‘º‘וãA–¾Î—²‹gA¼‘ºŒª“ñA씨“ÄŽj. äX‘Ÿ’É”Œ»‚É‚¨‚¯‚éƒvƒƒeƒA[ƒ[APAR2‚¨‚æ‚ÑTRPV1‚Ì–ðŠ„D‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
449. ŽO–Ø’—TA¼”g^”¿A‰ª“cŒ[ŠóA¼‰®G˜aA씨“ÄŽj. EP1ƒAƒ“ƒ^ƒSƒjƒXƒgONO-8130‚Ícyclophosphamide—U‹Nƒ}ƒEƒXäNã÷‰Š‚É”º‚¤’É‚Ý‚ð‹—Í‚É—}§‚·‚éD‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
450. ¼‰Y‰À“ߌbA¼”g^”¿AŽO–Ø’—TA씨“ÄŽj.
Cyclophosphamide—U‹NäNã÷‰Šƒ}ƒEƒX‚É‚¨‚¢‚ÄH2S‚Ì•W“I•ªŽqTŒ^Ca2+ƒ`ƒƒƒlƒ‹‚Í_Œoˆö«‰ŠÇ‚ÆäNã÷’É‚ÉŠÖ—^‚·‚é. ‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
451. ŽO’JŒ’Ž¡A“c’†—F—¢AŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjDƒ‰ƒbƒgŒãª_Œoß—R—ˆND7/23×–E‚É‚¨‚¢‚Äcyclic
AMP‚É‚æ‚è—U”‚³‚ê‚é_Œo“Ë‹NL’·‚¨‚æ‚уCƒIƒ“ƒ`ƒƒƒlƒ‹‹@”\‘‹‚Ì“Á’¥. ‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
452.
–ؗD‰ÀA’†ì•‘ŽqAŠÖŒû•x”üŽqA씨“ÄŽj. ƒTƒCƒNƒŠƒbƒNAMP‚É‚æ‚è—U‹N‚³‚ê‚é’ÉŠo‰ß•q‚Ö‚ÌTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^. ‘æ83‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2010, 3,
16-18, ‘åãD
453.
ŠÖŒû•x”üŽq, ‘O“c—D–, ¼–{—TŠì, ¼”g^”¿, ¼ì—T”V, 씨“ÄŽj. Helicobacter pylori’Šo‰t‚É‚æ‚è—U‹N‚³‚ê‚éŽíX‚Ì×–E”½‰žFProteinase-activated
receptorŠÖ—^‚Ì—L–³‚ɂ‚¢‚ÄD‘æ116‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2009, 11,
13, ‘å’ÃD
454.
‘å‹v•ÛŽõA¼”g^”¿A‚‹´’mŽqA씨“ÄŽjDŠà‰»Šw—Ö@‚É”º‚¤_ŒoáŠQ«áu’É‚Í—°‰»…‘f‡¬y‘f‘jŠQ–ò‚¨‚æ‚ÑTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‘jŠQ–ò‚É‚æ‚è—}§‚³‚ê‚éD‘æ116‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2009, 11,
13, ‘å’ÃD
455.
ŽO’JŒ’Ž¡A“c’†—F—¢AŠÖŒû•x”üŽqA‹g“c@”ÉA씨“ÄŽjDÒ‘Œãª_Œoß—R—ˆND7/23×–E‚É‚¨‚¯‚écyclic
AMP—U”_Œo“Ë‹NL’·‚¨‚æ‚Ñ“dˆÊˆË‘¶«ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì‹@”\“I‘‹D‘æ116‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2009, 11,
13, ‘å’ÃD
456.
¼”g^”¿AŽO–Ø’—TA¼‰Y‰À“ߌbA—Ñ—TŽqA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚Ì“à‘Ÿ’Éî•ñ“`’B‚É‚¨‚¯‚é–ðŠ„FäNã÷’É‚Ö‚ÌŠÖ—^D‘æ59‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïA2009, 10,
14, “Œ‘åãD
457.
ŽO–Ø’—TA¼”g^”¿A씨“ÄŽjDCyclophosphamide—U‹Nƒ}ƒEƒXäNã÷‰Š^äNã÷’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒfƒBƒ“EP1Žó—e‘̃Aƒ“ƒ^ƒSƒjƒXƒg‚Ìì—pD‘æ59‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïA2009, 10,
14, “Œ‘åãD
458.
Kawabata, A., Takahashi, T., Okubo, K., Matsunami, M., Kojima,
S., Nishikawa, H., Takemura, M. Buprenorphine strongly attenuates the
neuropathic pain induced by spinal nerve injury or chemotherapy in laboratory
animals. 13th Congress of the European Federation of Neurological
Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.
459.
Matsunami, M., Miki, T., Hayashi, Y., Kawabata, A. Hydrogen
sulfide is a key mediator for bladder pain during cyclophosphamide-induced
cystitis in mice. 13th Congress of the European Federation of
Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.
460.
Nishimura, S., Fukushima, O., Matsunami, M., Ishikura, H.,
Kawabata, A. Activation of ERK in the spinal dorsal horn neurons by distinct
pro-nociceptive stimuli in the pancreas: roles of hydrogen sulfide and
proteinase-activated receptor-2. 13th Congress of the European
Federation of Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence,
Italy.
461.
Okubo, K., Matsunami, M., Takahashi, T., Kawabata, A. Roles of hydrogen
sulfide and T-type calcium channels in chemotherapy-evoked neuropathic
hyperalgesia in rats. 13th Congress of the European Federation of
Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.
462.
Mitani, K., Tanaka, Y., Sekiguchi, F., Yoshida, S., Kawabata, A.
Neurite outgrowth and functional up-regulation of voltage-dependent calcium
channels caused by cyclic AMP in sensory neuron-like cells. 13th
Congress of the European Federation of Neurological Societies (EFNS 2009),
2009, 9, 12-15, Florence, Italy.
463.
Aoki, Y., Maeda, Y., Matsunami, M., Kawabata, A. Peripheral
hydrogen sulfide induces hypersensitivity to C-fiber-preferential sine-wave
stimulation and concomitant potentiation of ERK phosphorylation in the spinal
dorsal horn neurons. 13th Congress of the European Federation of
Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.
464.
Fukami, K., Tarui, T., Nagasawa, K., Yoshida, S., Sekiguchi, F.,
Kawabata, A. Involvement of downstream Src activation of Cav3.2
T-type calcium channels in hydrogen sulfide-induced neuronal differentiation in
NG108-15 cells. 13th Congress of the European Federation of
Neurological Societies (EFNS 2009), 2009, 9, 12-15, Florence, Italy.
465.
Miki, T., Matsunami, M., Hayashi, Y., Akaogi, K., Kamanaka, Y.,
Kawabata, A. Prostaglandin EP1 receptors participate in the development of
bladder pain in mice with cyclophosphamide-induced cystitis. 13th
Congress of the European Federation of Neurological Societies (EFNS 2009),
2009, 9, 12-15, Florence, Italy.
466.
Kawabata, A., Takahashi, T., Okubo, K., Matsunami, M.
Involvement of endogenous hydrogen sulfide and T-type calcium channels in
neuropathic pain induced by spinal nerve injury or chemotherapy. Pain in Europe
VI (6th Congress of the European Federation of IASP Chapters), 2009,
9, 9-12, Lisbon, Portugal.
467.
Matsunami, M., Miki, T., Hayashi, Y., Akaogi, K., Kamanaka, Y.,
Kawabata, A. The prostaglandin E2 receptor subtype EP1 mediates bladder pain/hyperalgesia
accompanying the cyclophosphamide-induced cystitis in mice. Pain in Europe VI
(6th Congress of the European Federation of IASP Chapters), 2009, 9,
9-12, Lisbon, Portugal.
468.
Kawabata, A., Takahashi, T., Matsunami, M., Kojima, S., Okubo,
K., Takemura, M., Nishikawa, H. Potent anti-hyperalgesic effect of buprenorphine
in two distinct neuropathic pain models induced by spinal nerve injury and by
paclitaxel. XXXVI International Congress of Physiological Sciences, 2009, 7, 27
– 8, 1, Kyoto.
469.
Sekiguchi, F., Maeda, Y., Ohi, A., Takaoka, K., Nishikawa, H.,
Kawabata, A. The time lag of PGE2 release and COX-2 up-regulation
triggered by PAR1 is due to deficiency of arachidonic acid in gastric
epithelial cells. XXXVI International Congress of Physiological Sciences, 2009,
7, 27 – 8, 1, Kyoto.
470.
Okubo, K., Matsunami, M., Takahashi, T., Kawabata, A.
Involvement of hydrogen sulfide and T-type calcium channels in the maintenance
of hyperalgesia in rats with chemotherapy-induced neuropathy. XXXVI
International Congress of Physiological Sciences, 2009, 7, 27 – 8, 1, Kyoto.
471.
Maeda, Y., Sekiguchi, F., matsumoto, Y., Nishikawa, H.,
Kawabata, A. Effect of Helicobacter
pylori extracts on prostaglandin E2 production in human lung
alveolar epithelial A549 cells. XXXVI International Congress of Physiological
Sciences, 2009, 7, 27 – 8, 1, Kyoto.
472.
ŠÖŒû•x”üŽqA‹v•Û‘ŽqA•‰Í—SŽqA‰ª–{—R‰À—œA“y]ˆÊ’mŽqA씨“ÄŽjD‚°‚ÁŽ•—Þ‚Ì‹C“¹‚¨‚æ‚ÑÁ‰»ŠÇ•½ŠŠ‹Ø‚Ì‹Ù’£«‚É‚¨‚æ‚Ú‚·—°‰»…‘f‚̉e‹¿D‘æ51‰ñ@“ú–{•½ŠŠ‹ØŠw‰ï‘‰ïA2009, 7,
21-23, –¼ŒÃ‰®D
473.
¼”g^”¿A씨“ÄŽjD“àˆö«—°‰»…‘f‚ÍäNã÷‰Š‚É”º‚¤’É‚Ý‚Ì”Œ»‚ÉŠÖ—^‚·‚éD‘æ31‰ñ“ú–{áu’ÉŠw‰ïA2009, 7,
17-18, –¼ŒÃ‰®D
474.
Kawabata, A. Roles of hydrogen sulfide in processing of
inflammatory pain. In a symposium, gHydrogen sulfide in inflammationh, The
First International Conference of Hydrogen Sulfide in Biology and Medicine,
2009, 6, 26-28, Shanghai, China. (Invited Speaker)
475.
Kawabata, A. Hydrogen sulfide and pain. In a symposium, gGases
as Neuromodulators in Sensing : From Nitric Oxide to Hydrogen sulfideh,
Experimental Biology 2009, 2009, 4, 18-22, New Orleans, USA. (Organizer and
Invited Speaker)@
476.
Sekiguchi, F., Tanaka, Y., Hong, H., Kawabata, A. IL-8 release
triggered by proteinase-activated receptor-2 stimulation involves both MEK/ERK
and PI3 kinase/Akt pathways in gastrointestinal epithelial cells. Experimental
Biology 2009, 2009, 4, 18-22, New Orleans, USA.
477.
Fukami, K., Sekiguchi, F., Takaoka, K., Miyake, K., Yamamoto, T.,
Tanaka, S., Ohno, K., Ishikura, H., Naruse, M., Kawabata, A. Relationship
between expression of PARs and infection with H. pylori in the stomach of gastric cancer patients. Experimental
Biology 2009, 2009, 4, 18-22, New Orleans, USA.
478.
Maeda, Y., Sekiguchi, F., Ohi, A., Takaoka, K., Nishikawa, H.,
Kawabata, A. The delayed release of PGE2 mediated by PAR1 involves
slowly developing production of arachidonic acid in rat gastric mucosal
epithelical cells. Experimental Biology 2009, 2009, 4, 18-22, New Orleans, USA.
479.
ŠÖŒû•x”üŽqA[ŠC˜aŽ÷A‚‰ª•Û—AŽO‘ìAŽR–{—²ŽkA“c’†ÑŒáA‘å–ìkˆêAΑqG‹±A¬£Œõ‰hA씨“ÄŽjDˆÝŠàŠ³ŽÒ‚æ‚è“Eo‚µ‚½ˆÝ‘gD‚̃wƒŠƒRƒoƒNƒ^[EƒsƒƒŠ—R—ˆƒEƒŒƒA[ƒ[’`”’—Ê‚ÆPAR1‚ ‚é‚¢‚ÍPAR2”Œ»—Ê‚Ì‘ŠŠÖ«‚ɂ‚¢‚ÄD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
480.
¼”g^”¿AŽO–Ø’—TA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚̃VƒNƒƒzƒXƒtƒ@ƒ~ƒh—U‹NäNã÷‰Š‚¨‚æ‚ÑäNã÷’É‚Ö‚ÌŠÖ—^D‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
481.
‘å‹v•ÛŽõA¼”g^”¿A‰¶’n‹I”ü]A씨“ÄŽjDƒAƒXƒRƒ‹ƒrƒ“Ž_‚Í—°‰»…‘f—U‹N’ÉŠo‰ß•q‚¨‚æ‚уpƒNƒŠƒ^ƒLƒZƒ‹—U‹N_Œoˆö«áu’É‚ð—}§‚·‚éD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
482.
•‰Í—SŽqA‹v•Û‘ŽqAŽRè—ÇŽqAŠÖŒû•x”üŽqA‰ª–{—R‰À—œA‘O“c—D–A‹v•Ä—˜–¾A•Ÿ“ˆL”VAÔ’rº‹IA씨“ÄŽjD—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚é‘å”]”玿_Œo×–EŽ€‚̃ƒJƒjƒYƒ€‚̉ðÍF“Á‚ÉMEK/ERKŒn‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
483.
‚‹´’mŽqAŽO’JŒ’Ž¡A’|‘ºŒ³GAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«—°‰»…‘f‚Ì•W“I•ªŽqCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Í_Œoˆö«áu’É‚Ì•ÛŽ‚É‚¨‚¢‚Äd—v‚È–ðŠ„‚ðŽ¦‚·D‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
484.
‚‹´’mŽqA¼ì—T”VA’|‘ºŒ³GA씨“ÄŽjD_Œoˆö«áu’Ƀ‚ƒfƒ‹ƒ‰ƒbƒg‚É‚¨‚¯‚éƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚Ì‹—Í‚È’Á’ÉŒø‰ÊD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
485.
’Mˆä ‹BA[ŠC˜aŽ÷A’·àVŒi‘¾A‹g“c ”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD—°‰»…‘f‚ÍCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠˆ«‰»‚É‘±‚SrcŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[‚ÌŠˆ«‰»‚ð‰î‚µ‚ÄNG108-15×–E‚Ì_Œo•ª‰»‚ð—U“±‚·‚éD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
486.
–ؗD‰ÀA‘O“c—C”üA¼”g^”¿A씨“ÄŽjD––½‘gD‚Ì—°‰»…‘f‚Í‚büˆÛ‚ð‰î‚·‚éáu’É”½‰ž‚ÆÒ‘ŒãŠpƒjƒ…[ƒƒ“‚É‚¨‚¯‚éERKƒŠƒ“Ž_‰»‚ð‘‘傳‚¹‚éD‘æ82‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2009, 3,
16-18, ‰¡•lD
487.
•‰Í—SŽqA‹v•Û‘ŽqAŽRè—ÇŽqAŠÖŒû•x”üŽqA‰ª–{—R‰À—œA‘O“c—D–A‹v•Ä—˜–¾A•Ÿ“ˆL”VAÔ’rº‹IA씨“ÄŽjDƒ}ƒEƒX‘ÙŽ™‘å”]”玿_Œo×–E‚É‚¨‚¯‚é“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚Ì_Œo×–E“Å«‚ÍMEK-ERKŒn‚ÌŠˆ«‰»‚Ɉˑ¶‚·‚éD‘æ114‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 11,
14, _ŒËD
488.
’Mˆä ‹BA[ŠC˜aŽ÷A’·àVŒi‘¾A‹g“c ”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD—°‰»…‘f‚É‚æ‚éNG108-15×–E‚Ì_Œo•ª‰»‚ÍTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹Šˆ«‰»‚É‘±‚SrcŒ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[Šˆ«‰»‚Ɉˑ¶‚·‚éD‘æ114‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 11,
14, _ŒËD
489.
–ؗD‰ÀA‘O“c—C”üA¼”g^”¿A씨“ÄŽjD––½‘gD’†‚Ì—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚é’mŠo_ŒoCüˆÛŠ´Žó«‘‘åFˆÙ”g’·ƒTƒCƒ“”gŽhŒƒ‚ɑ΂·‚锽‰ž«•Ï‰»‚ðŽw•W‚Æ‚µ‚½ŒŸ“¢D‘æ114‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 11,
14, _ŒËD
490.
Kawabata, A., Maeda, Y., Aoki, Y., Tarui, T., Mitani, K.,
Sekiguchi, F., Okubo, K., Yoshida, S., Nishikawa, H. Hydrogen sulfide is
pro-nociceptive in the spinal cord as well as peripheral tissues. 6th
FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.
491.
Sekiguchi, F., Kurokawa, Y., Okamoto, Y., Kubo, S., Yamasaki,
Y., Maeda, Y., Kume, T., Fukushima, N., Akaike, A., Kawabata, A. Cell damage
induced by hydrogen sulfide in cortical neurons from mouse embryos. 6th
FENS Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.
492.
Matsunami, M., Fukushima, O., Takemura, M., Kawabata, A.
Mechanisms underlying visceral pain induced by colonic luminal hydrogen sulfide
in mice. 6th FENS Forum of European Neuroscience, 2008, 7, 12-16,
Geneva, Switzerland.
493.
Nishimura, S., Fukushima, O., Ishikura, H., Takahashi, T.,
Matsunami, M., Tsujiuchi, T., Sekiguchi, F., Naruse, M., Kamanaka, Y.,
Kawabata, A. Involvement of endogenous hydrogen sulfide in acute
pancreatitis-related pain. 6th FENS Forum of European Neuroscience,
2008, 7, 12-16, Geneva, Switzerland.
494.
Tarui, T., Nagasawa, K., Yoshida, S., Ohi, A., Fukami, K.,
Matsunami, M., Sekiguchi, F., Ichida, S., Nishikawa, H., Kawabata, A. Hydrogen
sulfide induces neuronal differentiation via Cav3.2 T-type calcium
channels and Src family tyrosine kinase in NG108-15 cells. 6th FENS
Forum of European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.
495.
Takahashi, T., Maeda, Y., Kawabata, A. Neuropathic
pain involves sensitization of Cav3.2 T-type calcium channels by
endogenous hydrogen sulfide in sensory nerves. 6th FENS Forum of
European Neuroscience, 2008, 7, 12-16, Geneva, Switzerland.
496.
¼‘ºK—eA•Ÿ“‡@CA¼”g^”¿A씨“ÄŽjDäX‘Ÿ“à‚Ì—°‰»…‘f (H2S)
‚¨‚æ‚Ñproteinase-activated
receptor-2 (PAR2) ŽhŒƒ‚É‚æ‚Á‚Ä—U‹N‚³‚ê‚éÒ‘ŒãŠp•\‘wƒjƒ…[ƒƒ“‚ÌERKƒŠƒ“Ž_‰»D‘æ113‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2008, 6,
20, ‰ªŽRD
497.
씨“ÄŽjDTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚·‚é—°‰»…‘f‚ÌV‚½‚È‹@”\@\@“Á‚Éáu’Éî•ñ“`’B‚Ö‚ÌŠÖ—^‚ɂ‚¢‚ÄDƒVƒ“ƒ|ƒWƒEƒ€9u—°‰»…‘f‚ƈêŽ_‰»’Y‘fF“Å‚É‚àî•ñ•ªŽq‚É‚à‚È‚éƒKƒXvA‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lDiƒVƒ“ƒ|ƒWƒXƒgj
498.
—тЂƂÝA‹v•Û‘ŽqA¼ì—T”VAŠÖŒû•x”üŽqA씨“ÄŽjDƒEƒTƒMŒŒ¬”‚̋ÃW‚¨‚æ‚уJƒ‹ƒVƒEƒ€“®ˆõ‚É‚¨‚æ‚Ú‚·—°‰»…‘f‚̉e‹¿D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
499.
“c’†—S•ãAHao HongAŠÖŒû•x”üŽqA씨“ÄŽjDƒqƒgŒ‹’°Šà‚¨‚æ‚шݑBŠà—R—ˆ×–E‚É‚¨‚¢‚ÄPAR2ŽhŒƒ‚É‚æ‚è—U‹N‚³‚ê‚éƒCƒ“ƒ^[ƒƒCƒLƒ“-8—V—£‚ÉŠÖ—^‚·‚é×–EƒVƒOƒiƒ‹D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
500.
‚‹´’mŽqA‘O“c—C”üA씨“ÄŽjD“àˆö«—°‰»…‘f‚¨‚æ‚ÑTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚Ì_Œoˆö«áu’É‚Ö‚ÌŠÖ—^D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
501.
ŠÖŒû•x”üŽqA‘åˆäˆŸˆßA‚‰ª•Û—A¼ì—T”VA씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚É‚¨‚¯‚éproteinase-activated receptor-1ŽhŒƒ—U‹N’x”«ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ‚í‚é×–E“àî•ñ“`’BŒn‚ÌŒŸ“¢D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
502.
‹v•Û‘ŽqA—тЂƂÝA¼ì—T”VA씨“ÄŽjD“àˆö«ƒKƒXóƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚É‚æ‚郉ƒbƒgŒŒ¬”‹ÃW—}§‚Ì“Á’¥D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
503.
Žçs˜a”üA¼Œ´‚©‚¨‚èAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¢‚ÄPAR2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ɑ΂·‚éƒNƒ‹ƒNƒ~ƒ“‚ÌŒø‰ÊD‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
504.
‚‰ª•Û—AM‹MG‹éAŠÖŒû•x”üŽqA씨“ÄŽjDƒ‰ƒbƒg³íˆÝ”S–Œã”ç×–E‚É‚¨‚¢‚ă`ƒAƒ]ƒŠƒWƒ“ƒfƒBƒIƒ“Œn–ò•¨‚ÍPAR1Šˆ«‰»‚É‚æ‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ðPPARƒÁ”ñˆË‘¶«‚ÉCü‚·‚éD‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
505. ‘O“c—C”üA–ؗD‰ÀA‚‹´’mŽqAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDÒ‘“à‚¨‚æ‚Ñ––½‘gD’†‚Ì—°‰»…‘f‚É‚æ‚é’ÉŠo‰ß•q”Œ»‚É‚¨‚¯‚éCav3.2 TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÆNMDAŽó—e‘Ì‚Ì–ðŠ„D‘æ81‰ñ@“ú–{–ò—Šw‰ï”N‰ïA2008, 3, 17-19, ‰¡•lD
506. ŠÖŒû•x”üŽqA‘åˆäˆŸˆßA‚‰ª•Û—A¼ì—T”VA씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–ERGM1‚É‚¨‚¢‚Äproteinase-activated
receptor-1‚ð‰î‚µ‚½prostaglandin E2ŽY¶˜´i‚Ì’x‰„‚̓Aƒ‰ƒLƒhƒ“Ž_‹Ÿ‹‹•s‘«‚É‹Nˆö‚·‚éD‘æ26‰ñCytoprotectionŒ¤‹†‰ïA2008, 3,
14, ‹ž“sD
507. ¼”g^”¿A’Mˆä@‹BAŽO’JŒ’“ñA’·àVŒi‘¾A‹g“c@”ÉA•Ÿ“‡@CA’|‘ºŒ³GA씨“ÄŽjDŒ‹’°“ào—°‰»…‘f‚É‚æ‚è—U‹N‚³‚ê‚é“à‘Ÿ’É‚Ì”Œ»ƒƒJƒjƒYƒ€‚̉ðÍD‘æ26‰ñCytoprotectionŒ¤‹†‰ïA2008, 3,
14, ‹ž“sDi§—ãÜŽóÜj
508.
‘O“c—C”üA–ؗD‰ÀA‚‹´’mŽqAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDÒ‘“à‚¨‚æ‚Ñ––½‘gD“à‚Ì—°‰»…‘f‚É‚æ‚é’ÉŠo‰ß•qFCaV3.2
TŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ112‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2007, 11, 16, –L’†D
509.
‚‰ª•Û—AM‹MG‹éAŠÖŒû•x”üŽqA씨“ÄŽjDƒ‰ƒbƒg³íˆÝ”S–Œã”çRGM1×–E‚É‚¨‚¯‚éPAR1Šˆ«‰»—U‹NƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶‚ɑ΂·‚éƒ`ƒAƒ]ƒŠƒWƒ“ƒfƒBƒIƒ“Œn–ò•¨‚̉e‹¿D‘æ112‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2007, 11,
16, –L’†D
510.
Žçs˜a”üA¼Œ´‚©‚¨‚èAŠÖŒû•x”üŽqA¼ì—T”VA씨“ÄŽjDƒqƒg”x–E—R—ˆã”ç×–E‚É‚¨‚¯‚éPAR2—U‹NƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ɑ΂·‚éƒNƒ‹ƒNƒ~ƒ“‚Ì—}§Œø‰ÊD‘æ112‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2007, 11,
16, –L’†D
511.
Kawabata, A., Nishimura, S., Fukushima, O., Ishikura, H.,
Takahashi, T., Matsunami, M., Tsujiuchi, T., Sekiguchi, F., Naruse, M.,
Kamanaka, Y. Hydrogen sulfide as a nociceptive messenger in rat and mouse
pancreata. Neuroscience 2007, 2007, 11, 3-7, Dan Diego, USA.
512.
씨“ÄŽjDH2S‚Æ’É‚ÝDƒVƒ“ƒ|ƒWƒEƒ€u‹C‘̃ƒfƒBƒG[ƒ^[‚Æ‘n–òvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9,
13-14, ‹à‘òDiOrganizerEƒVƒ“ƒ|ƒWƒXƒgj
513.
ŠÖŒû•x”üŽqA‹v•Û‘ŽqA•‰Í—SŽqA—тЂƂÝA¼ì—T”VA‰ª–{—R‰À—œA씨“ÄŽjDH2S‚Æ•½ŠŠ‹Ø‰^“®DƒVƒ“ƒ|ƒWƒEƒ€u‹C‘̃ƒfƒBƒG[ƒ^[‚Æ‘n–òvA¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9,
13-14, ‹à‘òDiƒVƒ“ƒ|ƒWƒXƒgj
514.
’Mˆä@‹BA’·àVŒi‘¾A•Ÿ“ˆL”VA–ìèŽü‰pA씨“ÄŽjDƒ‰ƒbƒgŠŒF×–EŽî—R—ˆ×–EPC12‚É‚¨‚¯‚éNGF—U‹N_Œo“Ë‹NL’·‚ɑ΂·‚錌Ÿ÷—R—ˆthrombinŽŽ–ò’†šñŽG¶—Šˆ«•¨Ž¿‚Ì‘£iŒø‰ÊD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9,
13-14, ‹à‘òD
515.
‚‹´’mŽqA’Mˆä@‹BAŽO’JŒ’Ž¡A’·àVŒi‘¾A‘O“c—C”üA‹g“c@”ÉA씨“ÄŽjD_Œoˆö«áu’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚é—°‰»…‘f‡¬y‘f‘jŠQ–ò‚Ì’Á’ÉŒø‰ÊD¶‘Ì‹@”\‚Æ‘n–òƒVƒ“ƒ|ƒWƒEƒ€2007‹à‘òD2007, 9,
13-14, ‹à‘òD
516.
Kawabata, A., Nishimura, S., Fukushima, O., Ishikura, H.,
Takahashi, T., Matsunami, M., Sekiguchi, F., Naruse, M. A pro-nociceptive role
for hydrogen sulfide in the pancreas. The 4th Science and Research
Symposium: Gastrointestinal motility and Functional gastrointestinal disorders,
Basic to Clinic. 2007, 8, 28, Nagoya.
517. Matsunami,
M., Tarui, T., Mitani, K., Nagasawa, K., Yoshida, S., Fukushima, O., Takemura,
M., Kawabata, A. Luminal hydrogen sulfide in mouse colon: a novel mediator for
visceral pain. The 4th Science and Research Symposium:
Gastrointestinal motility and Functional gastrointestinal disorders, Basic to
Clinic. 2007, 8, 28, Nagoya. iExcellence AwardŽóÜ)
518.
Kawabata, A. Gastro-intestinal roles for
proteinase-activated receptors. Life Sciences 2007, 2007, 7, 8-12, Glasgow, UK. (Invited
lecture).
519.
Matsunami, M., Fukushima, O., Takemura, M., Kawabata, A. A novel
nociceptive role for luminal hydrogen sulfide in mouse colon. Life Sciences
2007, 2007, 7, 8-12, Glasgow, UK.
520.
Sekiguchi, F., Kubo, S., Kurokawa, Y., Okamoto, Y., Doe, I.,
Kawabata, A. Effects of hydrogen sulfide on the tone of gastrointestinal and
airway smooth muscle preparations from rodents. Life Sciences 2007, 2007, 7,
8-12, Glasgow, UK.
521.
Moriyuki, K., Matsubara, K., Sekiguchi, F., Nishikawa, H.,
Kawabata, A. Curcumin intervention of PAR2-triggered prostaglandin E2
(PGE2) release in human lung epithelial cells: what are the target
molecules downstream of PAR2?@Young Life Scientistsf Symposium
2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7,
8, Glasgow, UK.
522.
Takaoka, K., Shigi, H., Sekiguchi, F., Kawabata, A. Modulation
of PAR1-triggered prostaglandin E2 production by thiazolidinediones
through peroxisome proliferator-activated receptor-ƒÁ-independent pathways in
rat gastric mucosal epithelial cells. Young Life Scientistsf Symposium 2007 –
Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8,
Glasgow, UK.
523.
Taniguchi, E., Yonezawa, D., Kimura, T., Ishiki, T., Matsunami,
M., Sekiguchi, F., Nishikawa, F., Kawabata, A. Hydrogen sulfide (H2S) as a hypothetical pro-inflammatory
signaling molecule in ulcerative colitis (UC): impaired detoxification but not
generation of H2S in a mouse UC model. Young Life Scientistsf Symposium
2007 – Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7,
8, Glasgow, UK.
524.
Maeda, Y., Aoki, Y., Takahashi, T., Kawabata, A. T-Type calcium
channel-mediated nociceptive signaling triggered by hydrogen sulfide in rat
spinal cord and peripheral tissue. Young Life Scientistsf Symposium 2007 –
Advances in Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8,
Glasgow, UK.
525.
Kurokawa, Y., Kubo, S., Doe, I., Sekiguchi, F., Kawabata, A. Inhibition
of the activity of three recombinant nitric oxide synthase isoforms by hydrogen
sulfide. Young Life Scientistsf Symposium 2007 – Advances in Signalling (a
satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.
526.
Matsunami, M., Fukushima, O., Takemura, M., Kawabata, A. Colonic
pain induced by luminal hydrogen sulfide: a novel mechanism for visceral
nociceptive signaling. Young Life Scientistsf Symposium 2007 – Advances in
Signalling (a satellite to the Life Sciences 2007). 2007, 7, 8, Glasgow, UK.
527.
’JŒû‰lˆêA•Ä‘ò‘åŽ÷AΖØ@„A¼”g^”¿AŠÖŒû•x”üŽqA씨“ÄŽjD‰ŠÇ«’°Ž¾Š³(IBD)ƒ‚ƒfƒ‹‚É‚¨‚¯‚é—°‰»…‘fŽY¶E‰ð“Å‚ÉŠÖ—^‚·‚éy‘f‚Ì‹““®D‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3,
14-16, –¼ŒÃ‰®D
528.
•Ÿ“‡@CA¼‘ºK—eAΑqG‹±A‚‹´’mŽqA¼”g^”¿AŠÖŒû•x”üŽqA¬£Œõ‰hAŠ™’†Šì‹vA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚ÍäX‘Ÿ‚Ì’É‚Ý‚ÉŠÖ—^‚·‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3,
14-16, –¼ŒÃ‰®D
529.
¼”g^”¿A‘å‹v•ÛŽõA•Ÿ“‡@CA씨“ÄŽjD—°‰»…‘f‚Í“à‘Ÿ’É”Œ»‚ÉŠÖ—^‚·‚éV‚½‚ȃƒbƒZƒ“ƒWƒƒ[‚Æ‚µ‚Ä‹@”\‚µ‚Ä‚¢‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3,
14-16, –¼ŒÃ‰®D
530.
’·àVŒi‘¾A’Mˆä@‹BA‹g“c@”ÉAó–ì@”£AŠÖŒû•x”üŽqAŽs“c¬ŽuA¼ì—T”VA씨“ÄŽjD—°‰»…‘f‚ÍNG108-15×–E‚É‚¨‚¢‚ÄTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚̃ŒƒhƒbƒNƒX§Œä‚ð‰î‚µ‚Ä_Œo•ª‰»‚ð—U‹N‚·‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3,
14-16, –¼ŒÃ‰®D
531.
‹v•Û‘ŽqAΑqG‹±A’†Š_’qOA씨“ÄŽjDƒ‰ƒbƒgã’°ŠÔ–Œ“®–¬‚É‚¨‚¯‚éactivated
protein C‚Ì“à”çˆË‘¶«’oŠÉì—pD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3,
14-16, –¼ŒÃ‰®D
532.
‹v•Û‘ŽqA•‰Í—SŽqA“y]ˆÊ’mŽqA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚̓ŠƒRƒ“ƒrƒiƒ“ƒgNO‡¬y‘f‚ÌŠˆ«‚ð‘jŠQ‚·‚éD‘æ80‰ñ“ú–{–ò—Šw‰ï”N‰ï2007, 3,
14-16, –¼ŒÃ‰®D
533.
씨“ÄŽjDProteinase-activated receptor (PAR)‚Ì•a‘Ô¶—Šw“I–ðŠ„D“ú–{–òŠw‰ï–k—¤Žx•”‘æ115‰ñ—á‰ïA2006, 11,
12, •xŽRi“Á•Êu‰‰jD
534.
‹v•Û‘ŽqA•‰Í—SŽqA“y]ˆÊ’mŽqA씨“ÄŽjDƒKƒXóî•ñ“`’B•¨Ž¿H2S‚ÌNO‡¬y‘f (NOS) ‚ɑ΂·‚éì—p‚̉ðÍFnNOSAiNOS‚¨‚æ‚ÑeNOSŠˆ«‚Ì—}§‚ɂ‚¢‚ÄD‘æ110‰ñ@“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 11,
10, ‹ž“sD
535.
¼‘ºK—eA•Ÿ“‡@CAΑqG‹±A‚‹´’mŽqA¼”g^”¿AŠÖŒû•x”üŽqA¬£Œõ‰hAŠ™’†Šì‹vA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚ÌäX‰ŠŠÖ˜A’É‚Ö‚ÌŠÖ—^D‘æ110‰ñ@“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 11,
10, ‹ž“sD
536.
’·àVŒi‘¾A’Mˆä@‹BA‹g“c@”ÉA¼ì—T”VA씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚ÍTŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚ÄNG108-15×–E‚Ì_Œo•ª‰»‚ð—U“±‚·‚éD‘æ110‰ñ@“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 11,
10, ‹ž“sD
537.
‹v•Û‘ŽqA“y]ˆÊ’mŽqA•‰Í—SŽqA씨“ÄŽjDƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚É‚æ‚éNO‡¬y‘fŠˆ«‚Ì‘jŠQFŒŒŠÇ‰^“®’²ß‚Ö‚ÌŠÖ—^D‘æ56‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïA2006, 10,
28, ‹ž“sD
538.
¼ì—T”VA‰Í‡Œ’‘ A‘å’J—T–çAˆÀ•”’q”VAr–ØG¹A‰i––’mŽqA씨“ÄŽjDPAR-2ŠÖ˜Aƒyƒvƒ`ƒh‚É‚æ‚éPAR-2ˆË‘¶‚¨‚æ‚Ñ”ñˆË‘¶«—܉t•ª”å:\‘¢Šˆ«‘ŠŠÖ‚Æì—p‹@˜‚̉ðÍD‘æ56‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïA2006, 10,
28, ‹ž“si2005”N“xŽx•”§—ãÜŽóÜu‰‰jD
539.
ŠÖŒû•x”üŽqAÖ“¡Ž‡–ìA‚‰ª•Û—A—тЂƂÝA‰Í”ö’¼”VA’·‘ë^ŽÀA씨“ÄŽjDƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR1Šˆ«‰»‚ð‰î‚µ‚½ƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚©‚ç‚Ì’x‰„«ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àî•ñ“`’BŒn‚ÌŒŸ“¢D‘æ56‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ïA2006, 10,
28, ‹ž“si2004”N“xŽx•”§—ãÜŽóÜu‰‰jD
540.
Kawabata, A., Ishiki, T., Maeda, Y., Nagasawa, K., Takahashi,
T., Nishikawa, H. A pro-nociceptive role for hydrogen sulfide in peripheral
tissues. Neuroscience 2006, 2006, 10, 14-18, Atlanta. (Oral)
541.
Nagasawa, K., Ishiki, T., Yoshida, S., Maeda, Y., Sekiguchi, F.,
Wada, T., Ichida, S., Nishikawa, H., Kawabata, A. Hydrogen sulfide sensitizes
T-type calcium channels via redox modulation. Neuroscience 2006, 2006, 10,
14-18, Atlanta.
542.
Matsunami, M., Okubo, K., Fukushima, O., Takemura, M., Kawabata,
A. Hydrogen sulfide is pro-nociceptive in the
colon. Neuroscience 2006, 2006, 10, 14-18, Atlanta.
543.
Sugiyo, S., Sakai, Y., Masawaki, A., Shimoda, T., Utaka, S.,
Kawabata, M., Moritani, M., Yoshida, A., Matsunami, M., Kawabata, A., Takemura,
M. Estrous cycle dependent pain related behavior and c-Fos expression after
formalin injection into the upper lip. Neuroscience 2006, 2006, 10, 14-18,
Atlanta.
544.
ŠÖŒû•x”üŽqC‚‰ª•Û—CŽçs˜a”üC씨“ÄŽjDProteinase-activated receptorŠˆ«‰»‚É‚æ‚éƒvƒƒXƒ^ƒmƒCƒhŽY¶ƒVƒOƒiƒ‹‚Æ•a‘ÔD‘æ34‰ñ@–ò•¨Šˆ«ƒVƒ“ƒ|ƒWƒEƒ€A2006, 9,
28-29, ‚èiŒQ”njDiƒVƒ“ƒ|ƒWƒEƒ€j
545.
Kawabata, A., Ishiki, T., Nagasawa, K., Yoshida, S., Maeda, Y.,
Takahashi, T., Sekiguchi, F., Nishikawa, H. Evidence that hydrogen sulfide plays a pro-nociceptive role. The 18th
Japan-Korea Joint Seminar of Pharmacology, 2006, 9, 23-24, Fukui. (Oral)
546.
Kawabata, A., Moriyuki, K., Nagataki, M., Nishikawa, H.
Proteinase-activated receptor-2-triggered prostaglandin E2 formation
involves COX-1-dependent up-regulation of microsomal prostaglandin E synthase-1
in human lung epithelial cells. Half-day Symposium on G Protein-Coupled
Receptors (GPCRs) (a satellite symposium of 16th
International Symposium on Regulatory Peptides), 2006, 9, 2, Hakone.
547.
Moriyuki, K., Nagataki,
M., Nishikawa, H., Kawabata, A. Signal transduction for proteinase-activated
receptor-2-triggered interleukin-8 formation in human lung epithelial cells. Half-day
Symposium on G Protein-Coupled Receptors (GPCRs) (a
satellite symposium of 16th International Symposium on Regulatory Peptides),
2006, 9, 2, Hakone.
548.
Takaoka, K., Sekiguchi, F., Saito, S., Hayashi, H., Nagataki,
M., Nishikawa, H., Kawabata, A. Prostaglandin E2 production triggered
by proteinase-activated receptor-1 in rat gastric mucosal epithelial cells:
Cell signaling and modulation by peroxisome proliferator-activated receptor-ƒÁ
ligands. Half-day Symposium on G Protein-Coupled Receptors (GPCRs) (a satellite symposium of 16th International Symposium on
Regulatory Peptides), 2006, 9, 2, Hakone.
549.
Kubo, S, Ishikura, H., Nakagaki, T., Kawabata, A. Vasorelaxation
caused by activated protein C in rat superior mesenteric artery: Are proteinase-activated
receptors involved? Half-day Symposium on G Protein-Coupled Receptors (GPCRs) (a satellite symposium of 16th International Symposium on
Regulatory Peptides), 2006, 9, 2, Hakone.
550.
¼”g^”¿A씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚Í“à‘Ÿ’É‚ð—U‹N‚·‚éD‘æ28‰ñ“ú–{áu’ÉŠw‰ïA2006, 7, 14-15,
_ŒËD
551.
’·àVŒi‘¾A‹g“c@”ÉAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚É‚æ‚é‚sŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠ´Žó«‘‘å‚Æ’ÉŠo‰ß•q‚Ì”Œ»D‘æ28‰ñ“ú–{áu’ÉŠw‰ïA2006, 7,
14-15, _ŒËD
552.
Kawabata, A. Regulation of exocrine secretion by
proteinase-activated receptor-2 in the gastrointestinal tract. The Inernational
Mini-Symposium on Gastrointestinal Pharmacology – Tissue Injury, Protection and
Healing -, 2006, 7, 10, Kyoto. (Invited lecture)
553.
Takaoka, K., Sekiguchi, F., Saito, S., Shigi, H., Hayashi, H.,
Nagataki, M., Nishikawa, H., Kawabata, A. COX-2 up-regulation and prostaglandin
E2 production triggered by proteinase-activated receptor-1 (PAR1)
and their facilitation by peroxisome proliferator-activated receptor-ƒÁ ligands
in rat gastric mucosal epithelial cells. The Inernational Mini-Symposium on
Gastrointestinal Pharmacology – Tissue Injury, Protection and Healing -, 2006,
7, 10, Kyoto.
554.
¼”g^”¿A•Ÿ“‡@CA씨“ÄŽjDŒ‹’°“àH2S‚É‚æ‚é“à‘Ÿ’É‚¨‚æ‚Ñ“à‘Ÿ’ÉŠo‰ß•q‚Ì”Œ»D‘æ109‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 6,
16, ‘q•~D
555.
’·àVŒi‘¾AΖØ@„A‹g“c@”ÉA‘O“c—C”üAŠÖŒû•x”üŽqA˜a“c“NKAŽs“c¬ŽuA¼ì—T”VA씨“ÄŽjD“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚Í–¢•ª‰»NG108-15×–E‚É‚¨‚¢‚Ä‚sŒ^ƒJƒ‹ƒVƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠ´Žó«‚ð‘‘傳‚¹‚éD‘æ109‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2006, 6,
16, ‘q•~D
556.
씨“ÄŽjDProteinase-activated receptor (PAR) ‚ÌÁ‰»ŠÇ‹@”\‚Æ•a‘Ô‚Ö‚ÌŠÖ—^DƒVƒ“ƒ|ƒWƒEƒ€uÁ‰»ŠÇ•a‘ÔŒ¤‹†‚̃tƒƒ“ƒeƒBƒAvC‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lDiƒVƒ“ƒ|ƒWƒEƒ€j
557.
’·‘ë^ŽÀAŽçs˜a”üAŠÖŒû•x”üŽqA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¢‚ÄPAR2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚éIL-8‚¨‚æ‚Ñprostaglandin
E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lD
558.
ΖØ@„A‘O“c—C”üAŠÖŒû•x”üŽqA씨“ÄŽjDV‚µ‚¢“àˆö«áu’Éî•ñ“`’B•¨Ž¿‚Æ‚µ‚Ä‚Ì—°‰»…‘f‚Ì–ðŠ„D‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lD
559.
•Ä‘ò‘åŽ÷A‹{–{ŽÀ—¢A’JŒû‰lˆêA–{é‰ë”üAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚̃‰ƒbƒgˆÝ”S–Œ‚É‚¨‚¯‚é•ÛŒì“I–ðŠ„D‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lD
560.
‹v•Û‘ŽqAŠŒ´–]“nA“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA씨“ÄŽjDƒ‰ƒbƒgˆÝŒŒŠÇ‹Ù’£«‚¨‚æ‚Ñ”S–ŒzŠÂ“®‘Ô‚É‚¨‚æ‚Ú‚·ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚ÌŒø‰ÊD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lD
561.
“y]ˆÊ’mŽqA‹v•Û‘ŽqAŠÖŒû•y”üŽqA씨“ÄŽjDV‹K“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[—°‰»…‘f‚É‚æ‚éƒ}ƒEƒX‹CŠÇŽx•½ŠŠ‹Ø‚Ì’oŠÉD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lD
562.
¼‘ºK—eAΑqG‹±A¼”g^”¿A’Ò“àr•¶AŠÖŒû•x”üŽqA¬£Œõ‰hA’†’Jšæ’jAŠ™’†Šì‹vA씨“ÄŽjDäX‰ŠŠÖ˜A’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚郃Vƒ‹Ž_ƒJƒ‚ƒXƒ^ƒbƒg‚ÌRNŠQŽó—e“Iì—pD‘æ79‰ñ“ú–{–ò—Šw‰ï”N‰ïA2006, 3,
8-10, ‰¡•lD
563.
씨“ÄŽjDPAR (proteinase-activated receptor) ‚ð•W“I‚Æ‚µ‚½Á‰»ŠÇŽ¾Š³Ž¡—ÖòŠJ”‚̉”\«‚ɂ‚¢‚ÄD‘æ2‰ñ“ú–{Á‰»ŠÇŠw‰ïA2006, 2,
11-12, “Œ‹žDiƒ[ƒNƒVƒ‡ƒbƒvˆË—Šu‰‰j
564.
Kawabata, A. Proteinase-activated receptors in the
gastrointestinal systems: physiological/phathological roles and cell signaling.
Seminar at AstraZeneca, 2006, 1, 30, Gothenberg (Sweden). (Invited lecture)
565.
Kawabata, A., Nagataki, M., Moriyuki, K., Sekiguchi, F.,
Nishikawa, H. Cell signaling by proteinase-activated receptor-2 for
interleukin-8 formation in human lung epithelial cells. Cell Signaling World
2006, 1, 25-28, Luxembourg. (Oral presentation)
566.
Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nishikawa, H.,
Kawai, K., Kawabata, A. Distinct signaling and actions caused by intracellular
ligands (pepducins) for proteinase-activated receptor-1 in multiple
cells/tissues. Cell Signaling World 2006, 1, 25-28, Luxembourg.
567.
Kawabata, A. Proteinase-activated receptors in the respiratory
systems: physiological/phathological roles and cell signaling. Seminar at
Department of Physiology and Pharmacology, University of Strathclyde, 2006, 1,
23, Glasgow. (Invited lecture)
568.
Ζ؄A‘O“c—C”üAŠÖŒû•x”üŽqA씨“ÄŽjD“àˆö«ƒKƒXƒƒbƒZƒ“ƒWƒƒ[H2S‚Í––½‘gD‚É‚¨‚¢‚Ä’É‚Ý‚Ìî•ñ“`’B‚ÉŠÖ—^‚·‚éD‘æ108‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2005, 11,
11, ¼‹{D
569.
•Ä‘ò‘åŽ÷A‹{–{ŽÀ—¢A’JŒû‰lˆêA–{é‰ë”üAŠÖŒû•x”üŽqA씨“ÄŽjDV‹KƒKƒXóƒƒbƒZƒ“ƒWƒƒ[H2S‚̃‰ƒbƒgˆÝ”S–Œ‚É‚¨‚¯‚é•ÛŒìŒø‰ÊD‘æ108‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2005, 11,
11, ¼‹{D
570.
’·‘ë^ŽÀAŽçs˜a”üAŠÖŒû•x”üŽqA*¼ì—T”VA*r–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¯‚éPAR-2‚ð‰î‚·‚éInterleukin-8ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ108‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïD2005, 11,
11, ¼‹{D
571.
¼ì—T”VC‰Í‡Œ’‘ C‘å’J—T–çC–kì’m’ÃŽqCˆÀ•”’q”VCr–ØG¹C‰i––’mŽqC씨“ÄŽjDPAR-2ŠÖ˜Aƒyƒvƒ`ƒh‚É‚æ‚éPAR-2ˆË‘¶‚¨‚æ‚Ñ”ñˆË‘¶«—܉t•ª”åF\‘¢Šˆ«‘ŠŠÖ‚Æì—p‹@˜‚̉ðÍD‘æ55‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïD2005, 10,
29, _ŒËD i“ú–{–òŠw‰ï‹ß‹EŽx•”§—ãÜŽóÜj
572.
씨“ÄŽjDProteinase-activated receptor (PAR) ‚Ì‘½—l‚È‹@”\‚Æ•a‘Ô‚Ö‚ÌŠÖ—^D‘æ16‰ñ‹ãBŒŒŠÇŒŒðƒtƒH[ƒ‰ƒ€A2005, 10,
15-16, ‹{èi“Á•Êu‰‰j
573.
Kawabata, A., Sekiguchi, F., Saitoh, S., Nagataki, M., Takaoka,
K., Hayashi, H., Kawao, N., Nishikawa, H. Cellular signaling responsible for
delayed prostaglandin E2 production caused by proteinase-activated
receptor-1 activation in rat mucosal epithelial cells. 13th World
Congress of Gastroenterology, 2005, 9, 10-14, Montreal, Canada.
574.
Kubo, S., Doe, I., Sekiguchi, F., Kawabata, A. Dual modulation
by hydrogen sulfide, a novel endogenous gasomessenger, of the tension in rat
gastric artery. 13th World Congress of Gastroenterology, 2005, 9,
10-14, Montreal, Canada.
575.
Yonezawa, D., Miyamoto, M., Taniguchi, E., Honjo, M., Sekiguchi,
F., Kawabata, A. A protective role of H2S, a novel gasomessenger, in
rat gastric mucosa. 13th World Congress of Gastroenterology, 2005,
9, 10-14, Montreal, Canada.
576.
Matsunami, M., Kawao, N., Kitano, T., Tsutsumi, M., Ishiki, T.,
Satoh, R., Sekiguchi, F., Minami, T., Kanke, T., Kawabata, A. Proteinase-activated
receptor-2 plays distinct roles in colonic hypersensitivity and
pancreatitis-related abdominal allodynia. 13th World Congress of
Gastroenterology, 2005, 9, 10-14, Montreal, Canada.
577.
Kawabata, A. Proteinase-activated receptors (PARs): physiology, signaling
pathways and gastric mucosal function. Seminar at Faculty of Medicine,
University of Calgary, 2005, 9, 9, Calgary, Canada. (Invited lecture)
578.
씨“ÄŽjDPAR-2‚Æ’É‚ÝD–ò—ŠwƒTƒ}[ƒZƒ~ƒi[2005D2005, 9,
1-3, ’·èiµ‘Òu‰‰j
579.
¼”g^”¿A씨“ÄŽjDŒ‹’°’ÉŠo‰ß•q‚¨‚æ‚ÑäX‰ŠŠÖ˜A• •”ƒAƒƒfƒBƒjƒA‚Ì”Œ»‚É‚¨‚¯‚éPAR-2‚̈قȂé–ðŠ„D–ò—ŠwƒTƒ}[ƒZƒ~ƒi[2005D2005, 9,
1-3, ’·èD
580.
Kanke, T., Kabeya, M., Kondo, S., Yasuoka, K., Tagashira, J.,
Ishiwata, H., Saka, M., Doi, T., Hattori, Y., Kawabata, A., Plevin, R. A novel
peptide-mimetic PAR-2 antagonist, K-14585: inhibition on PAR-2-mediated signal
transduction and vascular responses. British Pharmacological Society Summer
Meeting, 2005, 7, 6-8, Cambridge, UK.
581.
Kawabata, A. Proteinase-activated receptors in gastric mucosa:
physiological roles and cellular signaling. Molecular Mechanisms of
Pathogenesis in Commemoration of 120th Anniversary of
Yonsei University College of Medicine, 2005, 6, 16-18, Seoul, Korea (Invited
Lecture)
582.
Yonezawa, D., Oono, Y., Hiramatsu, K., Inoi, N., Honjo, M.,
Hirofuchi, M., Ishiki, T., Sekiguchi, F., Iwaki, M., Kanke, T., Ishiwata, H.,
Kawabata, A. 2-furoyl-LIGRL-NH2 is a highly potent agonist for
proteinase-activated receptor-2 and orally effective gastric mucosal protective
agent in mice. Molecular Mechanisms of Pathogenesis in
Commemoration of 120th Anniversary of Yonsei University College of
Medicine, 2005, 6, 16-18, Seoul, Korea
583.
씨“ÄŽjA¼”g^”¿A‰Í”ö’¼”VA–k–ì’qŽqA’ç@‰ëOAΖØ@„A²“¡—æŽqAŠÖŒû•x”üŽqA“ì@•ŽuA›‰Æ@“ODPAR-2‚É‚æ‚é“à‘Ÿ’ɂ̧ŒäFäX‰ŠŽž‚ÌRNŠQ“IE•ÛŒì“I–ðŠ„‚Æ’x”«Œ‹’°’ÉŠo‰ß•qŒ`¬‚Ö‚ÌŠÖ—^D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
584.
’·‘ë^ŽÀA‰Í”ö’¼”VA’·àVŒi‘¾AKelly CushingAŠÖŒû•x”üŽqAWallace
K. MacNaughtonAMorley D. HollenbergA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¯‚éPAR-2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚é×–EƒVƒOƒiƒ‹‚ÆCOX-2‚Ì—U“±D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
585.
•Ä‘ò‘åŽ÷A‘å–ì—TŽqA’–ˆä’¼Ž÷A–{é‰ë”üALŸº—ÏŽqAŠÖŒû•x”üŽqAŠâé³GA›‰Æ“OAΓn”Ž”VA씨“ÄŽjD‚Šˆ«PAR-2ƒAƒSƒjƒXƒg2-furoyl-LIGRL-amide‚Í‹—Í‚©‚ÂŒoŒû“Š—^‰Â”\‚ȈݔS–Œ•ÛŒì–ò‚Å‚ ‚éD‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
586.
Î–Ø „A‹v•Û‘ŽqA“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA’·‘ë^ŽÀA¼ì—T”VA“c’† ½A씨“ÄŽjDPAR-1
pepducins i×–E“àƒAƒSƒjƒXƒgAƒAƒ“ƒ^ƒSƒjƒXƒgjFŽíX‚Ì×–EE‘gD‚É‚¨‚¯‚銈«•]‰¿D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
587.
ŠÖŒû•x”üŽqCÖ“¡Ž‡–ìC’·‘ë^ŽÀC‰Í”ö’¼”VC¼ì—T”VCr–ØG¹C씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚É‚¨‚¯‚éƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1Šˆ«‰»—U”ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹“`’B‚ÌŒŸ“¢D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
588.
‹v•Û‘ŽqA“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA씨“ÄŽjDV‚µ‚¢“àˆö«ƒKƒXóî•ñ“`’B•¨Ž¿H2S‚É‚æ‚郉ƒbƒg“Eo“®–¬‰^“®§Œä‚Ì“Á’¥D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
589.
›‰Æ“OA•Ç’JŒ¹ŽkAˆÀ‰ª‹žŽqA“c“ª–çAΓn”Ž”VAâ‰ëŽqA“y”ì•A•ž•”K’jA씨“ÄŽjARobin PlevinDV‹Kƒyƒvƒ`ƒhƒ~ƒƒeƒBƒbƒNPAR-2ƒAƒ“ƒ^ƒSƒjƒXƒgFƒPƒ‰ƒ`ƒmƒTƒCƒgƒVƒOƒiƒ‹“`’B‚ɑ΂·‚é‘jŠQì—pD‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
590.
‹ß“¡ÍŽsA‹v•Û‘ŽqA‘ê‘òr–¾A•Ç’JŒ¹ŽkAΓn”Ž”VA¼–{ŽŸ˜YA•ž•”K’jA›‰Æ“OA씨“ÄŽjDV‹Kƒyƒvƒ`ƒhƒ~ƒƒeƒBƒbƒNPAR-2ƒAƒ“ƒ^ƒSƒjƒXƒgK-14585FPAR-2ƒAƒSƒjƒXƒg‚É‚æ‚郉ƒbƒgŒŒŠÇ’oŠÉì—p‚È‚ç‚тɃ‚ƒ‹ƒ‚ƒbƒgŒŒŠÇ“§‰ß«˜´i‚ɑ΂·‚é‘jŠQì—pD‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
591.
¼ì—T”VC‰Í‡Œ’‘ C“c’†@½C‘å’J—T–çC“c’†CˆêC–kì’m’ÃŽqC¼“c@–«CˆÀ•”’q”VCr–ØG¹A씨“ÄŽjDPAR-2ŠÖ˜A•sŠˆ«Œ^ƒyƒvƒ`ƒhLSIGRL-NH2‚̗܉t•ª”åì—p‚ÉŠÖ‚·‚é\‘¢Šˆ«‘ŠŠÖŒ¤‹†D‘æ78‰ñ“ú–{–ò—Šw‰ï”N‰ïC2005, 3,
22-24, ‰¡•lD
592.
‹v•Û‘ŽqA씨“ÄŽjDƒ‰ƒbƒgã’°ŠÔ–Œ“®–¬‚ÌŒŒŠÇ‰^“®§Œä‚É‚¨‚¯‚éG’`”’‹¤–ðŒ^ƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR-1‚¨‚æ‚ÑPAR-2‚Ì–ðŠ„D‘æ34‰ñ“ú–{S–¬ŠÇì“®•¨Ž¿Šw‰ïD2005, 2, 4, ‹ž“sD
593.
›‰Æ“OAΓn”Ž”VA•Ç’JŒ¹ŽkAâ‰ëŽqAÄ“¡’¼LA•Ä‘ò‘åŽ÷AΖ؄A‹v•Û‘ŽqAŠÖŒû•x”üŽqAŠâé³GA씨“ÄŽjARobin
Plevin. V‹K‚Šˆ«PAR-2ƒAƒSƒjƒXƒgA2-furoyl-LIGRL-NH2‚̃AƒSƒjƒXƒgŠˆ«‚ÆŽó—e‘Ìe˜a«D‘æ12‰ñ“ú–{–òŠw‰ïˆã–ò•i‰»Šw•”‰ï”N‰ïD2004, 11,
24-26, ‚‚‚ÎD
594.
Kawabata, A., Kawao, N., Kitano, T., Matsunami, M., Ishiki, T.,
Yoshida, S., Satoh, R., Tachibana, M., Sekiguchi, F., Kanke, T. Involvement of
luminal trypsin and protease-activated receptor-2 in visceral hypersensitivity
to capsaicin. Advances in GI Pharmacology – From acid secretion to mucosal
protection, 2004, 11, 20-22, Otsu, Japan. (overview, invited)
595.
Sekiguchi, F., Kawao, N., Nagataki, M., Saito, S., Nishikawa,
H., Araki, H. and Kawabata, A. Intracellular signaling for prostaglandin E2
production caused by protease-activated receptor-1 activation in rat gastric
mucosal epithelial cells. Advances in GI Pharmacology – From acid secretion to
mucosal protection, 2004, 11, 20-22, Otsu, Japan. (oral)
596.
Yonezawa, D., Oono, Y., Hiramatsu, K., Inoi, N., Honjo, M., Hirofuchi,
M., Ishiki, T., Sekiguchi, F., Iwaki, M., Kanke, T., Ishiwata, H., Kawabata, A.
Salivation and gastric mukcosal cytoprotection caused by 2-furoyl-LIGRL-NH2,
the most potent agonist for protease-activated receptor-2, in mice. Advances in
GI Pharmacology – From acid secretion to mucosal protection, 2004, 11, 20-22,
Otsu, Japan.
597.
‰Í”ö’¼”VA’r“c‹v—YA‰ª“c´FA‰ª–{’m‰ÂŽqA㓈”ÉA¼”ö—A씨“ÄŽjDƒJƒvƒTƒCƒVƒ“—U‹N“à‘Ÿ’É‚É‚¨‚¯‚éPAR-1‚¨‚æ‚ÑPAR-2‚Ì–ðŠ„D‘æ79‰ñ‹ß‹E¶—Šw’k˜b‰ïA2004, 11,
6, ‹ž“sD
598.
’·‘ë^ŽÀA‰Í”ö’¼”VA’·àVŒi‘¾AKelly CushingA˜a“c“NKAŠÖŒû•x”üŽqAŽs“c¬ŽuAWallace
K. MacNaughtonAMorley D. HollenbergA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒqƒg”x–Eã”ç×–E‚É‚¨‚¯‚éPAR-2Šˆ«‰»‚É‚æ‚éCOX-2‚Ì—U“±‚Æ‚»‚ê‚ÉŠÖ—^‚·‚éƒVƒOƒiƒ‹‚̉ðÍD‘æ106‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2004, 11,
5, ‹ž“sD
599.
‹v•Û‘ŽqAΖ؄A“y]ˆÊ’mŽqAŠÖŒû•x”üŽqA’·‘ë^”üA¼ì—T”VA“c’†½A씨“ÄŽjD×–E“àPAR-1ƒAƒSƒjƒXƒgƒyƒvƒ`ƒh‚¨‚æ‚уAƒ“ƒ^ƒSƒjƒXƒgƒyƒvƒ`ƒh(pepducins)‚ÌŠeŽí×–EE‘gD‚É‚¨‚¯‚éì—p‚̉ðÍD‘æ106‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2004, 11,
5, ‹ž“sD
600.
씨“ÄŽjAŠÖŒû•x”üŽqDÁ‰»ŠíŽ¾Š³Ž¡—Âɂ¨‚¯‚éV‚µ‚¢‘n–ò•W“I•ªŽq‚Æ‚µ‚Ä‚Ìprotease-activated
receptors (PARs)D‘æ32‰ñ–ò•¨Šˆ«ƒVƒ“ƒ|ƒWƒEƒ€A2004, 11, 1-2, ‘åãiOrganizerEƒVƒ“ƒ|ƒWƒXƒgjD
601.
ŠÖŒû•x”üŽqA‰Í”ö’¼”VA’·‘ë^ŽÀAÖ“¡Ž‡–ìA¼ì—T”V*Ar–ØG¹*A씨“ÄŽjDƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1Šˆ«‰»‚ð‰î‚µ‚½ƒ‰ƒbƒgˆÝ”S–Œã”ç×–E‚©‚ç‚Ì’x‰„«ƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àî•ñ“`’BŒn‚ÌŒŸ“¢D‘æ‚T‚S‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïA2004, 10,
23, _ŒËDi“ú–{–òŠw‰ï‹ß‹EŽx•”§—ãÜŽóÜj
602.
Kawabata, A., Kawao, N., Kitano, T., Satoh, R., Sekiguchi, F.,
Matsunami, M., Tachibana, M., Ishiki, T., Kuroda, R. and Kanke, T. Luminal
trypsin causes delayed facilitation of capsaicin-evoked visceral nociception by
activating protease-activated receptor-2. Neuroscience 2004, 2004, 10, 23-27,
San Diego. (oral)
603.
Kawabata, A., Kawao, N., Nagataki, M., Kubo, S., Chushing, K.,
Ishiki, T., Nagasawa, K., Sekiguchi, F., Hollenberg, M.D., MacNaughton, W.K.
and Nishikawa, H. Protease-activated receptors (PARs) and respiratory
functions: cellular signaling and enhancement of prostanoid formation in the
epithelium. The 17th Korea-Japan Joint Seminar on Pharmacology,
2004, 9, 30 – 10, 1, Jeonju, Korea (oral)iŠØ‘A‘SBŽsj
604.
Sekiguchi, F., Hasegawa, N., Inoshita, K., Yonezawa, D., Kanke,
T., Saito, N. and Kawabata, A. Inhibitory and excitatory modulations of mouse
gastrointestinal motility by activation of proteinase-activated receptor
(PAR)-1 and PAR-2. The 17th Korea-Japan Joint Seminar on
Pharmacology, 2004, 9, 30 – 10, 1, Jeonju, Korea iŠØ‘A‘SBŽsj
605.
Kubo, S., Ishiki, T., Doe, I., Sekiguchi, F., Nagataki, M.,
Nishikawa, H., Tanaka, M. and Kawabata, A. The intracellular agonist and
antagonist (pepducins) for proteinase-activated receptor-1: distinct activity in
multiple cells/tissues. The 17th Korea-Japan Joint Seminar on
Pharmacology, 2004, 9, 30 – 10, 1, Jeonju, Korea iŠØ‘A‘SBŽsj
606.
씨“ÄŽjA›‰Æ@“OA•Ä‘ò‘åŽ÷AΖØ@„A‹v•Û‘ŽqAŠÖŒû•x”üŽqA‘å–ì—TŽqAâ@‰ëŽqA•Ç’JŒ¹ŽkAŠâé³GDProtease-activated
receptor-2‚ÌV‹K‚Šˆ«ƒAƒSƒjƒXƒg2-furoyl-LIGRL-NH2: in
vitro‚¨‚æ‚Ñin vivo‚É‚¨‚¯‚銈«•]‰¿D‘æ9‰ñ•a‘Ô‚ÆŽ¡—Âɂ¨‚¯‚éƒvƒƒeƒA[ƒ[‚ƃCƒ“ƒqƒrƒ^[Œ¤‹†‰ïA2004, 7,
30-31, –¼ŒÃ‰®D
607.
ŠÖŒû•x”üŽqA‰Í”ö’¼”VA’·‘ë^ŽÀAÄ“¡Ž‡–ìA¼ì—T”VAr–ØG¹A씨“ÄŽjDProtease-activated
receptor-1Šˆ«‰»‚É‚æ‚éˆÝ”S–Œã”ç×–E‚©‚ç‚Ìprostaglandin E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒƒJƒjƒYƒ€‚ÌŒŸ“¢D‘æ9‰ñ•a‘Ô‚ÆŽ¡—Âɂ¨‚¯‚éƒvƒƒeƒA[ƒ[‚ƃCƒ“ƒqƒrƒ^[Œ¤‹†‰ïA2004, 7,
30-31, –¼ŒÃ‰®D
608.
Kawabata, A., Kawao, N., Kitano, T., Satoh, R., Ikeda, H.,
Sekiguchi, F., Kuroda, R., Kanke, T. Protease-activated receptor-2 activation
induces delayed facilitation of capsaicin-evoked visceral pain in mice:
involvement of endogenous bradykinin. 11th International Pain Clinic
World Society of Pain Clinicians, 2004, 7, 11-16, Tokyo.
609.
ŠÖŒû•x”üŽqA‰Í”ö’¼”VA’·‘ë^ŽÀAÄ“¡Ž‡–ìA¼ì—T”VAr–ØG¹A씨“ÄŽjDƒ‰ƒbƒgˆÝ”S–Œã”ç×–ERGM1‚É‚¨‚¯‚éPAR-1Šˆ«‰»‚ð‰î‚µ‚½PGE2ŽY¶˜´i‚ÆŠÖ˜A‚·‚é×–E“àƒVƒOƒiƒ‹D‘æ105‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïA2004, 6,
17-18, “¿“‡D
610.
ŠÖŒû•x”üŽqCŽO“c—eŽqC‰Í”ö’¼”VC¼‰®G˜aC‘½‰êç—^”üCŠ™’†Šì‹vC씨“ÄŽjDƒJƒ‰ƒQƒjƒ“—U””M’ÉŠo‰ß•q‚ɑ΂·‚é—U“±Œ^NO‡¬y‘fiiNOSj‘jŠQ–òONO-1714‚Ì’Á’ÉŒø‰ÊD“ú–{–òŠw‰ï‘æ124”N‰ïC2004, 3,
29-31, ‘åãD
611.
‰Í”ö’¼”VA–k–ì’qŽqA²“¡—æŽqA’r“c‹v—YA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqA›‰Æ“OA씨“ÄŽjD“à‘Ÿ’É”Œ»‚É‚¨‚¯‚éPAR-2‚ƃvƒƒeƒA[ƒ[‚Ì–ðŠ„FPAR-2ƒmƒbƒNƒAƒEƒgƒ}ƒEƒX‚¨‚æ‚уƒVƒ‹Ž_ƒiƒtƒ@ƒ‚ƒXƒ^ƒbƒg‚ð—p‚¢‚½ŒŸ“¢D“ú–{–òŠw‰ï‘æ124”N‰ïC2004, 3,
29-31, ‘åãD
612.
Kawabata, A., Kawao, N., Nagataki, M., Wada, T., Ichida, S.,
Hollenberg, M.D., Kubo, S., Sekiguchi, F. Signal transduction mechanisms for
prostanoid formation caused by protease-activated receptor-2 activation in
human lung epithelial cells. XVIIth International Congress on Fibrinolysis and
Proteolysis, 2004, 3, 21-25, Melbourne. (Oral presentation)
613.
Sekiguchi, F., Hasegawa, N., Yonezawa, D., Kanke, T., Saito, N.
and Kawabata, A. Roles of protease-activated receptor-1 and -2 in modulation of
mouse gastrointestinal motility. XVIIth International Congress on Fibrinolysis
and Proteolysis, 2004, 3, 21-25, Melbourne.
614.
Kubo, S., Nakaya, Y., Ishiki, T., Sekiguchi, F., Kuroda, R.,
Nishikawa, H., Kawabata, A. Mechanisms underlying contraction/relaxation caused
by activation of protease-activated receptors 1 and 2 in rat superior
mesenteric artery. XVIIth International Congress on Fibrinolysis and
Proteolysis, 2004, 3, 21-25, Melbourne. (Oral presentation)
615.
씨“ÄŽjDŒÄ‹zŠíŒn‚É‚¨‚¯‚éprotease-activated receptors ‚ð‰î‚·‚éƒVƒOƒiƒ‹“`’BDƒVƒ“ƒ|ƒWƒEƒ€uƒvƒƒeƒA[ƒ[Šˆ«‰»Œ^Žó—e‘Ì‚Ì‹@”\‚Æ•a‘Ô¶—vC‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3,
8-10, ‘åãDiOrganizerEƒVƒ“ƒ|ƒWƒXƒgj
616.
›‰Æ@“OC‘ê‘òr–¾C•Ç‰®Œ¹ŽkC씨“ÄŽjD‘n–òƒ^[ƒQƒbƒg‚Æ‚µ‚Ä‚ÌProtease-activated
receptor-2 (PAR-2). ƒVƒ“ƒ|ƒWƒEƒ€uƒvƒƒeƒA[ƒ[Šˆ«‰»Œ^Žó—e‘Ì‚Ì‹@”\‚Æ•a‘Ô¶—vC‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3,
8-10, ‘åãDiƒVƒ“ƒ|ƒWƒXƒgj
617.
ŠÖŒû•x”üŽqC’·’Jì®”üC•Ä‘ò‘åŽ÷C’–ˆä’¼Ž÷A›‰Æ@“OCÄ“¡’¼LC씨“ÄŽjDPAR-1‚¨‚æ‚ÑPAR-2Šˆ«‰»‚É‚æ‚éƒ}ƒEƒXÁ‰»ŠÇ‰^“®’²ß‹@\D‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3,
8-10, ‘åãD
618.
‰Í”ö’¼”VAL’†–F”üA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqA씨“ÄŽjDƒrƒXƒzƒXƒzƒl[ƒgŒn–ò܃Gƒ`ƒhƒƒl[ƒg‚ÍATPŠ´Žó«ƒJƒŠƒEƒ€ƒ`ƒƒƒlƒ‹‚ð‰î‚µ‚ăAƒWƒ…ƒoƒ“ƒgŠÖ߉Šƒ‰ƒbƒg‚É‚¨‚¯‚éƒAƒƒfƒBƒjƒA‚ð—}§‚·‚éD‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3,
8-10, ‘åãD
619.
‹v•Û‘ŽqAΖ؄A‰Í”ö’¼”VAŠÖŒû•x”üŽqA•“c—Ç‘¾˜YAÄ“¡’¼OA•ž•”K’jAHollenberg,
M.D. A씨“ÄŽjDPAR-2‚¨‚æ‚ÑPAR-1Šˆ«‰»‚É‚æ‚éƒ}ƒEƒX‹C“¹•½ŠŠ‹Ø’oŠÉ”½‰žƒƒJƒjƒYƒ€‚̉ðÍD‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3,
8-10, ‘åãD
620.
¼ì—T”VA‰Í‡Œ’‘ A“c’†@½A‘å’J—T–çA“c’†CˆêAr–ØG¹A씨“ÄŽjDPAR-2ŠÖ˜Aƒyƒvƒ`ƒh‚É‚æ‚éPAR-2”ñˆË‘¶«—܉t•ª”嘴iì—pD‘æ77‰ñ“ú–{–ò—Šw‰ï”N‰ïC2004, 3,
8-10, ‘åãD
621.
Kawabata, A. Roles of protease-activated receptors in processing
of nociception including visceral pain. AstraZeneca Research Grant Symposium 2003
on GI, 2003, 11, 28, Osaka. (Invited lecture)
622.
‰Í”ö’¼”VA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqA›‰Æ@“OA씨“ÄŽjDPAR-2Šˆ«‰»ƒvƒƒeƒA[ƒ[‚É‚æ‚éƒJƒvƒTƒCƒVƒ“—U‹N“à‘Ÿ’É‚Ì‘‹FPAR-2 KOƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢D‘æ25‰ñ“ú–{áu’ÉŠw‰ïC2003, 12,
6, “Œ‹ž
623.
씨“ÄŽjA‰Í”ö’¼”VA•“c—Ç‘¾˜YAŠÖŒû•x”üŽqDƒrƒXƒzƒXƒzƒl[ƒgŒn–ò܃Gƒ`ƒhƒƒl[ƒg‚̃AƒWƒ…ƒoƒ“ƒgŠÖ߉Šƒ‰ƒbƒg‚É‚¨‚¯‚éRƒAƒƒfƒBƒjƒAì—pFATPŠ´Žó«ƒJƒŠƒEƒ€ƒ`ƒƒƒlƒ‹‚ÌŠÖ—^‚ɂ‚¢‚ÄD‘æ25‰ñ“ú–{áu’ÉŠw‰ïC2003, 12,
6, “Œ‹ž
624.
‰Í”ö’¼”VA’·‘ë^ŽÀA“yˆä@A˜a“c“NKAŠÖŒû•x”üŽqA•“c—Ç‘¾˜YAŽs“c¬ŽuAHollenberg,
M.D., 씨“ÄŽjDƒqƒgŒÄ‹zŠíã”ç×–E‚É‚¨‚¯‚éPAR-2‚ð‰î‚·‚éƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“E2ŽY¶˜´i‚ÉŠÖ—^‚·‚é×–E“àƒVƒOƒiƒ‹‚ɂ‚¢‚ÄD‘æ104‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 11,
7, ‘åã
625.
‹v•Û‘ŽqAΖØ@„AŠÖŒû•x”üŽqA•“c—Ç‘¾˜YA“üŒð´”ŽAÄ“¡’¼OA•ž•”K’jA씨“ÄŽjDPAR-2Šˆ«‰»‚É‚æ‚éƒ}ƒEƒX“Eo‹C“¹•½ŠŠ‹Ø’oŠÉ”½‰ž‚Ì“Á’¥FPAR-2 KO ƒ}ƒEƒX‚ð—p‚¢‚½ŒŸ“¢D‘æ104‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 11,
7, ‘åãD
626.
씨“ÄŽjA›‰Æ@“OA•Ä‘ò‘åŽ÷AΖØ@„A‹v•Û‘ŽqAŠÖŒû•x”üŽqA•“c—Ç‘¾˜YAâ@‰ëŽqA•Ç’JŒ¹ŽkAPlevin,
R. ƒtƒƒCƒ‹Šî“±“üPAR-2Šˆ«‰»ƒyƒvƒ`ƒh‚Ìin vitro‚¨‚æ‚Ñin vivo‚É‚¨‚¯‚銈«•]‰¿D‘æ104‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 11,
7, ‘åã
627.
‰Í”ö’¼”VA²“¡—æŽqA–k–ì’qŽqA’r“c‹v—YAŠÖŒû•x”üŽqA씨“ÄŽjDƒgƒŠƒvƒVƒ“‚¨‚æ‚Ñ compound
48/80 ‚̃JƒvƒTƒCƒVƒ“—U”“à‘Ÿ’É‘‹Œø‰Ê‚ɑ΂·‚郃Vƒ‹Ž_ƒiƒtƒ@ƒ‚ƒXƒ^ƒbƒg‚Ìì—pD‘æ53‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘å‰ïC2003, 11,
1, –‡•û
628.
Kawabata, A., Nishikawa, H., Kawao, N., Nakaya, Y., Saitoh, H.,
Hiramatsu, K., Inoi, N., Ohno, Y., Sekiguchi, F., Nishida, M. and Kuroda, R.
PAR-1 and PAR-2 modulate gastric mucosal functions. 11th
International Conference on Ulcer Research, 15th-20th
September, 2003, Dubrovnik – Croatia (Oral presentation)
629.
Kawabata, A. Roles for proteinase-activated receptors in the
gastrointestinal tract. The 4th International Symposium on Receptor
Mechanisms, Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui.
(Invited lecture)
630.
Kawao, N., Ikeda, H, Kuroda, R., Kamanaka, Y. and Kawabata, A.
Facilitation and suppression of capsaicin-evoked visceral pain by
protease-activated receptors in mice. The 4th International
Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003,
5, 22-24, Fukui.
631.
Nakaya, Y., Kuroda, R., Nishikawa, H., ›Sekiguchi, F. and
Kawabata, A. Endothelium-dependent
relaxation of rat gastric arterial rings caused by activation of
protease-activated receptor-1 and –2. The 4th International
Symposium on Receptor Mechanisms, Signal Transduction and Drug Effects, 2003,
5, 22-24, Fukui.
632.
Nishikawa, H., Tanaka, S., Kawai, K., Tanaka, M., Ohtani, H.,
Araki, H., Ryotaro Kuroda, R. and Kawabata, A. Protease-activated receptor-2
(PAR-2)-derived peptides trigger tear secretion via a pathway distinct from
PAR-2. The 4th International Symposium on Receptor Mechanisms,
Signal Transduction and Drug Effects, 2003, 5, 22-24, Fukui.
633.
Kawabata, A., Itoh, H., Kawao, N., Kuroda, K., Iwata, I., Ogawa,
A., Nakagawa, M. Parotid
protease-activated receptor-2 activation stimulates trigeminal
capsaicin-sensitive sensory neurons in rats. The 4th
International Symposium on Receptor Mechanisms, Signal Transduction and Drug
Effects, 2003, 5, 22-24, Fukui.
634.
‹v•Û‘ŽqC’†‰®—T”üŽqCŠÖŒû•x”üŽqCΖ؄C•“c—Ç‘¾˜YC“üŒð´”ŽC¼ì—T”VCr–ØG¹C씨“ÄŽjDƒ‰ƒbƒgã’°ŠÔ–Œ“®–¬ƒŠƒ“ƒO•W–{‚É‚¨‚¢‚ÄPAR-1‚¨‚æ‚ÑPAR-2Šˆ«‰»‚É‚æ‚è—U‹N‚³‚ê‚éŽûkE’oŠÉ”½‰ž‚Ì“Á’¥D‘æ103‰ñ“ú–{–ò—Šw‰ï‹ß‹E•”‰ïC2003, 5,
22, •Ÿˆä
635.
씨“ÄŽjC’†‰®—T”üŽqC•“c—Ç‘¾˜YDƒ‰ƒbƒg“EoˆÝ“®–¬‚É‚¨‚¯‚éƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR‚ð‰î‚µ‚½’oŠÉ”½‰ž‚Ì“Á’¥D“ú–{–òŠw‰ï‘æ123”N‰ïC2003, 3,
27-29, ’·è
636.
’†‰®—T”üŽqC•“c—Ç‘¾˜YC씨“ÄŽjDƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR-1‚¨‚æ‚ÑPAR-2Šˆ«‰»‚É‚æ‚郉ƒbƒg“EoˆÝ¬“®–¬Žûk«‚̕ω»‚Æin vivo‚ł̈ݔS–ŒŒŒ—¬‚̕ω»D‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3,
24-26, •Ÿ‰ª
637.
‰Í”ö’¼”VC’r“c‹v—YC•“c˜N‘¾˜YC씨“ÄŽjDƒJƒvƒTƒCƒVƒ“—U”ƒ}ƒEƒX“à‘Ÿ’Ƀ‚ƒfƒ‹‚É‚¨‚¯‚éPAR-1‚ ‚é‚¢‚ÍPAR-2ƒAƒSƒjƒXƒg‚ÌŒø‰ÊD‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003,3,
24-26, •Ÿ‰ª
638.
ˆÉ“¡GŽ÷C•“c—Ç‘¾˜YCŠâ“cKˆêC씨“ÄŽjDƒ‰ƒbƒgŽ¨‰º‘BŠÇŠJŒû•”‚Ö‹ts«’“ü‚µ‚½PAR-2ƒAƒSƒjƒXƒg‚É‚æ‚è—U”‚³‚ê‚éŽO³_Œo”ö‘¤ˆŸŠj‚É‚¨‚¯‚éFos”Œ»D‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3,
24-26, •Ÿ‰ª
639.
¼ì—T”VC씨“ÄŽjC•½¼DC¼“c–«C“c’†½C‰Í‡Œ’‘ C“c’†CˆêC‘å’J—T–çC•“c—Ç‘¾˜YCr–ØG¹Dƒ‰ƒbƒg‚̈ݎ_•ª”å‹@\‚É‚¨‚¯‚éG’`”’‹¤–ðŒ^ƒvƒƒeƒA[ƒ[Žó—e‘ÌPAR-1‚Ì–ðŠ„D‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3,
24-26, •Ÿ‰ª
640.
씨“ÄŽjC’†‰®—T”üŽqCÄ“¡m”üC•½¼DC‰Í”ö’¼”VC‹v•Û‘ŽqC•“c—Ç‘¾˜YC¼ì—T”VC–؉º[OCŠ|”óˆêWCr–ØG¹C—L‰’’¼Ž÷C¼“c–«Dƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1Šˆ«‰»‚É‚æ‚éˆÝ‚Ì‹@”\•Ï‰»‚ƈݔS–Œ•ÛŒìD‘æ76‰ñ“ú–{–ò—Šw‰ï”N‰ïC2003, 3,
24-26, •Ÿ‰ª
641.
씨“ÄŽjD’É‚Ý‚Ìî•ñ“`’BƒƒJƒjƒYƒ€‚ÉŠÖ‚·‚éÅ‹ß‚ÌŒ¤‹†“®ŒüD‘æ‚Q‰ñKampo
EyesƒVƒ“ƒ|ƒWƒEƒ€D2003, 2, 15, ‘åãDiŠî’²u‰‰j
642.
씨“ÄŽjDƒgƒƒ“ƒrƒ“Žó—e‘ÌPAR-1‚͈ݔS–Œ‚É‚¨‚¢‚Ä•ÛŒì“I‚É‹@”\‚·‚éD‘æ13‰ñ“ú–{•a‘Ô¶—Šw‰ï‘å‰ïC2003, 1,
25-26, ç—tD